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Abstract 
 
Intestinal microbiome dysbiosis and microbial infections have been implicated in a number 
of immune mediated diseases, including multiple sclerosis, inflammatory bowel disease 
(IBD), and type 1 diabetes. Bacterial infections in the gut and urogenital tract are known to 
trigger episodes of reactive arthritis, a form of spondyloarthropathy (SpA), a group of 
related inflammatory arthropathies of which ankylosing spondylitis (AS) is the prototypic 
disease.  There is a close relationship between the gut and SpA, exemplified in reactive 
arthritis patients, where a typically self-limiting arthropathy follows either gastrointestinal 
infection with Campylobacter, Salmonella, Shigella or Yersinia, or urogenital infection with 
Chlamydia.   Microbial involvement has been suggested in AS, however, no definitive link 
has been established. Multiple genes associated with AS also play a role in gut immunity, 
such as genes involved in the IL-23 pathway, which are important regulators of intestinal 
‘health’. There is a marked over-representation of genes associated with Crohn’s disease 
(CD) that are also associated with AS suggesting the two diseases my have similar 
aetiopathogenic mechanisms, possibly involving gut dysbiosis. Up to 70% of AS patients 
have subclinical gut inflammation with 5-10% of these patients developing clinically 
defined IBD resembling CD. Therefore unravelling the relationship between underlying 
host genetics, the intestinal microbiome and the immune system is imperative for 
furthering out understanding of AS pathogenesis.  
 
This thesis sought to examine the role of the gut microbiome in AS by characterising the 
AS microbiome, examining how changes in host genetics influences intestinal microbial 
composition and then exploring at the association between AS susceptibility loci and 
microbiome composition in healthy twins.  
 
To date, no comprehensive characterisation, using culture-independent methods, of 
intestinal microbiota from terminal ileal (TI) biopsies from AS patients has been performed. 
I firstly optimised the methods required for 16S rRNA characterisation of human intestinal 
tissue. This included the intestinal biopsies extraction method, 16S PCR development, 
next generation library construction and sequencing as well as the analysis methods 
employed for characterisation and comparison of the intestinal microbiome.  
 
 
 
3 
Secondly I profiled the microbiome of TI biopsies from patients with recent-onset, TNF-
antagonist naïve AS and healthy controls (HC), using the methods detailed in Chapter 2 of 
this thesis, to investigate if the AS gut carries a distinct microbial signature. Results 
showed that AS patients carried a clear and distinct microbial signature when compared to 
HC (P<0.001) higher abundance of five families of bacteria Lachnospiraceae (P=0.001), 
Ruminococcaceae (P=0.012), Rikenellaceae (P=0.004), Porphyromonadaceae (P=0.001), 
and Bacteroidaceae (P=0.001), and a decreases in abundance of two families 
Veillonellaceae (P=0.01) and Prevotellaceae (P=0.004). The microbial composition was 
found to correlate with disease status and greater differences were observed between 
than within disease groups. Further investigation of the AS intestinal microbiome 
demonstrated that an assemblage or ‘core’ of five families of bacteria were driving the 
intestinal profile. These results are consistent with the hypothesis that genes associated 
with AS act at least in part through effects on the gut microbiome. 
 
I then further examined the role of host genetics in microbiome composition by examining 
the effect of Endoplasmic reticulum aminopeptidase-1 (ERAP1) in a murine model. 
Genome wide association studies have currently identified over 40 loci associated with 
ankylosing spondylitis, with ERAP1 is one of the strongest associations, along with HLA-
B27.  ERAP1 plays a critical role in overall immune system modulation with systemic 
effects.  In this chapter, I asked how a lack or down regulation of ERAP1 influences the 
inherent gut microbiome composition, and how this impacts on the antigen repertoire and 
ensuing affects the immune system. 
 
In the final component of this thesis I further investigated the influence of host genetics, 
specifically AS risk loci, on microbiome composition by examining the association between 
AS SNPs and intestinal microbiome composition in a non-AS, otherwise healthy 
individuals. To investigate the relationship between genes known to be associated with AS 
and the gut microbiome, results of matched genetic and 16S rRNA profiling of 982 twins 
from the United Kingdom Adult Twin Registry (TwinsUK) were examined to determine if 
SNPs, either individually or in combination, were associated with specific microbes. We 
have shown, in an otherwise healthy Twin cohort, that genes associated with developing 
AS were linked to families of bacteria known to be inflammatory and key indicator species 
in the AS microbiome. The allelic risk score linked an AS genetic profile with the families of 
Ruminococcaceae, Lachnospiraceae and the order Clostridiales, which are keystone 
species of the AS microbiome and members of the core microbiome. Further investigation 
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of individual genes involved in microbial response, peptide processing, trimming and 
presentation were also correlated with these same families of bacteria. This intimates that 
host genetics play a role in not only overall microbiome composition, but also structure of 
core microbiome. 
 
Collectively the work presented in this thesis highlights of the role the human gut 
microbiome in AS. It demonstrates evidence for a discrete microbial signature in the TI of 
patients with AS compared to HC. The microbial composition was found to correlate with 
disease status and driven by a core group of five bacterial families. Genes associated with 
developing AS were linked to families of bacteria known to be inflammatory and key 
indicator species in the AS microbiome, and investigation of individual genes involved in 
microbial response, peptide processing, trimming and presentation were also correlated 
with these same families of bacteria. This indicates that underlying host genetics plays a 
role in core microbiome as well as overall microbiome structure. Final discussion chapter 
of this thesis discusses implications of these associations, limitations of the research as 
well as future directions to be explored. 
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1 Chapter 1 Introduction and Literature Review 
 
 
1.1 Introduction 
 
It is increasingly clear that the interaction between host and microbiome profoundly affects 
health. There are ten times more bacteria in and on our bodies than the total of our own 
cells, with the human intestine containing ~100 trillion bacteria. Our microbial communities 
are not passive bystanders, and we are only just beginning to appreciate the influence our 
microbial residents have on our health. Until recently interrogation of our microbial 
communities using classical microbiology techniques offered a very restricted view of 
these communities, only allowing us to see what we can grow in isolation. However, recent 
advances in sequencing technologies have greatly facilitated systematic and 
comprehensive studies of the microbiome, and elucidate its role in human health and 
disease.  
 
1.2 Ankylosing spondylitis 
 
Ankylosing spondylitis (AS) is a common and highly heritable autoimmune disease 
belonging to a group of arthritides called spondyloarthropathies (SpA) and affects over 
22,000 Australians (1). This group of seronegative diseases comprises of AS, psoriatic 
arthritis (PsA), reactive arthritis (ReA), Juvenile onset SpA, and Undifferentiated SpA 
associated with inflammatory bowel diseases including Crohn’s disease (CD) and 
ulcerative colitis (UC) (2). All members of SpA are characterised by a strong association 
with the human leukocyte antigen (HLA) allele HLA-B*27, combined with the absence of 
an association with rheumatoid factor or anti-nuclear antibodies. Additionally, they all show 
a certain degree of enthesitis, which is inflammation of the site of insertion of ligaments, 
tendons or joint capsules to bone, such as the Achilles tendon (3). 
 
AS is a life long condition with first symptoms appearing at a young age. AS is 
characterised by excessive bone formation (ankylosis) that gradually bridges the gap 
between joints, eventually fusing and causing stiffness, inflexibility, pain, significant 
morbidity and increased mortality.  The mechanism that triggers AS in a genetically 
susceptible person is poorly understood. There is a close relationship between the gut and 
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SpA, exemplified in reactive arthritis patients, where a typically self-limiting arthropathy 
follows either gastrointestinal infection with Campylobacter, Salmonella, Shigella or 
Yersinia, or urogenital infection with Chlamydia. AS has a global distribution, with no 
outbreaks or clustering being reported. The gene identified as having the strongest 
association with AS development is the major histocompatibility complex (MHC) gene 
HLA-B27. However, only 1-5% of HLA-B27+ individuals go on to develop AS. Monozygotic 
twin studies suggest that the trigger for AS in a genetically susceptible person is a 
ubiquitous environmental factor that is most likely widely distributed (4, 5).  
 
1.2.1 The gastrointestinal tract and AS 
 
The co-existence of AS and intestinal inflammation has been known for some time (6), 
with between 5-10% of AS patients developing clinically diagnosed inflammatory bowel 
disease (IBD). Up to 70% of AS patients have either clinical or subclinical gut disease, 
which suggests that intestinal inflammation is important in disease (7, 8). The human 
gastrointestinal tract is not a complete barrier and can become permeable to especially 
when there is a loss or impairment of modulation of tight junctions (9). Permeability of the 
gut is increased in conditions including IBD and celiac disease (10), and also in AS (11, 
12). The increased gut permeability in AS has been mostly attributed to the use of non-
steroidal anti-inflammatories (NSAID) (6) however, first-degree relatives of AS patients 
have also demonstrated increased gut permeability when compared with unrelated healthy 
controls (6, 11-13). This is consistent with the hypothesis that increased ‘leakiness’ of the 
gut may increase the microbial dissemination and drive inflammation in the disease.  
 
In reactive arthritis (ReA), a member of the SpA family, inflammatory arthritis develops 
following urogenital infection with Chlamydia trachomatis or gastrointestinal infection with 
Campylobacter, Salmonella, Shigella or Yersinia (14). Such cause and effect relationships 
are not established for other SpA. Studies in the B27 transgenic rat model of AS, supports 
the idea of a ubiquitous environmental trigger. The B27 transgenic rat when exposed to 
normal commensal bacteria, developed disease while the rats that were maintained in a 
germ-free environment remained disease free (15). Microbial involvement, especially 
arising from the gut, has been associated in both diseases however in AS, no definitive 
link has been established (16, 17). 
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1.3 Genetics and overlap between AS and gut disease 
 
Strong genetic overlap exists between AS and IBD (Table 1.1), particularly CD, with the 
two conditions commonly occurring together in families (18, 19). Danoy et al., 2010 
examined genes known to be associated with IBD in a large AS cohort (20) identifying new 
loci and genes. Of particular interest were genes involved in the IL-23 pathway, such as 
STAT3, IL23R, and IL12B (which encodes IL-12p40, the share subunit of IL-23 and IL-12 
(20-22). How these genetic lesions influence gut homeostasis and function still remains 
unclear although, many of the genes associated with disease are associated with microbial 
handling, processing and response such as IL23R, NOD2, NOS2 and CARD9. Genetic 
studies in CD, one of the two common forms of IBD, shows a marked over-representation 
of genes including NOD2 and TNFRSF18, that correlated with an increased risk of 
developing mycobacterial diseases, including leprosy and tuberculosis, (23). Seven of the 
eight known genetic variants, which include SLC11A1, VDR and LGALS9, are associated 
with increased risk of developing leprosy and were also found to increase and individual’s 
risk of CD (23), A high proportion of genes associated with AS are genes involved in 
mucosal immunity (24). Variants in transcription factors RUNX3, EOMES, and TBX21, as 
well as the cytokine receptors IL7R and IL23R (24), are key regulators of the differentiation 
and activation of innate lymphoid cells, which are themselves critical components of 
mucosal immune defences. 
 
Major differences also exist between the genetics of IBD and AS, with AS showing no 
association to date with NOD2/CARD15 or the autophagy gene ATG16L1, which are major 
susceptibility factors in IBD, whereas IBD shows no association with HLA-B or ERAP1 
which are the strongest AS-susceptibility genes (18, 24). 
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Table 1.1  Genes associated with ankylosing spondylitis (AS) and their association with 
inflammatory bowel disease (IBD). 
 
Reported gene SNP Locus AS 
Risk/Non-
risk 
Alleles 
IBD 
association 
RUNX3 rs6600247 1p36 C/T - 
IL23R rs11209026 1p31 G/A Concordant 
 rs12141575 1p31 A/G  
GPR25-KIF21B rs41299637 1q32 T/G Concordant 
PTGER4 rs12186979 5p13 C/T Concordant 
ERAP1-ERAP2-LNPEP rs30187 5q15 T/C - 
 rs2910686 5q15 G/A Concordant 
ERAP1-ERAP2 rs10045403 5q15 A/G - 
IL12B rs6871626 5q33 T/G Concordant 
 rs6556416 5q33 G/T Concordant 
CARD9 rs1128905 9q34 C/T Concordant 
LTBR-TNFRSF1A rs1860545 12p13 C/T - 
 rs7954567 12p13 A/G - 
NPEPPS-TBKBP1-
TBX21 
rs9901869 17q21 T/C - 
21q22 rs2836883 21q22 G/A Concordant 
IL6R rs4129267 1q21 G/A - 
FCGR2A rs1801274 1q23 T/C Concordant 
 rs2039415 1q23 C/T - 
UBE2E3 rs12615545 2q31 C/T - 
GPR35 rs4676410 2q37 A/G - 
NKX2-3 rs11190133 10q24 C/T Concordant 
ZMIZ1 rs1250550 10q22 C/A Concordant 
SH2B3 rs11065898 12q24 A/G - 
GPR65 rs11624293 14q31 C/T Concordant 
IL27-SULT1A1 rs7282490 16p11 A/G Concordant 
 rs35448675 16p11 A/G - 
TYK2 rs35164067 19p13 G/A Concordant 
 rs6511701 19p13 A/C - 
ICOSLG rs7282490 21q22 G/A Concordant 
EOMES rs13093489 3p24 A/C - 
IL7R rs11742270 5p13 G/A - 
UBE2L3 rs2283790 22q11 C/T - 
BACH2 rs17765610 6q15 G/A Discordant 
 rs639575 6q15 A/T - 
NOS2 rs2531875 17q11 G/T - 
 rs2297518 17q11 A/G - 
HHAT rs12758027 1q32 C/T - 
IL1R2-IL1R1 rs4851529 2q11 G/A Concordant 
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1.4 The gut, barrier regulation and intestinal epithelial cells 
 
Homeostasis of the normal microbial flora in the gut is essential for intestinal health. The 
gastrointestinal tract is heavily populated with microbes and is the primary site for 
interaction between these microorganisms and the immune system (25, 26). Furthermore, 
microbes found in the gut help to shape host immune systems from an early age. The 
incomplete development of the immune system in neonates and under germ-free 
conditions tells us that microbiota play a role in sculpt the host immune system (27, 28). 
 
Maintenance of intestinal and microbial homeostasis is being increasingly recognised as 
playing a pivotal role in overall health (29), and dysregulation of either gut or microbial 
homeostasis may play a role in autoimmunity. Physiological processes in the host that 
maintain gut homeostasis and respond to perturbance in the gut microenvironment involve 
both the adaptive and innate immune system, and the barrier function of the intestines 
themselves. 
 
1.4.1 The physical barrier 
 
The human gastrointestinal tract is not a complete barrier. It is comprised of a single layer 
of intestinal epithelial cells (IECs), which form a physical barrier separating the intestinal 
lumen from the lamina propria (Figure 1.1). IECs secrete soluble factors that are crucial to 
intestinal homeostasis, such as mucins, anti-microbial peptides (AMP), including 
lysozymes, defensins, cathelicidins, lipocalins and C-type lectins such as RegIIIγ (30-32). 
Release of these molecules into luminal crypts is thought to prevent microbial invasion into 
the crypt microenvironment as well as limit bacteria-epithelial cell contact (31, 33). CD 
patients have pronounced decreases in the human α-defensins DEFA5 and DEFA6 in the 
ileum compared to healthy controls, resulting in altered mucosal function and overgrowth 
or dysregulation of commensal microbial flora (33, 34). Furthermore, depletion of the 
mucin layer leads to an IBD-like phenotype and endoplasmic reticulum stress, potentially 
driving IL-23 production (35). IL-23 excess alone is sufficient to induce spondyloarthritis in 
 rs2192752 2q11 C/A - 
2p15 rs6759298 2p15 C/G Concordant 
GPR37 rs2402752 7q31 T/C - 
HLA-B27 rs4349859 6p21 A/G - 
ANTRX2 rs4333130 4q21 A/G - 
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mice (36), and genetic evidence in particular indicates that the cytokine plays a key role in 
development of spondyloarthritis in humans. 
 
 
Figure 1.1 The physical barrier. Separating the intestinal lumen and its inhabiting commensal 
bacteria from the underlying lamina propria is a single layer of intestinal epithelial cells (IECs). 
These IECs are stitched together, creating a tight junction and regulating the paracellular flux. IECs 
also secrete soluble factors that are crucial to intestinal homeostasis, such as mucins and anti-
microbial peptides (AMPs), including lysozymes, IgA, defensins, and C-type lectins such as 
RegIIIγ. Release of these molecules into luminal crypts is thought to prevent microbial invasion into 
the crypt microenvironment as well as limit bacteria-epithelial cell contact. Toll-like receptors 
(TLRs) are also expressed on IECs to sense a breach of barrier or bacterial invasion. Underneath 
the IECs, the lamina propria contains T cells, bacteria-sampling dendritic cells (DCs), and 
macrophages. Figure from: Costello et al. Arthritis Research & 
Therapy 2013 15:214   doi:10.1186/ar4228 
1.4.1.1 Permeability and Disease 
 
The dynamic crosstalk between IECs, microbes and the local immune cells is fundamental 
to intestinal homeostasis but is also suggested to play a part in disease pathogenesis (37, 
38). There are a multitude of factors capable of altering the permeability of epithelial 
junctions. Once considered fixed and unchanging, epithelial tight junctions are remarkably 
dynamic and responsive component of the intestines. The tight junctions constantly open 
and close in response to a number of stimuli including diet, neural signals, mast cell 
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productions as well as a variety of cellular pathways, all of which can be hijacked by 
microbial as well as viral pathogens (39-42).  
 
In IBD and celiac disease, epithelial tight junctions are dysregulated causing increased 
permeability between IECs and resulting in a ‘leaky gut’ (10, 43). While the causes and 
ramifications of a ‘leaky gut’ in the disease setting are still under investigation, It has been 
suggested that an increase in intestinal permeability may lead to bacteria, either 
pathogens or normal resident bacteria, entering the lumen and triggering an inflammatory 
immune response (43, 44). Intestinal permeability in AS patients has always been 
considered a side effect due to the long term use of NSAIDs (6). However, studies looking 
at first-degree relatives of AS patients showed they also have increased gut permeability, 
suggesting that there may be an underlying genetic process operating in the gut (11, 45). 
 
1.4.1.2 Innate immunity 
 
Dendritic cells (DC) densely populate the intestinal lamina propria and form a widespread 
microbial sensing network. DC recognise a broad repertoire of bacteria, sensing with 
receptors such as toll-like receptors (TLRs) and monitoring the bacteria on the mucosal 
surface (46). Intestinal DC orchestrate production of intestinal specific IgA to limit bacterial 
contact with the intestinal epithelial cell surface (47). Activated DC can secrete a number 
of cytokines and chemokines, including IL-23 and IL-6, that are involved in inflammation 
and migration of DC (48). 
 
Macrophages patrol the gastrointestinal systems in high numbers. They frequently come in 
contact with ‘stray’ bacteria, including commensals that have breached the epithelial cell 
barrier. Circulating macrophages phagocytose and rapidly kill such bacteria using 
mechanisms that include production of antimicrobial proteins and reactive oxygen species 
(49). However, intestinal macrophages have several unique characteristics including the 
expression of the anti-inflammatory cytokine IL-10, both constitutively and after bacterial 
stimulation (50, 51). This makes intestinal macrophages non-inflammatory cells that still 
have the capacity to phagocytose. The importance of this pathway is highlighted by the 
fact that loss-of-function mutations in IL10R lead to early onset IBD (52). Intestinal 
macrophages also play a role in the restoration of the physical integrity of the epithelial cell 
barrier following injury or bacterial insult (9). Re-establishing this barrier post injury is 
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imperative to avoid bacterial penetration and sepsis in such a microbe-laden environment 
(53). 
 
1.4.2 Adaptive Immunity 
1.4.2.1 IL-23-responsive cells 
 
IL-23 is a key cytokine in the development of IL-17 and IL-22-secreting cells. IL-23 signals 
through a receptor consisting of the specific IL-23 receptor (IL-23R) subunit and IL-12Rβ1, 
also shared with IL-12R (54). Loss of function polymorphisms in IL23R are associated with 
protection from AS (55), psoriasis (56) and IBD (57), and many other genes in the IL-23 
pathway are associated with these diseases. Under physiological conditions, IL-23, IL-17 
and IL-22 producing cells are enriched in gut mucosa and IL-17 and IL-22 are known to be 
important regulators of intestinal ‘health’. IL-17 plays important roles in intestinal 
homoeostasis in several ways, including maintenance of epithelial barrier tight junctions 
(58) and induction of anti-microbial proteins such as β-defensins, S100 proteins and REG 
proteins. IL-22 induces secretion of anti-microbial peptides (59). In the gut, innate-like 
immune cells act as sentinels, responding very rapidly to alterations to the microbial 
composition of the gut with rapid secretion of IL-17. Key among these sentinels are γδ T 
cells, Natural killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells and 
lymphoid tissue inducer (LTi)-like cells (Figure 1.2).   
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Figure 1.2 The immune barrier. Dendritic cells (DCs) and macrophages patrol the gastrointestinal 
tract in high numbers. They densely populate the intestinal lamina propria and form a widespread 
microbe-sensing network. Activated DCs can secrete a number of cytokines and chemokines, 
including interleukin-23 (IL-23), IL-6, and IL-1, activating IL-23-responsive cells. IL-23-, IL-17-, and 
IL-22-producing cells are enriched in gut mucosa, and IL-17 and IL-22 are known to be important 
regulators of intestinal 'health'. IL-17 plays important roles in intestinal homoeostasis in several 
ways, including maintenance of epithelial barrier tight junctions. LTi, lymphoid tissue inducer; 
MAIT, mucosa-associated invariant T; NKT, natural killer T; T reg, regulatory T; TNF, tumour 
necrosis factor. Figure from: Costello et al. Arthritis Research & 
Therapy 2013 15:214   doi:10.1186/ar4228 
 
1.4.2.2 γδ T cells  
 
γδ T cells are found in large numbers at epithelial surfaces such as the gut and skin, 
where they can account for up to 50% of T cells. γδ T cells not only bear an antigen-
specific T cell receptor (TCR), but also have many properties of cells of the innate immune 
system, including expression of the major innate immunity receptors and TLRs (60) and 
dectin-1(61), which recognises microbial β-glucans. Expression of these receptors 
supports a role for γδ T cells in early responses to microbes. Of further relevance, we and 
others, have recently confirmed that CARD9, part of the dectin-1 response pathway, is a 
susceptibility gene for AS and for IBD (62). γδ T cells are potent producers of inflammatory 
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cytokines such as IFN-γ, TNF-α and IL-17 (63, 64). They are pathogenic in the collagen-
induced arthritis model (65) and mouse models of colitis (66), and IL-17-secreting γδ T 
cells are expanded in patients with AS (67). Intraepithelial γδ T cells also play an important 
role in modulating intestinal epithelial growth through secretion of fibroblast growth factor 
(68). Alterations to γδ T cell numbers or functions may, therefore, have profound effects on 
intestinal health. 
 
1.4.2.3 Natural killer T cells 
 
Natural killer T (NKT) cells are characterised by expression of an invariant T cell receptor, 
Vα24Jα18 in humans and the orthologous Vα14Jα18 in mice. NKT cells recognise 
glycolipd structures presented to them by the non-classical antigen presenting molecule 
CD1d. Like γδ T cells, NKT cells are rapid responders to antigenic stimuli and are capable 
of producing a range of immunoregulatory cytokines (69-72). Within the gut, NKT cells are 
protective in Th1-mediated models of inflammatory bowel disease but pathogenic in Th2 
models (73, 74). Recently, it has been shown that microbial stimulation of NKT cells in the 
gut of mice affects NKT cell phenotypic and functional maturation (75). Given that NKT 
cells have protective roles in models of arthritis (76) and spondyloarthropathy (77, 78) their 
functional maturation in the gut provides evidence for a role for mucosal T cell priming in 
inflammatory joint disease. 
1.4.2.4 Mucosal-associated invariant T cells 
 
Mucosal-associated invariant T (MAIT) cells are a population of innate-like T cells that are 
abundant in human gut, liver and blood and secrete a range of inflammatory cytokines 
such as IL-17 and IFN-γ in response to antigenic stimulation (79-81). Like NKT cells, MAIT 
cells bear an invariant T cell receptor (Vα7.2 in humans) that recognises antigen presented 
by the non-classical MHC-like molecule, MR1 (82). In blood, MAIT cells display a memory 
phenotype (81) and express the transcription factor ZBTB16 (83), allowing them to rapidly 
secrete cytokine in response to antigenic stimuli. Furthermore, they express high levels of 
IL-23R (84). MAIT cells react to a wide range of microbial stimuli, including Gram positive 
and Gram negative bacteria as well as yeasts (79, 80). While the precise role of MAIT cells 
in maintenance of the mucosal barrier remains unclear, the rapid postnatal expansion of 
MAIT cells and their acquisition of phenotypic markers of memory likely represents 
interaction with developing commensal microflora (85).  
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1.4.2.5 Lymphoid tissue inducer- like cells 
 
Lymphoid tissue inducer (LTi)-like cells are found in spleen, lymph node and gut lamina 
propria. LTi-like cells constitutively express hallmarks of IL-17-secreting cells including IL-
23R, RORγt, AHR and CCR6 (86, 87). LTi cells in the intestine represent an increasingly 
interesting and heterogeneous population of innate lymphoid cells (ILC) with or without 
CD4 expression (88). A common characteristic of ILCs is the expression RORγt, a 
transcription factor important for the development of these cells.  ILC have been linked to 
gut inflammation through colitis models where IL-23 responsive ILC secrete IL-17, IL-22 
and IFN-γ and to promote intestinal inflammation (89).  RORγt, ILCs are abundant in the 
intestinal lamina propria and produce IL-17 and/or IL-22 in order to preserve mucosal 
integrity against extracellular pathogens. These NKp46+ ILCs have been found to be 
critical for host defence against pathogens such as Citrobacter rodentium infection through 
secretion of IL-22 (87, 90).  
 
 
1.4.3 Cytokines and gut homeostasis 
1.4.3.1 IL-17  
 
IL-17 is primarily described as a T cell-secreted cytokine however much of the IL-17 
released during an inflammatory response is in fact produced by innate immune cells in 
response to injury, stress or to pathogens (91). IL-17 has been shown to be produced 4-
8hrs after a microbial infection and is secreted by T cells including γδ T cells (63, 92, 93). 
Innate IL-17 producing cells have been found to reside mainly in the skin and mucosal 
tissues, especially the gastrointestinal tract, and act as a first line of defence. They also 
promote mobilisation of neutrophils and cytokines that are produced by epithelial cells for 
protective immunity as well as controlling physiological process such as epithelial tight 
junctions and angiogenesis. The hallmark of the innate immune response is its rapid 
reaction to pathogens by secreting factors that recruit large numbers of neutrophils 
through increasing the activity of IL-1, IL-6 and tumour necrosis factor (TNF), which 
promote tissue infiltration, which is crucial for effective and rapid control of bacterial and 
fungal pathogens (91).  
 
1.4.3.2 IL-22 
 
IL-22 has been shown to play a critical role in host defence, tissue homeostasis and 
inflammation and the IL-22-IL-22R pathway contributes to regulating immunity, 
 
 
34 
inflammation and tissue repair. IL-22 is expressed by innate and adaptive cells and seems 
to act almost exclusively on non-haematopoietic cells, with basal IL-22R expression in the 
skin, pancreas, intestine, liver, lung and kidney (94). First described in the skin by 
Dumoutier et al., 2000, who showed that the stimulation of keratinocytes with IL-22 
resulted in marked induction of genes encoding several proteins involved in anti-microbial 
host defences including S100A7, S100A8, S100A9, β-defensin-2 and β-defensin-3 (95-
97). Further studies have shown that the induction of two intestinal antimicrobial peptides 
that regulate gut homeostasis, RegIIIβ and RegIIIγ are also dependent on the production 
of IL-22 (98, 99). IL-22 can act synergistically or additively with IL-17A, IL-17F or TNF to 
promote the expression of many of the genes that encode molecules involved in host 
defence in the skin, airway or intestine. This demonstrates the functional importance of IL-
22 in promoting barrier immunity and mucosal integrity, particularly against Gram negative 
pathogens, where IL-22 is critical for limiting bacterial replication and dissemination, 
possibly in party by inducing the expression of antimicrobial peptides from epithelial cells 
at these barrier surfaces (98, 99).  Containment of normal flora is another important arm of 
homeostasis. IL-22 producing innate lymphoid cells (ILCs) found throughout the gut play a 
critical role in the physical containment of resident microbes (100). Loss of epithelial 
integrity leads to dissemination of intestinal commensals and systemic inflammation.  
1.4.4 Interaction between intestinal microbes and the immune system 
 
There is strong evidence from murine studies to indicate that interaction between the gut 
microbiome and the host determines the overall level of activation of the immune cells 
producing these cytokines.  Segmented filamentous bacteria (SFB) are commensal 
bacteria that induce IL-17 secretion. Mice lacking SFB have low levels of intestinal IL-17 
and are susceptible to infection with pathogenic Citrobacter spp. (27, 101) Restoration of 
SFB in these mice increased the number of gut-resident IL-17-producing cells and 
enhanced resistance to infection through induction of specific epithelia cell-specific genes, 
as well as inflammatory response host genes, which were found to be up regulated by the 
bacteria leading to an inflammatory environment (27).  Lachnospiraceae, 
Ruminococcaceae and Prevotellaceace are families of bacteria that have been observed 
in IBD gut microbiomes and are strongly associated with colitis and CD (102-104), with 
Prevotellaceace especially known to elicit a strong inflammatory response in the gut (104). 
The demonstration that bacteria can directly influence the host response highlights the 
effect commensal bacteria have on the immune response and their role in inflammation. 
Conversely, members of the gut microbiota such as Clostridium have been found to play a 
 
 
35 
protective role by inducing T regulatory cells (Tregs) in the colonic mucosa. Tregs are an 
important counter balance in the immune system and promote homeostasis. It was found 
that a specific mix of cluster IV and XIVa of Clostridium was sufficient to promote Treg 
accumulation in the colon (105).  
 
1.5 Interrogating the human gut microbiome 
 
Together, the multi-factorial components of the immune system shape the microbial 
population that inhabits the gut and, to an extent, vice versa, with each side pushing to 
establish a stable state. Understanding the yin and yang of this relationship is at the heart 
of current microbiome research. 
 
Microbiome refers to the totality of microbes, their genetic elements and environmental 
interaction in a defined environment (106). The aim of metagenomic studies is to profile 
the microbes within the community, identify functions and pathways of the communities 
and how the communities compare. Projects such as the Human Microbiome Project run 
by the National Institute of Health, and the Metagenomics of the Human Intestinal Tract 
(MetaHit) consortium, aim to determine what constitutes a ‘normal’ or healthy microbiome. 
Research in this field has recently been greatly accelerated by the development of 
methods for microbial profiling without the requirement to culture organisms, using high-
throughput sequencing methods. 
 
1.5.1 Microbial amplicon sequencing 
 
Culture independent molecular investigations using the 16S rRNA have become the 
foundation for identifying and characterising microbes.  With the advent of next generation 
sequencing, 16S rRNA profiling has taken a back seat to newer approaches such as 
metagenomics. Metagenomics has been favoured as it facilitates a more comprehensive 
view of the microbial community by providing the communities overall functional potential 
as opposed to simply a list of microbial inhabitants. However, 16S rRNA marker genes 
studies are making a return to more widespread use and are becoming the standard 
method for community profiling. This is due to significant advances in sequencing 
methodology and analysis programs (107).  
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1.5.2 The 16S rRNA 
 
16S ribosomal RNA (rRNA) is a section of prokaryotic DNA found in all bacteria and 
Archaea. 16S rRNA sequences are used to differentiate between organisms across all 
major phyla of bacteria and to classify strains down to species level (108). 16S rRNA 
sequencing has dramatically changed our understanding of phylogeny and microbial 
diversity because it provides an unbiased assessment of the microbiome, and is not 
restricted by the ability to culture the bacteria present. This commonly used ribosomal 
RNA gene sequence analysis is a powerful method for identifying and quantifying 
members of microbial communities (109). The 16S rRNA gene can be compared not only 
among all bacteria but also with the 16S rRNA gene of Archaebacteria and the 18S rRNA 
gene of Eukaryotes (109).  The 16S rRNA sequence is ~1,550 bp long, highly conserved 
and is composed of both variable and conserved regions (Figure 1.3). The gene is large 
enough and has sufficient interspecific polymorphisms as to provide distinguishing and 
statistically valid measurements with the variable portions of the 16S rRNA is used for 
comparative taxonomy (110). There are nine diverse, species-specific variable regions 
denoted as V1-9 (Figure 1.3), which can be used to infer phylogenetic relationships. This 
gene also allows the analysis of microbial communities by way of high-throughput 
sequencing. The 16S rRNA gene sequences allows for differentiation between organisms 
across all major phyla of bacteria and has the ability to classify strains at multiple levels 
including the species and subspecies level. Similar 16S sequences are then clustered 
together to form operational taxonomy units (OTUs). Sequences can be clustered two 
ways; the first is open reference where sequences are clustered by similarity with respect 
to the other sequences clustered at the same time. The second is closed reference where 
sequences are clustered at a certain threshold of sequence similarity, such as 97% (111) 
against a specific reference database. Clustering at a maximum sequence identity 
threshold of 97% has been widely adopted as a measure to avoid over estimating diversity 
by inadvertently mapping sequence error (112).  The sequence clusters are then mapped 
to a database, such as Greengenes or ARB/Silva, and assigned taxonomy based on 
sequence similarity (113). One drawback of the 16S rRNA technique cannot be used to 
compare strains for epidemiological purposes or to detect a specific strain virulence 
factors.  The 16S rRNA gene does not contain enough variation for strain resolution and 
does not encode virulence factors. However variations on this gene analysis using variable 
regions, can infer functionality including metabolism (114, 115). 
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Figure 1.3 Cartoon depiction of the 16S rRNA gene. Modified 16S rRNA gene highlighting the 
variable regions of the gene commonly used for taxonomy. Circled in red are the two constant 
commonly used and circled in yellow is the V3-V5 region commonly used for amplicon sequencing 
in the gut.  
1.5.3 Metagenomic sequencing  
 
Further improvements in sequencing technologies have reduced the need for targeted 
studies such as 16S sequencing, and enabled high throughput shotgun sequencing. This 
type of sequencing randomly samples all genes present in a habitat rather than just 16S 
rRNA. Shotgun sequencing provides more information about the microbiome than just the 
16S characterisation, which is of particular benefit in determining the functional capacity of 
the microbial community, rather than just its phylogeny.  However shotgun sequencing is 
more complex to analyse, including the challenge of distinguishing between host and 
bacterial genomic material, and requires far more sequencing to be performed.  Therefore 
most studies to date have relied on 16S rRNA sequencing approaches. 
 
1.5.4 Advances in tools for metagenomic studies 
 
Several sequencing technologies have been developed for human genetic studies and 
have since been adapted to metagenomics. Roche’s 454 sequencing platform uses large-
scale parallel pyrosequencing to produce reads of between 450bp to 1000bp length. Read 
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lengths produced by the 454 platform are well suited to 16S rRNA amplicon metagenomics 
studies as well as shotgun sequencing as they are easily aligned to reference bacterial 
genetic datasets. Illumina’s sequencing platforms, the HiSeq2000 and MiSeq, produce 
shorter reads than the Roche 454 however, in the last 2yrs or so, the MiSeq has over 
taken from Roche as the standard platform for 16S rRNA amplicon sequencing. The HiSeq 
was primarily designed for human genomic sequencing and current chemistry produces 
100bp paired-end reads. Illumina sequencing is best suited for shotgun sequencing or 
indexed amplicon sequencing of multiple samples. The MiSeq however has rapidly 
become the go to platform for amplicon sequencing due to its reduced shorter sequencing 
runs, longer amplicon reads  
 
This is a rapidly developing field. Advances in chemistry are predicted to increase both 
read-lengths and output for both of these platforms over the next 12-24 months, 
particularly for the Illumina platforms that are less mature than the Roche 454. New 
platforms coming to the market are likely to have a major impact on metagenomics study 
design. For example, the Pacific Biosystems sequencing technology provides reads of 
~3000 bases, which will make it particularly suited to this field, despite its lower overall 
output (~450Mb – 1GB of sequence per run). Life Technologies Ion Torrent technology is 
reported to produce up to 400 base reads and up to 1Gb of sequence per run. The relative 
position of these competing technologies in metagenomics has yet to be established. 
 
1.6 Dynamics of the gut microbiome 
 
There are more microbes on the human body than cells, and about 29% of all these reside 
in the gut.  The human gut microbiome contains a dynamic and vast array of microbes that 
are essential to health as well as provide important metabolic capabilities. Until recently 
studying this community has been difficult and generally limited to classical phenotypic 
techniques (109, 116). The application of molecular techniques, particularly sequencing, 
has shown the remarkable amount of diversity in the human gut, exceeding all previous 
held beliefs. Originally the dominant species was thought to be E. coli, pathogen detection 
was the primary aim with normal flora disregarded and considered inconsequential. 
Recent studies using sequencing as the investigative tool have shown that members of the 
phyla Firmicutes, Actinobacteria and Bacteroidetes are abundant in healthy individuals 
(114, 116). Given that the gut plays a major role in metabolism, pathogen resistance, as 
well as the body’s immune response, it is important to ascertain what role the human gut 
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microbiome plays with respect to illness and disease; and what influence these 
communities have on disease pathogenesis. To explore this, it must be possible to 
compare microbial communities within and across individuals in different states of disease 
and health (116). 
 
Understanding how the intestinal microbiome is assembled and maintained is becoming 
increasingly relevant not only to general healthy, but also potentially for the treatment of 
complex chronic diseases. In recent years only a handful of studies have examined the 
composition, diversity and function of the human gut microbiome.  
 
Studies comparing the gut microbiota of lean and obese twins have shed light on the 
importance of intestinal microbes and how a change in microbiome composition can affect 
food metabolism in the gut (114, 117, 118). Turnbaugh et al showed that even with a 
similar genetic make-up, obese twins had substantial differences in the composition and 
diversity of their gut flora with a dominance of Gram Positive bacteria from the phylum 
Firmicutes, compared with discordant or lean twins (114). This shift in gut flora 
composition altered how food was broken down and metabolised in the gut, leading to 
increased body mass index, adiposity and obesity (114, 117, 119). This demonstrates that 
shifts in the intestinal microbiome have functional consequences on the health of the 
individual (120). To further interrogate structure and function of the gut microbiome, and 
the consequences of shifts and alterations, faecal samples from four twin pairs discordant 
for obesity were transplanted into germ free mice (121). The authors found that the 
Firmicute phylum dominated microbial communities from the obese twin lead to obesity in 
the germ-free mice. The Bacteroides dominated microbial communities from the lean mice 
kept the germ-free mice lean. When the mice were co-housed, the invasion of Bacteroides 
from the lean mice lead to a decrease in adiposity and body mass in obese mice and 
transformed their microbiota’s metabolic profile to a lean-like state (121).  
 
Maslowski, Vieira et al. 2009 suggests that not only can diet induce changes in the gut 
microbial community, but these associated changes may also be underpinning 
inflammatory disease.  The authors suggest that a lower intake of fibre from complex plant 
polysaccharides adversely affects the makeup of the intestinal microbiota, which leads to 
less production of immunomodulatory products in particular short-chain fatty acids (SCFA). 
These SCFA are produced by the phylum Bacteroidetes, so a shift in the flora from 
predominantly Bacteroidetes to Firmicutes due to a more western diet with less fibre, 
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reduces the amount of SCFA secreted. The effect SCFA has on the immune response 
was investigated in a mouse strain deficient in single G protein–coupled receptor, GPR43 
(122).  Mice lacking GPR43 failed to suppress inflammation in models of colitis, arthritis 
and asthma, as did germ-free wild-type mice also lacking SCFA.  Wild type mice raised in 
non-germ-free conditions were able to suppress inflammation.  This suggests that diet-
induced reduction in faecal SCFA leads to a reduced ability to suppress a variety of 
inflammatory conditions.  
 
1.7 The normal microbiome 
 
These studies have shown that shifts in microbiome can change metabolism; however, 
they do not provide details of what constitutes a ‘normal’ microbiome or how it behaves. 
Two large studies interrogating and cataloguing microbiomes from various regions of the 
body in health and disease have been undertaken by the National Institute of Health 
Human Microbiome Project in the USA and the European MetaHit project (123-125). The 
Human Microbiome Project was established for the purpose of identifying and cataloguing 
the human microbiome by sequencing samples from 242 individuals (129 males, 113 
females) across five major body sites, including the mouth, skin, stool and vaginal tract, 
multiple times with the aim of interrogating within subject variation, between subject 
variation as well as microbiome variation over time. A total of 4,788 specimens were 
sequenced with females sampled from 18 different habitats and males from 15 habitats 
(126). Diversity and abundance of each habitat’s signature microbes was found to vary 
greatly amongst the healthy subjects, with strong niche specialisation found both within 
and between individuals, demonstrating the dynamic nature of the microbiome (126-128). 
Metagenomic carriage of metabolic pathways was found to be stable amongst individuals, 
despite the variation seen within community structure. When clinical metadata was 
present, ethnic background proved to be one of the strongest predictors of both pathways 
and microbes. This suggests that environmental factors such as diet, location/region and 
host genetics could play a role in sculpting the microbiome. These studies further define 
the range of structural and functional configurations that are present in normal microbial 
communities in a healthy population (123, 126). 
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1.7.1 Enterotypes 
 
The European MetaHit consortium combined published data sets from across the world 
and added 22 newly sequenced faecal metagenomes from four different European 
countries. They identified three robust clusters, termed ‘enterotypes’, that were not nation 
or continent specific. These enterotypes characterised the microbial phylogenetic variation 
as well as the function variation of the clusters at gene and functional class levels (123).  
 
Each enterotype had a dominant bacterial genus: Enterotype 1 dominated by the genus 
Bacteroides; enterotype 2 by Prevotella; and enterotype 3 by Ruminococcus. The three 
enterotypes were also shown to be functionally different.  For example enterotype 2, which 
is Prevotella dominant, also contains Desulfovibrio, which may act in synergy with 
Prevotella to degrade mucin glycoproteins present in the mucosal layer of the gut. It may 
be that different enterotypes may be associated with diseases such as obesity and IBD, 
rather than necessarily specific bacterial species, given their differing functional capacities.  
However, recent work suggests that the boundaries between the enterotypes are more 
vague than initially described. Multiple datasets including the Human Microbiome Project 
16S rRNA gene sequence data and metagenomes with similar published data were 
interrogated for the existence of enterotypes across multiple body sites. However, rather 
than forming enterotypes, many of the samples examined fell into sliding scale based on 
taxonomic abundances of bacteria such as Bacteroides, rather than discrete enterotypes 
(129). Moreover, metatanalysis demonstrated that many of the methods used in the 
analysis of enterotypes, such as clustering approaches and distance metrics affected the 
likelihood of identifying enterotypes in particular body habitats.  This suggests enterotypes 
are not discrete but are continuous and vary widely amongst individuals (130).  
1.7.2 Homeostasis 
 
Microbes and humans have evolved over time to live in symbiosis with each other. Many 
of these diverse communities carry out specific tasks that benefit the host, as well as the 
microorganisms A balancing act between war and peace exists within the gut between 
resident microbial members of the gut and potential pathogenic and non-pathogenic. It is 
well documented that changes in the microbial composition in the gut by a pathogen, elicit 
an innate immune responses (131). However, it is still unknown if a shift or dysbiosis in the 
gut flora has the capacity to illicit the same response as an infection as the gut tries to 
defend its self and restore homeostasis (132). Homeostasis of the normal flora in the gut 
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microbiome is essential, and both the bacteria that inhabit the gut and the human immune 
system have developed strategies to regulate and protect it. Bacteria in the intestine have 
several techniques including competitive exclusion, biosurfactant production and 
modulation of tight junctions (9). The human body has a number of physiological 
processes that respond to a disruption in gut homeostasis or bacterial insult. If a bacterial 
insult is detected by antigen presenting cells (APC), such as a dendritic cell, naïve T cells 
are then activated and recruited to the area. IL-17 secreting Th17 cells are sequestered to 
induce epithelial cells to recruit neutrophils to the area to neutralise the disruption and in 
concert, IL-22 is secreted to promote epithelial repair and antibacterial proteins (133). The 
epithelial cells lining the intestine can also respond to a disturbance or insult and attempt 
to restore homeostasis by secreting a range of soluble factors such as mucins and AMPs 
that aim to prevent the invasion of microbes into the intestinal crypt (30-32, 134). 
 
1.8 Influence of underlying host genetics on the intestinal microbiome 
 
A key issue in microbiome research is determining whether host genetics directly 
influences changes in microbiome composition or indirectly via the immune system.  The 
extent that underlying host genetics influences intestinal microbial community composition 
in humans is unclear. Host gene deletions have been shown in animal models to cause 
shifts in microbiota composition (135). Moreover, a recent quantitative trait locus mapping 
study linked specific genetic polymorphisms with microbial abundances (136). These 
studies highlight the importance of underlying host genetics in community composition in 
animals. The role of host genetics is of interest in diseases such as IBD, where many of 
the genes associated with disease are involved in handling, processing and response to 
microbes such as IL23R, NOD2, NOS2 and CARD9. Genetic studies in CD, one of the two 
common forms of IBD, shows a marked over-representation of genes, notably NOD2 and 
TNFRSF18, which are associated with an increased risk of developing mycobacterial 
diseases, including leprosy and tuberculosis (23). There is significant overlap between the 
risk of developing leprosy and CD, with seven of the eight known genetic variants 
associated with an increased risk of leprosy, including SLC11A1, VDR and LGALS9, also 
associated with an increase the risk of CD; compared with only two being associated with 
risk of any other immune-mediate disease. Combined with dramatic shifts in the gut 
microbiota composition associated with IBD (23, 135), this strongly indicates a potential 
link between host genetics and the microbiome in IBD patients. The genetic influence over 
microbiome composition is further highlighted in a study of 416 monozygotic and dizygotic 
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twin pairs investigating the heritability of the gut microbiome in obesity. The authors found 
the most heritable taxon was the family Christensenellaceae (137).This particular family of 
bacteria is only recently described and was shown to be central to a network of co-
occurring heritable microbes associated with lean body mass index. Animal studies 
showed that the introduction of any of the members of the Christensenellaceae family had 
the capacity to protected the mice from weight gain (137). Variation and shifts in the gut 
microbiome have until recently been associated with diet and the environment or natural 
variation. Even though the exact gene-microbe association with the Christensenellaceae 
family still remains unknown, this study demonstrates that microbiome composition may in 
part be due to host genetics (137).  
 
1.9 The microbiome in immune mediated disease 
 
1.9.1 Ankylosing spondylitis 
 
To date no study has been reported investigating the gut microbiome using sequencing 
based methods in AS.  One study using denaturing gradient gel electrophoresis to profile 
the microbiome using faecal samples found no differences between AS cases and healthy 
controls (16). .  Many studies largely using antibody tests have suggested an increased 
carriage of Klebsiella species in AS patients, however this has not been universally 
supported (17). Several specific bacteria have been suggested to have a role in AS 
pathogenesis particularly Klebsiella pneumoniae (138, 139) and Bacteroides vulgatus 
(140) although current studies using antibody tests have been unable to produce 
convincing evidence demonstrating increased infection with any specific triggering agent 
influencing AS development. K. pneumoniae and B. vulgatus have been of considerable 
focus for several reasons. Increased levels of B. vulgatus have linked to colitis in the HLA‐
B27/β2 microglobulin transgenic rats. When the HLA‐B27/β2 microglobulin transgenic rats 
were raised germ free and subsequently colonised with an intestinal bacterial cocktail, the 
rats developed more several colitis when increased amounts of B. vulgatus were present 
(141). Substantial research effort has been directed towards the possible involvement of K. 
pneumoniae. Early work examining the faeces of AS patients during active disease, 
reported the presence of K. pneumoniae (142). As well as during active disease, Studies 
have also reported elevated levels of serum antibodies against K. pneumoniae in patient 
sera (143). Adding to the suspected involvement of K. pneumoniae, the antigenic similarity 
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noted between Klebsiella and HLA‐B27 (144) have been noted. However, recent studies 
have been unable to confirm a role of Klebsiella AS pathogenesis.  
 
As well as specific bacteria triggering disease, it has also been speculated that 
antimicrobial reactivity can develop during intestinal inflammation. There have been a 
number of antibodies described over the years, including anti-Saccharomyces 
cerevisiae antibodies (ASCA), anti-I2 antibodies (which are associated with anti-
Pseudomonas activity), perinuclear antineutrophil cytoplasmic antibodies (pANCA), anti-
Escherichia coli outer membrane porin C (anti-OmpC) antibodies, as well as anti-flagellin 
antibodies (anti-CBir1), that have shown to have clinical significance in IBD (145, 146). 
Given the overlap between IBD and AS, the prevalence of several of the above 
antimicrobial antibodies were examined in the serum of 80 AS patients and healthy 
controls. While there was no difference in the number of antibody positive results between 
AS patients and healthy controls, AS patients were more likely than healthy controls to 
have elevated levels of anti-I2 and ASCA antibodies (147).  A recent study has shown of 
anti-CBir1 antibodies are elevated in patients with AS with IBD compared to patients who 
only have AS (148). Moreover, patients with AS only had increased levels of anti-CBir1 
antibodies when compared to healthy controls.  This data suggests that AS patients have 
an increased exposure of the immune system to commensal bacteria, causing the 
antibody production. Increased levels of anti-CBir1 antibody in AS patients, compared to 
healthy controls, could be accounted for, at least in part, by microscopic gut inflammation 
even in the absence of clinical gastrointestinal symptoms (149). While this observation 
requires further investigation, the development of anti-CBir1 antibodies in patients with AS 
raises the intriguing question of their pathophysiological significance with regards to 
commensal bacteria, and more specifically commensal bacteria with flagella.  
1.9.2 Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is the only inflammatory arthritis for which modern metagenomic 
studies have been reported. Community profiling studies of RA patients’ gut flora reveal 
differences in the composition of RA patient’s gut microbiota compared with healthy 
controls, with a lower abundance of Bifidobacterium and Bacteroides bacteria observed in 
RA cases (150, 151). However, these studies were undertaken using faecal samples and 
not intestinal biopsies, possibly influencing the populations and the proportions observed 
(152, 153). It is not just the intestinal microbiome that has an implicated in RA 
pathogenesis. There is microbial profiling data that suggests that the oral microbiome, 
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specifically a periodontal infection with the common pathogen Porphyromonas gingivalis, 
may be important in RA pathogenesis. P.gingivalis, which has also been identified in 
synovial fluids of RA patients (154), has the ability to citrullinate host peptides like 
smoking, which subsequently generates auto antigens that drive autoimmunity in RA 
(155).  
 
1.9.3 Inflammatory Bowel Disease 
 
Several lines of evidence indicate that the gut microbiome plays an important role in IBD, 
including the association of genes involved in mucosal immunity with IBD (such as 
CARD15, CARD9, IL23R and ATG16L1), the therapeutic effect of antibiotics on the 
condition, and the beneficial effect of faecal stream diversion in CD.  Previous studies of 
human IBD have been undertaken using standard culture techniques (156) or molecular 
analysis (157, 158). These studies noted alterations in intestinal microbiota when 
compared to non-IBD patients, a finding recently confirmed using 16S rRNA sequencing of 
intestinal biopsies (159). A recent study examined the intestinal microbiome in treatment 
naïve new-onset CD, and described microbial signature. 16S community profiling intestinal 
and faecal samples showed that the signature comprised of an increased abundance in 
bacteria including Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and 
Fusobacteriaceae, and decreased in abundance of Erysipelotrichales, Bacteroidales, and 
Clostridiales and correlate strongly with disease status (153).  
 
1.9.4 Psoriasis 
 
The microbiome is thought to play a significant role in psoriasis, another AS-related 
condition. It has long been suggested that streptococcal infection, especially throat 
infections, may trigger psoriasis in a genetically susceptible individual (160).  Recent 
studies using 16S rRNA sequencing have found significant differences between the 
cutaneous microbiota of psoriasis cases and controls, and in psoriasis involved and control 
skin in psoriasis cases, with less Staphylococci and Propionibacteria observed in cases 
and in affected skin (161).  Again, further studies will be required to determine if there is a 
particular microbial profile or specific bacterial species involved in psoriasis. These studies 
are thus consistent with the hypothesis that the microbiome contributes to the 
aetiopathogenesis of the immune mediated arthritis or seronegative diseases like IBD and 
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psoriasis.  However at this point, with the exception of reactive arthritis, there is no 
definitive evidence of specific bacterial infections or changes in microbial profile that play a 
causative role in these conditions. 
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1.10 The Chicken and the egg  
 
Whether the changes noted in these microbiome studies of immune mediated disease are 
a consequence of disease or are involved in its development or persistence still remains 
unclear.  This distinction may prove impossible to dissect in human studies, but there is 
considerable evidence in studies in mice to support a role for the microbiome in driving 
immune mediated diseases. 
 
In the B27 rat model of AS, rats housed under germfree (GF) conditions did not develop 
disease (141) demonstrating that microbes in this model are important disease 
penetrance. In contrast, in the New Zealand black (NZB) model of Systemic lupus 
erythematosus, mice maintained under GF conditions produced higher levels of 
antinuclear antibodies and developed worse disease (162) demonstrating a protective role 
for commensal microbes.  
 
Considering the IL-17/IL-22 cytokines, which are of relevance to AS, IBD and psoriasis in 
particular, there is strong evidence from murine studies to indicate that interaction between 
the gut microbiome and the host determines the overall level of activation of the immune 
cells producing these cytokines.  Segmented filamentous bacteria (SFB) are a commensal 
bacteria that induce IL-17 secretion. Mice lacking SFB have low levels of intestinal IL-17 
and are susceptible to infection with pathogenic Citrobacter spp. Restoration of SFB in 
these mice increased the number of gut-resident IL-17-producing cells and enhanced 
resistance to infection (27). Further, using recolonisation studies, investigators have 
recently demonstrated that in neonatal mice, commensal microbes influence iNKT cell 
intestinal infiltration and activation, establishing mucosal iNKT cell tolerance to later 
environmental exposures (163).  
 
The mechanism by which the microbiome influences IL-17 producing cell activation is still 
being determined.  Ivanov and colleagues demonstrated that serum amyloid A, produced 
in the TI, can induce TH17 differentiation of CD4+ T-lymphocytes (27).  It has also been 
shown that development of TH17 lymphocytes in the intestine is stimulated by microbiota 
induced IL-1b (but not IL-6) production (164).  Colonisation with Clostridia species has 
been shown to stimulate intestinal TGFb production, in turn increasing IL-10+ CTLA4high 
Treg activation (105).  Clostridia colonisation of neonatal mice reduced severity of induced 
colitis using DSS or oxazolone, and reduced serum IgE levels in adulthood. So it is likely 
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that alterations to the gut microflora, or invasion of the gut by pathogenic bacteria, 
influence the balance of IL-17- and IL-22-producing cells, and other immune cells, 
influencing susceptibility to local and systemic immune mediated disease.   
 
Dissecting out what is genetic influence on microbiome composition and what is 
environmental is inherently complicated. A recent study by Hildebrand et al., 2013, 
investigated exactly that across five common laboratory healthy mouse strains BALB/c, 
FVB, B6, NOD and Swiss. They found that the gut microbiota differed according to 
genotype, caging and inter-individual variation (165). These factors contributed on average 
19%, 31.7% and 45.5% respectively to the variance in the microbial composition. Genetic 
distance was also found to positively correlate to microbiota distance, indicating that 
strains that are more closely related genetically have more similar microbiota than distantly 
related strains. Microbiota composition was also correlated with inflammation marker 
calprotectin. Mice that displayed low microbial richness had higher levels of calprotectin 
but no obvious signs of inflammation suggesting low-grade inflammation. This study 
demonstrates the influence of genetic background on microbiota composition as well as 
the environmental influences albeit in a controlled setting. This work highlights the 
complexity of host-environment-microbiota interactions (165). 
 
The above studies highlight that changes in the microbiome can lead to inflammation 
which may have far reaching effects, and demonstrate experimental approaches by which 
findings of metagenomic studies in mice and humans can be explored to successfully 
dissect the role of the microbiome in human immune mediated diseases.
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1.11 Thesis outline 
 
This thesis investigates the role of the human gut microbiome in AS by characterising the 
AS microbiome, examining how changes in host genetics influences intestinal microbial 
composition and then exploring at the association between AS susceptibility loci and 
microbiome composition in healthy twin cohort.  
 
1.12 Aims 
 
Aim 1: To establish a pipeline for 16S community profiling the microbial communities 
present in the terminal ileum of patients with AS, compared to CD and HC. 
 
Aim 2: To characterise the terminal ileum of patients with AS and determine if the AS gut 
carries a distinct microbial signature in comparison to HC. 
 
Aim 3: To investigate how loss of ERAP influences the gut microbiome composition, the 
impact this has on the antigen repertoire presented and ensuing affects on the immune 
system. 
 
Aim 4: To investigate the causality between AS susceptibility loci and gut microbiome 
composition.  
 
The above aims will be discussed in separate results chapters that will form the body of 
this thesis. 
1.13 Significance 
 
The human gut microbiome is a dynamic and complex ecosystem that is only now 
beginning to be understood. It is increasingly clear that the interaction between host and 
microbiome profoundly affect health. It is still unclear how interactions between host 
genes, microbes and environmental factors can predispose patients to the development 
autoimmune diseases such as AS. We are only beginning to grasp the influence the 
microbiome has on health. Improved knowledge of the composition and function of the gut 
microbiome in AS patients and how the microbiome shapes the immune response and 
influences inflammation, both local and systemic, will likely provide important insights into 
early events in the pathogenesis of AS. 
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2 Chapter 2 Community profiling the terminal ileal microbiome 
 
2.1 Introduction	  
 
It is increasingly clear that the interaction between host and microbiome profoundly affects 
health. We are more microbe than we are human with over ten times more bacteria and 
their genes living in and on our bodies, with the human intestine containing ~100 trillion 
bacteria. Our ‘second genome’ of microbes are not passive bystanders and only now are 
we beginning to appreciate the influence our microbial residents have on our health. Until 
recently, interrogation of our microbial communities using classical microbiology 
techniques offered a very restricted view of these communities, only allowing us to see 
what we can grow in isolation. Advances in sequencing technologies in the past few years 
have greatly facilitated systematic and comprehensive studies of the microbiome, and 
elucidate its role in human health and disease.  
 
AS has a global distribution, with no outbreaks or clustering being reported. The gene 
identified as having the strongest association with AS development is the major 
histocompatibility complex (MHC) gene HLA-B27. However only 1-5% of HLA-B27+ 
individuals go on to develop AS. Monozygotic twin studies suggest that the trigger for AS 
in a genetically susceptible person is a ubiquitous environmental factor that is most likely 
widely distributed (4, 5). There is a close relationship between the gut and SpA, 
exemplified in reactive arthritis patients, where a typically self-limiting arthropathy follows 
either gastrointestinal infection with Campylobacter, Salmonella, Shigella or Yersinia, or 
urogenital infection with Chlamydia. The mechanism by which AS is triggered, in a 
genetically susceptible individual, is not well understood. Studies in the B27 transgenic rat 
model of AS, supports the idea of a ubiquitous environmental trigger. The B27 transgenic 
rat when exposed to normal commensal bacteria, develop disease while the rats that were 
maintained in a germ-free environment remain disease free (15). CD is a common form of 
IBD where, again, interplay between host genetic factors and largely undefined 
environmental factors are thought to drive the disease.   Microbial involvement, especially 
from the gut, has been associated in both diseases however in AS, no definitive link has 
been established (16, 17). 
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There is a strong overlap between AS and CD, 70% of AS patients have subclinical gut 
inflammation with 5-10% of these patients with more severe intestinal inflammation 
developing clinically defined IBD resembling CD (7).  Multiple genes associated with AS 
also play a role in gut immunity, and there is a marked over-representation of genes 
associated with CD also being associated with AS (20). Of these loci and genes identified, 
of particular interest are genes involved in the IL-23 pathway including STAT3, IL23R, and 
IL12B (which encodes IL-12p40, the share subunit of IL-23 and IL-12 (20-22). In the 
intestinal mucosa IL-23, IL-17 and IL-22 producing cells are enriched with IL-17 and IL-22 
are known to be important regulators of intestinal ‘health’. IL-17 plays important roles in 
intestinal homoeostasis. In the gut, innate-like immune cells act as sentinels, responding 
very rapidly to alterations to the microbial composition of the gut with rapid secretion of IL-
17. Loss of function polymorphisms in IL23R are associated with protection from AS (55) 
and IBD (57), and many other genes in the IL-23 pathway are associated with these 
diseases.  This suggests that similar aetiopathogenic mechanisms may likely involve the 
gut microbial communities and that dysbiosis of the gut flora is a significant contributor to 
disease.  There have been several studies have shown that AS patients and their first-
degree relatives have increased intestinal permeability relative to unrelated healthy 
controls, again consistent with a role for the gut microbiome in the disease (11). Whilst 
there are significant genetic similarities, major differences also exist between the genetics 
of IBD and AS, with AS showing no association to date with NOD2/CARD15 or the 
autophagy gene ATG16L1, which are major susceptibility factors in IBD, whereas IBD 
shows no association with HLA-B or ERAP1 which are the strongest AS-susceptibility 
genes (166).  
 
Together, the multi-factorial components of the immune system shape the microbial 
population that inhabits the gut and, to an extent, vice versa, with each side pushing to 
establish a stable state. Understanding the yin and yang of this relationship is at the heart 
of current microbiome research. Microbiome refers to the totality of microbes, their genetic 
elements and environmental interaction in a defined environment (106). The human body 
has more microbes living on it or in it, than it does human cells with approximately 29% of 
all these microbes residing in the gut.   Homeostasis of the intestinal microbiome and 
relationship between the microbes that inhabit the gut and the immune system is critical. 
The gastrointestinal tract is heavily populated with microbes and is the primary site for 
interaction between these microorganisms and the immune system (25, 26). Furthermore, 
microbes found in the gut help to shape host immune systems from an early age. The 
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incomplete development of the immune system in neonates and under germ-free 
conditions tells us that microbiota sculpt the host immune system (27, 28). Maintenance of 
intestinal and microbial homeostasis is being increasingly recognised as playing a pivotal 
role in overall health (29), and dysregulation of either gut or microbial homeostasis may 
play a role in autoimmunity. Physiological processes in the host that maintain gut 
homeostasis and respond to perturbance in the gut micro-environment involve both the 
adaptive and innate immune system, and the barrier function of the intestines themselves, 
have been implicated in a number of immune mediated diseases, including multiple 
sclerosis, inflammatory bowel disease, and type I diabetes (25, 102, 167, 168).  
 
The human gut microbiome contains a dynamic and vast array of microbes that are 
essential to health as well as provide important metabolic capabilities. Until recently 
studying these complex communities has been difficult and generally limited to classical 
phenotypic techniques (109, 116). The application of molecular techniques, particularly 
sequencing, has shown the remarkable amount of diversity in the human gut, exceeding 
all previous held beliefs and expectations. Development of high-throughput sequencing 
methods has greatly improved our ability to profile complex microbial communities without 
the requirement to culture organisms. The gene commonly used for community profiling is 
the 16S ribosomal RNA (rRNA). This ~1,550bp section of prokaryotic DNA is found in all 
bacteria and archaea, is highly conserved and is composed of both variable and 
conserved regions. The 16S rRNA is able to differentiate between organisms across all 
major phyla of bacteria and to classify strains down to species level (108). 16S rRNA 
sequencing has dramatically changed our understanding of phylogeny and microbial 
diversity because it provides an unbiased assessment of the microbiome, and is not 
restricted by the ability to culture the bacteria present.  
 
The aim of this chapter was to establish a pipeline to characterise the microbial community 
present in the terminal ileum of patients with AS compare to CD and healthy controls (HC). 
This included tissue extraction methods for optimal microbial recovery, choice of 16S 
amplicon sequencing as well as analysis strategy. To validate the pipeline, a pilot study 
was undertaken consisting of four AS patients, three CD patients and four HC to determine 
whether the gut microbiome of AS patients is different and distinct from CD patients and 
HC. This pilot study also included the use of two mock communities consisting of well 
characterised bacteria of known concentrations that served as internal sequencing and 
analysis controls. In addition to exploring community-level composition and differences 
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between affection states, we also evaluated technical replication by sequencing from both 
forward and reverse primers and analysing them separately.  Biological replication was 
assessed by halving biopsies, then processing and analysing them independently. The 
resulting sequence libraries were analysed using the QIIME pipeline as described in the 
Material and Methods (169).  To determine differences in microbial load, total microbial 
biomass in biopsy samples was quantified using real-time qPCR of the 16S rRNA gene as 
described in Willner et al., 2013 (170). 
 
2.2 Materials and Methods 
 
2.2.1 Optimisation of 16S primers 347F 803R and 517F 803R 
These two primer pairs spanning the V3-V5 region were optimised using a mock 
community of enteric bacteria, a human cell line control and a TI biopsy. The mock 
community consists of five enteric bacteria Escherichia coli, Klebsiella pneumonia, 
Klebsiella oxytoca, Enterobacter spp., Citrobacter spp. and as well as Listeria 
monocytogenes. A human cell line control was used to test if the primer set amplified 
human DNA as well as bacterial DNA. The primer pairs 347F 803R and 517F 803R were 
taken through to sequencing as their amplicon size was compatible with the requirements 
of Illumina sequencing of 300-500bp including linkers and adaptors.  
 
2.2.2 16S rRNA PCR 
The master mix for the reactions in a 25ul total volume using Bioline 10x reaction buffer, 
dNTP(0.625mM), mgcl2 (2.0mM), 1U of Bioline TAQ, both primers 5uM each and 2ul 
DNA. Thermocycling conditions comprised 10 min 94ºC then 30 cycles at 94ºC 50 s, 54º 
30 s, 72ºC 45 s and 72ºC 10 min. 
2.2.3 In silico assessment of Primer pairs 
To compare the spectrum of diversity of our two primer sets in silico library simulation was 
conducted using Grinder was used to generate mock data sets from the microbial refseq 
library (NCBI) aligning to whole genomes (171). These data sets consisted of 10 patients 
that contained 1000 reads per library. Reads were generated this way to best represent 
what will likely happen with patient gut biopsies as well as to cache the microbial diversity.  
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Data sets were analysed using the QIIME pipeline (qiime.sourceforge.net) (172). OTU 
assignment was based on 97% similarity with taxonomic assignments made using BLAST 
to Greengenes (113) as implemented in QIIME.    
2.2.4 Pipeline optimisation Intestinal Biopsies 
Resected colon Biopsies were collected from patients with diagnosed with either 
Ulcerative colitis (UC) or Crohn’s disease (CD) courtesy of A/Prof Graham Radford-Smith 
for the purpose of the pilot study and protocol optimisation (Table 2.1). 
 
 
Table 2.1 Intestinal biopsies utilised for pipeline optimisation.  
 
Biopsy ID Sample 
description 
Histology Diagnosis DNA 
Concentration 
ng/ul 
Q1462 Ileum Non-Inflamed UC 128.15 
A457 Ileum Non-inflamed UC 54.57 
12.001.08 Ileum Inflamed CD 48.95 
53.001 Colon Inflamed UC 9.77 
83.001.03 Ileum Inflamed CD 113.82 
 
2.2.5 Sequencing of Pilot intestinal biopsies 
To compare the two primer sets five gut biopsies were amplified with 347F 803R and the 
same six were amplified with 517F 803R, multiplex and run on the HiSeq.  10 16S rRNA 
amplicon libraries were generated from five gut biopsies and converted to Illumina HiSeq 
compatible prior to adaption of ligation of barcodes the amplicon libraries were QC 
checked using the bioanalyzer (Agilent) looking for discrete peaks at 286bp and 456bp. 
1µg amplicon library were constructed using the TruSeq DNA sample preparation kit 
(Illumina) as per manufacturer’s instructions, commencing at the end repair stage and 
omitting both the fragmentation and gel purification steps. The final library underwent QC 
on the Agilent Bioanalyzer to confirm that indexing was successful, by looking for a shift in 
the discrete peaks to 386bp and 556bp respectfully. These libraries were then pooled for 
multiplexing using equimolar proportions of each library to a final concentration of 2µM.   
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Table 2.2  Pipeline optimisation sequencing metrics. 
 
Gut biopsy  Primer set Number of 
sequences per 
library  
Q1462347F 347F 803R 2681259 
Q1462517F 517F 803R 2341819 
A457347F 347F 803R 2281754 
A457517F 517F 803R 2263814 
12.08347F 347F 803R 2739502 
12.08517F 517F 803R 2198014 
53.01D347F 347F 803R 2265574 
53.01517F 517F 803R 2347683 
83.03347F 347F 803R 1384798 
83.03517F 517F 803R 1421586 
 
 
2.2.6 Bioinformatics 
10 16S rRNA amplicon libraries were generated from five gut biopsies using the two primer 
sets and sequenced on the Illumina HiSeq (Table 2.2). The multiplexed reads were de-
multiplexed using the Illumina program CASAVA. Fastq reads were converted to QIIME 
format using custom script. Samples were analysed using the QIIME pipeline 
(qiime.sourceforge.net) (169). OTU assignment was based on 97% similarity with 
taxonomic assignments made using BLAST to Greengenes(113) as implemented in 
QIIME. 
 
Sequence depth analysis was conducted by sub setting samples at –n 1000, 5000, 10 
000, 50 000, 100 000, 500 000 and 1 000 000 reads per sample and then graphed using 
the plot_rank_abundance_graph.py as implemented in QIIME.  
 
2.2.7 Community profiling the terminal ileal microbiome 
2.2.7.1 Ethics statement 
Written informed consent was obtained from all subjects, and the study protocol was 
approved by the local ethics committee of the University of Palermo. 
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2.2.7.2 Patient clinical data 
AS patients were diagnosed according to the modified New York criteria for the disease 
(173).  No AS and CD patients were receiving biological agents such as TNF-inhibitors, 
and only one AS patient was on nonsteroidal anti-inflammatory (NSAIDs) drugs at time of 
biopsy sampling.  Healthy controls were undergoing ileocolonoscopy for routine evaluation 
(Table 2.3). 
 
2.2.7.3 DNA extraction and sequencing 
TI biopsies were thawed and then divided to create biological replicates. Each was then 
manually disrupted using a polypropolene disposable pestle from Sigma. DNA extractions 
were performed using the Qiagen DNeasy tissue extraction kit as per manufacturer’s 
instructions.  
 
 
 
 
57 
Table 2.3 Clinical details of patients used in preliminary community profiling studies. 
 
 
 
 
 
 
 
 
 
 
ID Diagnosis Biopsy 
Site 
Age Disease 
duration 
CRP mg/l  
(0-10mg) 
HLA-B27 Treatment 
AS01 Ankylosing 
spondylitis 
Ileum 56 7 years 18 Pos NSAID 
AS02 Ankylosing 
spondylitis 
Ileum 33 4 years 1 Pos None 
AS03 Ankylosing 
spondylitis 
Ileum 24 5 years 5 Pos None 
AS04 Ankylosing 
spondylitis 
Ileum 22 3 years 3 Pos None 
CD01 Crohn’s 
disease 
Ileum 44 12 months 12 N/A Mesalazine 
CD02 Crohn’s 
disease 
Ileum 32 4 months 6 N/A none 
CD03 Crohn’s 
disease 
Ileum 47 7 months 8 N/A Mesalazine 
HC01 
 
None Ileum 58 N/A 0.3 N/A N/A 
HC02 
 
None Ileum 43 N/A 0.5 N/A N/A 
HC03 
 
None Ileum 38 N/A 0.05 N/A N/A 
HC04 
 
None Ileum 65 N/A 0.8 N/A N/A 
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2.2.7.4 Bacterial Mock communities 
Mock communities consisting of six different bacteria, Gram positive and Gram negative, 
was employed as a control for both sequencing and bioinformatic analysis and was 
processed alongside the TI biopsies. The six bacteria used were Staphylococcus aureus 
(ATCC 25923), Enterococcus faecalis (ATCC 51299), Haemophilus influenzae 
(ATCC49247), Klebsiella oxytoca (ATCC 700324), Escherichia coli (ATCC 35218) and 
Yersinia enterocolitica (ATCC2 3715). Bacteria were extracted using the Qiagen DNeasy 
tissue extraction kit as per manufacturer’s instructions. Two communities were then 
constructed using differing and varying concentrations of the seven bacteria and labelled 
Mock1 and Mock2.  
 
Two mock communities (Tables 2.4 and 2.5) were created as PCR and sequencing 
controls. The first mock community (Mock1) contains six bacteria at varying concentrations 
and then pooled.  The second mock community (Mock2) contains the same six bacteria 
and was normalised for 16S copy number to 10ng/ul and then pooled at varying ratios.  
 
 
Table 2.4 Mock1 construction using bacteria at varying concentrations.   
 
Bacteria Concentration 
ng/ul 
Dilution Pooled 
amount 
ul 
Relative 
abundance  % 
Y. enterocolitica 28.39 Neat 10 89.1 
E. faecalis 7.49 1:10 10 8.9 
K. oxytoca 31.08 1:100 10 0.9 
H. influenzae 5.47 1:100 10 0.9 
S. aureus 17.89 1:1000 10 0.1 
E. coli 12.47 1:1000 10 0.1 
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Table 2.5 Mock2 – 16S copy number normalised to 10ng/ul at varying ratios. 
 
Bacteria Concentration 
ng/ul 
16S copy 
number 
Pooled 
amount 
ul 
Relative 
abundance  % 
Y. enterocolitica 28.39 7 3 21.4 
E. faecalis 7.49 4 1 7.1 
K. oxytoca 31.08 8 4 28.7 
H. influenzae 5.47 6 2 14.3 
S. aureus 17.89 5 1 7.1 
E. coli 12.47 4 3 21.4 
 
 
 
2.2.7.5 16S rRNA PCR 
Bacterial 16S rRNA amplicon PCR was conducted using the V4 primer spanning the 
region 517F 803R of the 16S gene. The master mix for the reactions in a 25ul total volume 
using Bioline 10x reaction buffer, dNTP(0.625mM), mgcl2 (2.0mM), 1U of Bioline TAQ, 
both primers 5uM each and 2ul DNA. Thermocycling conditions comprised 10 min 94ºC 
then 30 cycles at 94ºC 50 s, 54º 30 s, 72ºC 45 s and 72ºC 10 min. 
 
2.2.7.6 Sequencing Library preparation  
16S rRNA amplicon libraries were assembled and indexed for multiplexing using the 
Illumina TruSeq DNA library protocol as per manufacturer’s instructions. Samples were 
then normalized using the Agilent Bioanalyzer and pooled for sequencing at a 
concentration of 2nM.  To create the required complexity for sequencing, PhiX was added 
to the pool at 50/50 for a final pool concentration of 4pM.  
 
2.2.7.7 Illumina MiSeq Sequencing 
Barcoded 16S amplicon sequences were sequenced with 2x150bp paired-end on an 
Illumina MiSeq with approximately 100 000 reads per sample (Table 2.6).  
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Table 2.6  Counts of 16S rRNA sequence reads obtained per biopsy. 
 
Sample name Total sequences 
AS01a 279,668 
AS01b 170,508 
AS02a 132,010 
AS02b 262,060 
AS03a 115,598 
AS03b 178,534 
AS04a 237,744 
AS04b 219,418 
CD01a 103,896 
CD01b 124,414 
CD02a 185,934 
CD02b 200,200 
CD03a 237,004 
CD03b 272,198 
HC01a 688,184 
HC01b 121,098 
HC02a 316,964 
HC02b 327,222 
HC03a 235,822 
HC03b 241,690 
HC04a 226,356 
HC04b 242,772 
Mock1 284,316 
Mock2 244,840 
 
2.2.7.8 Bioinformatics and statistics 
Reads were de-multiplexed using the Illumina program CASAVA. Fastq reads were 
converted to QIIME format using and amplicon orientated using custom scripts. Samples 
were normalised at 10,000 reads per sample and then analysed using the QIIME pipeline 
(qiime.sourceforge.net) (169). OTU assignment was based on 97% similarity with 
taxonomic assignments made using BLAST to Greengenes(113) as implemented in 
QIIME.    
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Alpha diversity metrics, which look at the diversity within a sample, were generated using 
the QIIME workflow alpha_rarefaction.py with five repetitions at each sampling point. 
Rarefaction curves for the observed number of OTUs were based on the outputs of 
alpha_rarefaction.py. UniFrac distances between microbial communities were evaluated 
using FastUniFrac (174). UPGMA clustering was employed both weighted and 
unweighted, to detect significant differences between microbial communities between AS, 
CD and HC (175). FastUniFrac was also used to generate sample distance metrics as well 
as Principle Coordinates Analysis. 
 
PERMANOVA analysis was conducted on the genus level OTU table using the R package 
vegan to test the relationship between the whole microbial community and disease (176). 
Indicator species analysis, using the ‘labdsv’ R package, was employed to investigate 
what microbial species are driving the microbial community and driving the signature 
(177).  
 
2.3 Results 
 
2.3.1 In silico assessment of Primer Pairs  
 
In silico library simulation of the primer pairs 347F 803R and 517F 803R returned 14 and 
21 different phyla respectively. The dominant phyla previously reported to inhabit the gut 
are Bacteroidetes and Firmicutes with lower abundance of Actinobacteria, Proteobacteria, 
Fusobacteria and Verrucomicrobia (152, 178). The purpose of this experiment was to 
demonstrate that the primer pairs covered the range of expected phyla as well as the 
capacity to discriminate other phyla. The results show that, as expected, both primer sets 
were able to classify all dominant and minor phyla as previously reported to inhabit the 
gastrointestinal tract (Table 2.7). This demonstrates that either primer set would 
adequately profile the intestinal microbiome. However, 517F 803R identified seven more 
phyla, including some phyla that have been reported as being low in abundance such as 
Verrucomicrobia and Lentisphaerae (178). Based on the in silico simulation, the primer set 
517F 803R would be better suited to interrogate human gut biopsies moving forward.  
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Table 2.7 Taxon output by Grinder.  
 
Phyla 347f 803R Phyla 517F 803R 
Acidobacteria Acidobacteria 
Actinobacteria Actinobacteria 
Bacteroidetes Bacteroidetes 
Flavobacteria Flavobacteria 
Sphingobacteria Sphingobacteria 
Chlorobia Chlorobia 
Chrysiogenetes Chloroflexi 
Deferribacteres Chrysiogenetes 
Fibrobacteres Deferribacteres 
Firmicutes Deinococci 
Fusobacteria Dictyoglomi 
Nitrospira Fibrobacteres 
Proteobacteria Firmicutes 
Mollicutes Fusobacteria 
 Lentisphaerae 
 Nitrospira 
 Planctomycetacia 
 Proteobacteria 
 Spirochaetes 
 Mollicutes 
 Verrucomicrobia 
 
 
2.3.2 Sequencing of Pilot intestinal biopsies 
 
Preliminary analysis of primer pairs in a pilot study using five colon biopsies showed that 
there were three major phyla observed across the gut biopsies were Bacteroidetes, 
Firmicutes and Proteobacteria (Figure 2.1). This is consistent with what has been reported 
in the literature (114, 152). The minor phyla present include Actinobacteria, Fusobacteria, 
Cyanobacteria, and Acidobacteria with a very low unclassified ‘other’. These ‘others’ may 
be members of the phylum Archea, such as Methanobacteria, which are also common in 
the gut. Using an alternate reference database, such as Silva, may possibly resolve these 
unclassified sequences or they may not be present in the reference databases.  
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The phylum level classification illustrates that the 517F 803R primer set seems to classify 
slightly more members of the Firmicutes phylum, while the 347F possibly classified 
Bacteroidetes better.  The Komolgorov-Smirnov test was run at the phylum level in order to 
evaluate the differences between the two primer sets and to compare the similarities and 
differences between the overall sequences corresponding to the same phyla. Neither of 
the primer pairs came up significantly different from each other as all p-values were 
greater than 0.90. This means that using one primer compared to the other did not cause 
significant differences detected in the community profiles at the phylum level.  
 
 
 
Figure 2.1 Phyla represented in gut biopsies showing percentage abundance. Comparison of 
primer pairs 347F 80R and 517F 803R demonstrating no significant differences when trialled in five 
colon biopsies for the purpose of pipeline optimisation  
 
2.3.3 Sequence depth analysis 
 
Illumina high-throughput sequencing is capable of producing millions of reads, so 
ascertaining the appropriate number of reads required per sample for amplicon 
sequencing is important not only for taxonomy assignment but sample multiplexing as well.  
12.08347F	  
12.08517F	  
53.01D347F	  
53.01517F	  
83.03347F	  
83.03517F	  
A457347F	  
A457517F	  
Q1462347F	  
Q1462517F	  
55.02347F	  
0%	   10%	   20%	   30%	   40%	   50%	   60%	   70%	   80%	   90%	   100%	  
Firmicutes	  
Bacteroidetes	  
Proteobacteria	  
Actinobacteria	  
Fusobacteria	  
Cyanobacteria	  
Acidobacteria	  
Other	  
 
 
64 
Whilst deep sequencing of PCR amplicons enables the detection of rare or low abundant 
organisms, this can also lead to over estimation of microbial diversity by the generation of 
reads containing errors (112, 179).  Recent work by Bokulich et al., 2012 demonstrated 
that strict quality filtering of reads greatly improves taxonomy assignment and α-diversity 
measures for microbial community profiling (180). The five samples from the pilot study 
were sampled at varying read depths ranging from 1000 reads to 1 000 000 reads and 
compared (Figure 2.2). The analysis showed that 1000 and 5000 reads per sample 
detected the least number of species with 500 000 and 1 000 000 reads per sample 
detecting the greatest number. The concern is that the more species being detected may 
not be true and may in fact be sequence error (112). With this in mind the taxonomy 
assignment from 1000 to 50 000 reads was compared, with on minor differences found. 
Based on this 10 000 reads was the depth selected to continue with as it identified the 
same taxa as 50 000 reads and allowed for more samples to be multiplexed.  
 
 
 
Figure 2.2 Rank abundance graph showing number of reads (read depth) with number of 
species identified for the sample Q1462.  
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2.3.4 Community profiling the terminal ileal microbiome 
 
The microbial communities present in the TI of AS patients were found to be significantly 
different and more diverse than those communities associated with CD and healthy 
controls (P<0.001; PERMANOVA). Alpha diversity, a measure of richness and/or 
evenness of taxa within an individual community, was increased in AS samples. The CD 
and HC communities were more similar to each other than AS, but were less diverse 
overall than the AS microbial community (Figure 2.3). 
 
  
 
Figure 2.3 Rarefaction curves for microbial communities in AS patients (red curve), CD 
patients (blue curve), healthy controls (orange curve) and the mock communities (green 
curve).  
 
Communities were compared using weighted and Unweighted UniFrac distances, a 
phylogenetic metric that accounts for differences in both community membership and 
relative abundance (174).  The Weighted UniFrac distance metric is used to detect 
changes in how many organisms are present in a community. It takes into account the 
relative abundance of microbes present, which is particularly important for looking at 
changes in bacterial abundances between communities. The Unweighted UniFrac 
distances metric informs us about community membership is used to measure the core 
differences between communities in terms of presences or comparative absence of taxa. 
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Hierarchical clustering based on both Weighted and Unweighted UniFrac distances 
indicated the primary factor influencing differentiation of communities is disease, and that 
the microbial communities present in AS patients are distinct from those in CD and HC 
(Figure 2.4).  
 
 
 
Figure 2.4 Hierarchical clustering of microbial communities based on Weighted Unifrac 
distance clustering of terminal ileal biopsies of patients with ankylosing spondylitis (AS), Crohn’s 
disease (CD), healthy controls (HC) as well as the two mock community controls.  
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Figure 2.5 Principal coordinates analysis of technical and biological replicates (transparent 
points) showing the grouping of ankylosing spondylitis (AS) samples compared to Crohn’s disease 
(CD) and healthy controls  (HC) with the grouping of the replicates shown in the red circles.  
 
PERMANOVA analysis confirmed the presence of a significant relationship between 
disease status and microbial community composition (P<0.001). This was not due to 
heterogeneity in biopsy samples as the biological replicates showed no significant 
difference between each other (P<0.001) (Figure 2.6). Nor was it due to a lack of technical 
reproducibility, as the technical replicates, like the biological, were not statistically different 
from each other (P<0.001) and cluster tightly together (Figure 2.5).   
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Figure 2.6 Comparison of variation between and within samples and affection status 
showing greater significance between and within affection status than between biological and 
technical replicates Significance was assessed using Mann-Whitney test (P<0.001 = ***). 
 
Average UniFrac distances demonstrated that the differences between both biological and 
technical replicates were significantly less than differences between individuals and 
disease states (Figure 2.6). Total microbial load was investigated using Biomass q-PCR. 
Total microbial load is of interest as this is an indicator of the overall amount of bacteria 
that are present in the community. In our samples, Biomass q-PCR showed that the 
apparent microbial signature in AS patients was not due to bacterial overgrowth as there 
was no significant difference on average in 16S rRNA copy number between AS, CD, and 
HC (Figure 2.7). One sample, AS02, displayed a higher microbial load than the other AS 
samples, while AS04 exhibited a lower overall microbial mass, illustrating the variability of 
microbial community load across people and the disease. The biomass of CD and HC 
samples were relatively similar to each other, with no outstanding increases or decreases 
in microbial load.  
 
 
 
 
 
69 
 
Figure 2.7 Microbial community profiles of terminal ileal (TI) biopsies from ankylosing 
spondylitis (AS), Crohn’s disease (CD) patients and healthy controls (HC). Biological replicates are 
indicated as ‘a’ and ‘b’. Each row represents a different OTU with the abundance as a percentage 
of the total population as represented by colour. Phyla and selected families are noted on the left, 
and a subset of OTU classifications on the right. Microbial biomass of each biopsy is shown by the 
bar graph at the bottom of the heat map. 
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2.4 Discussion 
 
Whether the changes in the microbiome are a consequence of disease or are involved in 
its development or persistence is unclear.  This distinction may prove difficult to dissect in 
human studies, but there is considerable evidence in studies in mice to support a role for 
the microbiome in driving immune mediated diseases such as AS. In order to understand 
the role of the gut microbiome in human disease, it is important to first be able to 
accurately and confidently profile the microbiome. This requires confidence in tissue 
extraction techniques, 16S rRNA primer choice to ensure diversity is sufficiently captured 
and that the analysis strategy employed is appropriate (181).  
 
During 16S pipeline validation, nine different primer sets spanning the 16S rRNA gene 
were evaluated to determine which set provided the best coverage and discrimination of 
intestinal flora. Emerging literature coupled with in silico analysis of the primer sets, we 
focused two primer sets in the V3-V5 region of the 16S rRNA gene (127, 169). Two primer 
sets 347F 803R and 517F 803R demonstrated ability to classify all expected major and 
minor phyla, as previously reported to inhabit the intestinal microbiome, not only in silico 
but also when trialled on human colonic biopsies (127, 128, 152, 182, 183). As well as 
capturing the diversity of the bacteria in the intestinal microbiome, ability to selectively 
amplify bacteria over human DNA was crucial in when considering primers. 16S rRNA 
shares significant homology with human mitochondrial DNA and amplification of human 
DNA is an issue. The final decision to move forward with the 517F 803R primer set was 
also influenced by choice of sequencing platform and chemistry. Sequencing of the TI 
biopsies was 2x150bp on the Illumina MiSeq, therefore sequencing read length was an 
important determinant when considering primer sets for amplicon sequencing. Two 
bacterial mock communities, consisting of six well-characterised bacteria at varying 
concentrations, were used as internal standards to determine reproducibility across 
multiple runs. These two mock communities enabled us to accurately compare PCRs and 
sequencing runs, as well as serving as internal controls to validate the pipeline and 
analysis approach.  
 
There is increasing evidence that these indigenous microbes are also driving the 
development and/or function of different of immune cells in the intestine. In the intestinal 
mucosa, innate lymphoid cells (ILCs) have emerged as an important innate lymphocyte 
population involved in immunity to intestinal infections, especially in conjunction with IL-22 
 
 
71 
(184). The transcription factor T-bet, encoded by the TBX21 gene, controls the fate of ILCs 
and is yet another gene in the list of genes found to be controlled by cues from the 
intestinal microbiome and IL-23. Meaning that the commensal microbiota are instructing T-
bet expression and therefore ILC development. (185).  
 
Inflammation is a critical component in autoimmune disease. In the K/BxN mouse model of 
arthritis it was shown that the introduction of a single gut-residing species, segmented 
filamentous bacteria (SFB), into germ free animals was sufficient to cause proliferation of 
Th17 cells, which led to the production of autoantibodies and rapidly progressed to 
arthritis. Neutralisation of IL-17 in specific-pathogen-free K/BxN mice prevented arthritis 
development. Thus, a single commensal microbe, via its ability to promote a specific T 
helper cell subset, can drive autoimmune disease (101).  Conversely, members of the gut 
microbiota such as Clostridium spp., have been found to play a protective role by inducing 
T regulatory cells (Tregs) in the colonic mucosa. Tregs are an important counter balance in 
the immune system and promote homeostasis. It was found that a specific mix of cluster 
IV and XIVa of Clostridium was sufficient to promote Treg accumulation in the colon (105).  
 
To date no comprehensive characterisation of intestinal microbiota in AS patients has 
been performed.  Here we described the optimisation and validation of 16S rRNA culture-
independent microbial sequencing for the purpose of profiling TI biopsies. The choice to 
examine intestinal biopsies, rather than less invasive stool samples, was in order to fully 
characterise the mucosal microbiome at a site of initial inflammation. Several studies have 
shown that while stool is routinely used for large scale investigations of the intestinal 
microbiome (123, 126, 137), examining the mucosal microbiome has tremendous value as 
the mucosal microbes are in a position to influence the immune system (152, 153, 186).  
Four AS patients, three individuals with CD, four HC and two microbial mock communities 
were profiled using the optimised 16S rRNA pipeline to determine if the AS gut carries a 
distinct microbial signature.  Hierarchal clustering showed that the microbiome of AS 
patients is distinct and different from CD and HC, with the PCoA confirming that the AS 
cases group separately. Statically the relationship between disease status and microbial 
community composition was confirmed indicating that the differences between the 
microbial community compositions were not due to heterogeneity in the biopsy or lack of 
technical reproducibility, but that the driving force is disease state. These results 
demonstrate that the tissue extraction method coupled with choice of 16S rRNA primers, 
was able to capture and profile the intestinal microbiome in human TI samples.  
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Given what we know from murine experiments, the differences we see in the microbial 
composition in AS gut compared to CD and HC may have wider reaching implications. The 
evidence is mounting that not just the overall composition of the intestinal microbiome, but 
presences and/or absences of specific microbes that have a substantial impact on host 
response, regulation of inflammation and development of intestinal cells. What is clear is 
that the interactions between our genetics, immune system and resident microbiota are 
complex but critical. Our intestinal microbiota are clearly not just bystanders but are in fact 
orchestrators of our health and disease, so having the capacity to accurately profile the 
microbiome is imperative. Further studies are needed into whether the changes in 
intestinal microbial composition are due to genetics, and how this affects the overall 
function of the gut microbiome in AS patients, including how the microbiome then goes on 
to shape the immune response and influence inflammation. Now have the tools to 
sequence and analyse intestinal microbial communities, these investigations will likely 
provide new insights and help us to better understand AS disease pathogenesis. 
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3.1 Abstract	  
 
Objective. Ankylosing spondylitis (AS) is a common highly heritable immune mediated 
arthropathy that occurs in genetically susceptible individuals exposed to an unknown but 
likely ubiquitous environment trigger. There is a close relationship between the gut and 
SpA, exemplified in reactive arthritis patients, where a typically self-limiting arthropathy 
follows either gastrointestinal or urogenital infection. Microbial involvement has been 
suggested in AS, however, no definitive link has been established. We sought to 
determine if the AS gut carries a distinct microbial signature, in comparison to healthy 
controls (HC).  
 
Methods. Microbial profiles from terminal ileal (TI) biopsies from subjects with recent-
onset, TNF-antagonist naïve AS and HC, were generated using culture-independent 16S 
rRNA gene sequencing and analysis techniques.  
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Results. Our results show the TI microbial communities of patients with AS differ 
significantly (P<0.001) from HC, driven by higher abundance of five families of bacteria 
Lachnospiraceae (P=0.001), Ruminococcaceae (P=0.012), Rikenellaceae (P=0.004), 
Porphyromonadaceae (P=0.001), and Bacteroidaceae (P=0.001), and a decreases in 
abundance of two families Veillonellaceae (P=0.01) and Prevotellaceae (P=0.004).  
 
Conclusions. We show evidence for a discrete microbial signature in the TI of cases with 
AS, compared to HC. The microbial composition was found to correlate with disease 
status and greater differences were observed between than within disease groups. These 
results are consistent with the hypothesis that genes associated with AS act at least in part 
through effects on the gut microbiome. 
 
3.2 Introduction 
 
Intestinal microbiome dysbiosis and microbial infections have been implicated in a number 
of immune mediated diseases, including multiple sclerosis, inflammatory bowel disease 
(IBD), and type 1 diabetes. Bacterial infections in the gut and urogenital tract are known to 
trigger episodes of reactive arthritis, a form of spondyloarthropathy (SpA), a group of 
related inflammatory arthropathies of which ankylosing spondylitis (AS) is the prototypic 
disease.  There is a close relationship between the gut and SpA, exemplified in reactive 
arthritis patients, where a typically self-limiting arthropathy follows either gastrointestinal 
infection with Campylobacter, Salmonella, Shigella or Yersinia, or urogenital infection with 
Chlamydia.   Microbial involvement has been suggested in AS, however, no definitive link 
has been established (16, 17).  
 
Up to 70% of AS patients have subclinical gut inflammation with 5-10% of these patients 
with more severe intestinal inflammation go on to develop clinically defined IBD resembling 
Crohn’s disease (CD) (7). The high heritability of AS (5), the global disease distribution 
and the absence of outbreaks of the disease, suggest that AS is triggered by a common 
environmental agent in genetically susceptible individuals (187). Multiple genes associated 
with AS also play a role in gut immunity such as genes involved in the IL-23 pathway (22, 
24), which are important regulators of intestinal ‘health’. There is a marked over-
representation of genes associated with CD that are also associated with AS (18, 20); this 
suggest the two diseases my have similar aetiopathogenic mechanisms, possibly involving 
gut dysbiosis (188).  
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Several studies have shown that AS patients and their first-degree relatives have 
increased intestinal permeability relative to unrelated healthy controls, again consistent 
with a role for the gut microbiome in the disease (6, 11, 12). To date, no comprehensive 
characterization of intestinal microbiota in AS patients has been performed.  Here we 
performed culture-independent microbial community profiling of terminal ileal (TI) biopsies 
from nine AS and HC to determine to investigate differences the gut microbiome in these 
disease states in comparison with each other and with HC. 
 
3.3 Materials and Methods 
 
3.3.1 Patient clinical data 
Terminal ileal biopsies were collected at colonoscopy from nine consecutively enrolled 
TNF-inhibitor naïve, recently diagnosed AS cases (defined according to the modified New 
York classification criteria for AS (173)) and nine healthy controls (Table 3.1).  All patients 
gave written informed consent and the study protocol was approved by the relevant 
Universities of Palermo and Queensland research ethics committees. Disease duration 
listed in Table 3.1 is from onset of symptoms, as reported by the patients, not duration 
since diagnosis. One AS patient was on NSAIDs at the time of biopsy. AS03, AS04 and 
AS10 had reported occasional although interrupted use of NSAIDs due to gastrointestinal 
upset. Other AS patients did not report use of NSAIDs but were using either paracetamol 
and/or tramadol.  
 
 Table 3.1. Clinical details of patients supplying biopsies at time of collection.  Disease duration is from date of onset of symptoms. 
 
ID Diagnosis Biopsy 
site 
Age Gender Disease 
duration 
ESR 
mm/Hr 
CRP 
mg/l 
BASDAI HLA-B27 
status 
NSAID 
treatment 
Histological 
inflammation 
AS01 AS Ileum 56 M 7 years 34 18 7 Pos Current Chronic 
AS02 AS Ileum 33 M 4 years 22 1 5.5 Pos None Acute 
AS03 AS Ileum 24 F 5 years 18 5 4.8 Pos None Normal 
AS04 AS Ileum 22 M 3 years 33 3 5.5 Pos None Normal 
AS05 AS Ileum 33 M 5 years 41 2.7 6 Pos None Chronic 
AS06 AS Ileum 28 M 6 years 28 1.5 6.2 Pos None Normal 
AS08 AS Ileum 36 M 8 years 34 1.5 5.6 Pos None Acute 
AS09 AS Ileum 38 F 6 years 45 2.2 6.7 Pos None Chronic 
AS10 AS Ileum 31 M 11 years 27 1.3 8 Pos None Normal 
HC01 HC Ileum 58 F N/A N/A 0.3 N/A N/A N/A N/A 
HC02 HC Ileum 43 M N/A N/A 0.5 N/A N/A N/A N/A 
HC03 HC Ileum 38 F N/A N/A 0.05 N/A N/A N/A N/A 
HC04 HC Ileum 65 M N/A N/A 0.8 N/A N/A N/A N/A 
HC05 HC Ileum 48 F N/A N/A 0.02 N/A N/A N/A N/A 
HC06 HC Ileum 34 F N/A N/A 0.03 N/A N/A N/A N/A 
HC07 HC Ileum 45 M N/A N/A 0.5 N/A N/A N/A N/A 
HC08 HC Ileum 44 F N/A N/A 0.8 N/A N/A N/A N/A 
HC09 HC Ileum 56 F N/A N/A 0.02 N/A N/A N/A N/A 
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3.3.2 DNA extraction and sequencing 
Samples were preserved in liquid nitrogen or on dry ice till processed. TI biopsies were 
thawed and divided in two to create biological replicates. Each sample was manually 
disrupted using a polypropylene disposable pestle from Sigma. DNA was extracted from 
tissue biopsies using Qiagen DNeasy tissue extraction kits after manual disruption as per 
manufacturer’s instructions. 
 
3.3.3 Mock community 
A mock community consisting of six different bacteria, Gram positive and Gram negative, 
was employed as a control for both sequencing and bioinformatic analysis and was 
processed alongside the TI biopsies. The mock community contained Staphylococcus 
aureus (ATCC 25923), Enterococcus faecalis (ATCC 51299), Haemophilus influenzae 
(ATCC49247), Bacteroides fragilis (ATCC 25285), Corynebacterium renale (ATCC 19412) 
and Yersinia enterocolitica (ATCC2 3715). The bacteria were extracted using the Qiagen 
DNeasy tissue extraction kit as per manufacturer’s instructions. The bacterial mock 
community was constructed using differing amounts of the six bacteria and labelled Mock 
(Table 3.2).  
 
Table 3.2 Bacterial mock community composition. 
 
Bacteria Concentration ng/ul Pooled amount 
Y. enterocolitica 28.39 1ul 
E. faecalis 7.49 2ul 
B. fragilis 7.3 4ul 
H. influenzae 5.47 4ul 
S. aureus 17.89 1ul 
C. renale 2.4 2ul 
 
 
3.3.4 16S rRNA PCR 
Bacterial 16S rRNA amplicon PCR was conducted using the V4 primer spanning the 
region 517F GCCAGCAGCCGCGGTAA and 803R CTACCRGGGTATCTAATCC of the 
16S rRNA gene.  All samples, including the samples presented previously in Chapter 2 
(AS01-AS04 and HC01-HC04), were processed in one batch together in this experiment. 
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The master mix for the reactions in a 50ul total volume using Invitrogen Platinum PCR 
SuperMix High Fidelity. Mastermix consisted of 45ul of SuperMix, 1ul each of both primers 
at 10uM and 3ul of DNA. Thermocycling conditions comprised of 2min at 94ºC then 25 
cycles of 94ºC for 30s, 54ºC for 30s, 68ºC for 45 s and a single 72ºC for 10 min. 
 
3.3.5 Sequencing Library preparation  
16S rRNA amplicon libraries for all samples presented in this chapter, including the 
samples presented previously in Chapter 2 (AS01-AS04 and HC01-HC04), were 
assembled and indexed for multiplexing using the Illumina 16S Metagenomic Sequencing 
library protocol as per manufacturer’s instructions. All samples were normalised using the 
Agilent Bioanalyzer and pooled for sequencing at a concentration of 2nM.  To create the 
required complexity for sequencing, PhiX was added to the pool at 25/75 for a final pool 
concentration of 4pM.  
 
3.3.6 Illumina MiSeq Sequencing 
Barcoded 16S amplicon sequences were sequenced with 2x250bp paired-end reads on a 
single Illumina MiSeq run.  A total of 6.1M reads were generated with an average of 
200,000 reads per sample.  
 
3.3.7 Bioinformatics and statistics 
Samples were demultiplexed and quality filtered using split_libraries_fastq.py (Table 3.3), 
then analysed using the QIIME package and workflow scripts (qiime.sourceforge.net) 
(169). Operation Taxonomy Unity (OTU) assignment was based on 97% similarity with 
taxonomic assignments made using BLAST to Greengenes (113) as implemented in 
QIIME.    
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Table 3.3 16S rRNA sequence read counts per sample post quality control and filtering  
Sample names Sequence counts 
 AS01a  82,363  
 AS01b  132,597  
 AS02a  117,012  
 AS02b  77,983  
 AS03a  123,111  
 AS03b  126,647  
 AS04a  131,851  
 AS04b  150,298  
 AS05a  127,339  
 AS05b  81,085  
 AS06a  238,920  
 AS06b  121,211  
 AS07a  105,164  
 AS08a  113,490  
 AS08b  94,585  
 AS09a  117,119  
 AS09b  139,181  
 AS10a  120,418  
 AS10b  124,143  
 HC01a  111,807  
 HC01b  103,234  
 HC02a  161,879  
 HC02b  168,001  
 HC03a  166,127  
 HC03b  172,902  
 HC04a  92,936  
 HC04b  132,558  
 HC05a  100,554  
 HC05b  99,696  
 HC06a  121,273  
 HC06b  137,985  
 HC07a  91,674  
 HC07b  119,069  
 HC08a  94,205  
 HC08b  63,347  
 HC09a  110,494  
 HC09b  112,864  
 Mock  103,896  
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Alpha diversity metrics were generated using the QIIME workflow alpha_rarefaction.py 
with five repetitions at each sampling point. Rarefaction curves for the observed number of 
OTUs were based on the outputs of alpha_rarefaction.py. UniFrac distances between 
microbial communities were evaluated using FastUniFrac (174).  
 
Hierarchical clustering was employed using Unweighted Pair Group Method with 
Arithmetic mean (UPGMA) both weighted and Unweighted UniFrac distance, to detect 
significant differences within microbial communities between AS and HC (175). The 
Weighted UniFrac distance metric detects changes in how many organisms are present in 
a community, taking into account the relative abundance of microbes present. The 
Unweighted UniFrac distance metric describes community membership. UniFrac enabled 
in QIIME was used to generate sample distance metrics as well as Principal Coordinate 
Analysis (PCoA) (189). To determine differences in microbial load, the total microbial 
biomass in biopsy samples was quantified using real-time qPCR of the 16S rRNA gene as 
described in Willner et al., 2013 (170). 
 
PERMANOVA analysis was conducted on the genus level OTU table using the R package 
‘vegan’ to test the relationship between the whole microbial community and disease (176). 
Indicator species analysis, using the ‘labdsv’ R package, was employed to investigate 
what microbial species are driving the microbial community and driving the signature 
(177). Co-occurrence network analysis, utilizing the R package ‘Spaa’, was carried out to 
further investigate correlations between microbial families in the AS microbiome. Core 
microbiome analysis, as well as supervised learning, was performed to further characterise 
the intestinal microbial signature using the workflows compute_core_microbiome.py and 
supervised_learning.py in QIIME.  
 
To interrogate the function of bacteria and communities, Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict the 
metagenome functional content from the 16S rRNA OTU table (115).  Using the workflow 
normalize_by_copy_number.py in PICRUSt, the OTU table was normalised by copy 
number to limit copy number bias by dividing each OTU by the known or predicted 16S 
copy number.  The metagenome was predicted using predict_metagenomes.py, which 
creates the prediction by multiplying each normalized abundance by the predicted 
functional trait abundance, to produce a table of function by samples. The table produced 
by the predict_metagenomes.py workflow is then analysed as a metagenome table. The 
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functions were collapsed into categories using the categorize_by_function.py script for 
further analysis in R.  Metagenomic pathways were compared between AS and HC using 
generalized linear model glm in R.   
 
The core microbiomes at varying thresholds were also investigated for metagenomic 
pathways of interest. As described above, the Core 100, 90, 75 and 50 OTU tables were 
processed through PICRUSt and then compared using Wilcox test and glm in R.  
 
 
3.4 Results 
 
The TI microbial and mock communities were profiled by high-throughput barcoded 
amplicon sequencing. In addition to exploring community-level differences between 
disease states, we evaluated biological replication by halving biopsies, then processing 
and analysing them independently 
 
The microbial communities in the TI of AS cases were significantly different (Figure 3.1) 
and more diverse (Figure 3.2C) than those communities associated with HC (P<0.001; 
PERMANOVA).  It was noted that three of the HC samples had higher levels of 
Proteobacteria (HC01, HC08 and HC09) (Figure 3.1). The mock community profile was 
consistent with control components (Table 3.2, Figure 3.1) showing 55% Proteobacteria 
(Y. enterocolitica and H. influenzae), 37% Firmicutes (E. faecalis and S. aureus), 7.5% 
Bacteroides (B. fragilis) and 0.5% Actinobacteria (C. renale).  
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Figure 3.1 Differences between AS and HC microbial communities. Bar chart showing the 
difference in taxonomy at the Phylum level between AS and HC noting the increase in Bacteroides 
and the change in the Bacteroides to Firmicutes ratio in the AS samples. 
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Figure 3.2 Shift in microbiome composition driven by disease status. (A) Weighted Principal 
Coordinates Analysis, which detects differences in organisms present in a community and taking 
into account their relative abundance, showing the distinct clustering of AS samples compared to 
HC, and supported by the supervised learning predicting disease status based off microbiome 
composition (B) Weighted Principal Coordinates Analysis, having removed the four outlying HC, 
still showing the distinct clustering of AS samples compared to HC (C) Alpha diversity box plot 
showing an increase of microbial diversity (observed species) in AS samples compared to CD and 
HC. (D) Comparison of variation between and within samples and affection status showing greater 
significance between and within affection status than between biological and technical replicates 
significance was assessed using Mann-Whitney test (P<0.001 = ***). 
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Figure 3.3. Weighted and Unweighted Principal Coordinates Analysis of the samples and 
their biological replicates (A) Weighted Principal Coordinates Analysis of the samples and their 
biological replicates (open symbols) showing not only distinct clustering samples by disease status, 
but tight clustering of the biological replicates. The bacterial (Mock) control included as a known 
positive control. (B) Unweighted Principle Coordinates Analysis, which detects differences in the 
presence and absences of microbes in a community, of samples and their biological replicates 
showing general but not distinct discrimination of AS samples and their biological replicates to HC, 
indicating there are some differences in the AS microbial community due to presence/absence of 
microbes. 
 
PCoA showed AS samples group separately to HC (Figure 3.2), including biological 
replicates (Figure 3.3), indicating that disease is the primary factor influencing community 
differences.  Four HC samples group separately and away from the other HC, and closer 
to the mock community control. Three of the four HC samples contained increased 
proportion of Proteobacteria (HC01, HC08 and HC09) and HC04 that had increased levels 
of Actinobacteria, compared to the other HC samples. Therefore to examine if these 
outlying samples were affecting the clustering seen on PCoA (Figure 3.2A), the four 
outlying samples were removed and the remained samples reanalysed (Figure 3.2B). The 
reanalysed PCoA showed the AS samples still clustered separately from HC, with the 
exception of AS02 which also contained more Proteobacteria than the other AS samples 
(Figure 3.2B).  
 
To further demonstrate the distinct grouping of AS samples to HC, supervised learning 
was conducted to test the predictive capacity of the microbiome differences, with all nine 
AS cases predicted as AS (Figure 3.2A).  PERMANOVA analysis further confirmed the 
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presence of a significant relationship between disease status and microbial community 
composition (P<0.001). This was not due to heterogeneity in biopsy samples as biological 
replicates showed no significant difference between each other (Figure 3.2D). Biomass q-
PCR showed no significant difference on average in 16S rRNA copy number between AS 
and HC; indicating that the observed differences were not due to overgrowth or dominance 
of bacteria driving community differences (Mann-Whitney test, P>0.05 = NS). Average 
UniFrac distances demonstrated that differences between both biological and technical 
replicates were significantly less than differences between individuals and disease states 
(P<0.001; Mann Whitney) (Figure 3.2D).  
 
16S community profiling, where sequencing reads were clustered against the Greengenes 
reference database at 97% similarity (112, 113) showed 51 genera present across all 
biopsies, with major differences observed at the phylum level between AS and HC (Figure 
3.1). Indicator species analysis was performed to determine if alterations in specific 
species were driving the differences observed between communities in cases with AS and 
HC. Analysis showed that compared to HC, the microbial communities in AS cases were 
characterized by higher abundances of Lachnospiraceae including Coprococcus spp. and 
Roseburia spp. (P=0.001), Ruminococcaceae (P=0.012), Rikenellaceae (P=0.004), 
Porphyromonadaceae including Parabacteroides spp. (P=0.001), and Bacteroidaceae 
(P=0.001). Decreases were noted in Veillonellaceae (P=0.01) and Prevotellaceae 
(P=0.004) (Figure 3.4A).  Further drilling down into the AS microbiome signature, co-
occurrence analysis, which examines at the correlation between microbes, showed that 
bacterial interactions further shape the AS microbial community signature with positive 
correlations observed between the indicator species Lachnospiraceae and 
Ruminococcaceae, and negative correlations observed between Veillonellaceae and 
Prevotellaceae  (Figure 3.4B).  
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Figure 3.4 Differences in bacterial family abundances and co-occurrence network. (A) 
Differences in relative abundances of bacterial families in AS (orange) microbiome compared to 
HC (red). The first seven families of bacteria are AS indicator species, including P-values, with the 
last three bacterial families being HC indicator species. (B) Co-occurrence network showing the 
positive (blue lines) correlations, between AS indicator species Lachnospiraceae and 
Ruminococcaceae families, and negative (red lines) correlations between families such as 
Veillonellaceae, Porphyromonadaceae and Prevotellaceae. The thickness of the line denotes the 
strength of the correlation (Pearson correlation). 
 
Given the distinct differences seen between the AS and HC intestinal microbiome 
composition, we were interested in seeing how changes in composition affect microbiome 
function. Microbial function was inferred from the 16S rRNA data using the prediction 
software PICRUSt (115). PICRUSt analysis indicated 31 significant pathways with 
differential representation in AS compared to HC (Bonferroni corrected P<0.02) (Table 
3.4). These included a decrease in Bacterial invasion of epithelial cells (P=4.33x10-5), an 
increase in antimicrobial production in the Butirosin and neomycin biosynthesis pathway 
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(P=0.002), which is consistent with an increase in bacteria from Bacteroidaceae family, 
and an increase in the Secondary bile acid biosynthesis pathway (P=0.004) consistent 
with an increase in the order Clostridia and Ruminococcaceae species (190).  
 
Table 3.4 Significant KEGG pathways comparing AS to HC as identified by PICRUSt analysis 
P<0.02. 
 
KEGG Pathway name AS to HC 
Pvalue  
Bacterial invasion of epithelial cells  0.0001 
Electron transfer carriers  0.0009 
Fluorobenzoate degradation 0.0021 
Butirosin and neomycin biosynthesis 0.0021 
Germination 0.0021 
Transcription related proteins 0.0030 
Caprolactam degradation 0.0030 
alpha-Linolenic acid metabolism 0.0030 
Secondary bile acid biosynthesis 0.0041 
Primary bile acid biosynthesis 0.0041 
Ether lipid metabolism 0.0041 
Flavone and flavonol biosynthesis 0.0057 
Flavonoid biosynthesis 0.0057 
Phenylpropanoid biosynthesis 0.0057 
Glycan biosynthesis and metabolism 0.0076 
Linoleic acid metabolism 0.0076 
Adipocytokine signaling pathway 0.0101 
Phosphonate and phosphinate metabolism 0.0101 
Sporulation 0.0101 
Sphingolipid metabolism 0.0101 
Polycyclic aromatic hydrocarbon degradation 0.0101 
Pathogenic Escherichia coli infection 0.0113 
Carotenoid biosynthesis 0.0133 
Cyanoamino acid metabolism 0.0133 
Phosphotransferase system (PTS) 0.0172 
Amoebiasis 0.0172 
Bisphenol degradation 0.0172 
Photosynthesis 0.0172 
Photosynthesis proteins 0.0172 
Cell cycle - Caulobacter 0.0172 
Other glycan degradation 0.0172 
 
 
 
 
 
88 
Further interrogating the AS microbiome signature, which is the overall combination of 
microbes which distinguishes AS from HC, by seeing if there was an assemblage or ‘core’ 
microbes present in all AS and HC samples at varying levels (127) and to probe their 
functional capacity. Exploring the core microbiome is imperative, to better understand the 
stable and consistent components across complex microbial communities, given the 
distinct AS microbial signature. We began by looking at Core 100, which requires microbes 
to be present in all samples 100% of the time, which included Clostridia, 
Actinomycetaceae, Bacteroidaceae, Lachnospiraceae, Porphyromonadaceae, 
Rikenellaceae, Ruminococcaceae and Veillonellaceae families of bacteria (Table 3.5). 
These families of bacteria are also AS indicator species suggesting that the core 
microbiome is driving the AS microbial signature (Figure 3.4).  
 
Table 3.5 Significant KEGG pathways comparing in Core100 microbiome comparing AS to 
HC as identified by PICRUSt analysis P<0.02. 
 
KEGG Pathway name AS to HC 
Pvalue  
Basal transcription factors 0.0003 
Atrazine degradation  0.0004 
Renal cell carcinoma 0.0015 
Flavone and flavonol biosynthesis 0.0021 
Germination 0.0021 
African trypanosomiasis 0.0041 
Bacterial invasion of epithelial cells 0.0041 
Bladder cancer 0.0041 
Chagas disease (American trypanosomiasis) 0.0041 
Butirosin and neomycin biosynthesis 0.0076 
Electron transfer carriers 0.0076 
Phenylpropanoid biosynthesis 0.0079 
Carotenoid biosynthesis 0.0101 
Caprolactam degradation 0.0101 
Flavonoid biosynthesis 0.0101 
Pathogenic Escherichia coli infection 0.0126 
Shigellosis 0.0126 
Fluorobenzoate degradation 0.0133 
Primary bile acid biosynthesis 0.0133 
Secondary bile acid biosynthesis 0.0133 
Alpha-Linolenic acid metabolism 0.0133 
Sphingolipid metabolism 0.0172 
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Given that these microbes were present in all samples 100% of the time, we were 
interested in their function, the biological pathways they were involved in and whether they 
involved in known AS associated pathways. For Core 100 there were 22 significant 
pathways (Table 3.5) (P< 0.02) that again included Bacterial invasion of epithelial cells (P= 
0.004), antimicrobial production in the Butirosin and neomycin biosynthesis pathway 
(P=0.007) and the Secondary bile acid biosynthesis pathway (P=0.013). Members of 
Bacteroides, Clostridium and Ruminococcus are known to be involved in cholesterol 
metabolism and secondary bile synthesis with this pathway also implicated in colorectal 
cancer.  
 
As the threshold for core membership was reduced to 90, 75 and 50% of the time, the 
families of bacteria present remained the same however the number of genus and species 
within these families increased, especially in the order Clostridiales, Lachnospiraceae and 
Ruminococcaceae. This demonstrates the structure of the core microbiome is robust and 
that decreasing the threshold only expands the number of genera and species of bacteria 
within these families. However, as the core threshold was decreased the number of 
significant pathways also decreased suggesting that as the threshold is relaxed, the 
expansion of genera and OTUs dilutes pathway signals.  This was reflected in the 
metagenome prediction with PICRUSt. As the core threshold was relaxed, the number and 
types of pathways that were significantly different between AS and HC was reduced.  
 
No significant differences were noted between AS cases and controls in abundance of 
bacteria known to be associated with reactive arthritis such as Campylobacter, 
Salmonella, Shigella, Yersinia and Chlamydia. Also, there was no significant difference in 
abundance of Klebsiella in AS cases, which has been proposed to play a role in triggering 
AS (142). 
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3.5 Discussion  
 
Here we present the first characterisation and identification of intestinal dysbiosis is the AS 
microbiome using 16S rRNA community profiling of TI biopsies.  We performed culture-
independent microbial community profiling of TI biopsies from nine AS patients, nine HC 
and a bacterial mock community, and show evidence for a discrete microbial signature in 
the TI of cases with AS. A mock community consisting of six bacteria was constructed and 
used as an internal positive control for the purpose of determining if the methods used 
accurately captured the microbial communities examined (112, 191). All members of the 
mock community belong to bacterial families that are commonly found in the gut, with the 
exception of Pasteurellaceae. Y. enterocolitica is a known intestinal pathogen belonging to 
Enterobacteriaceae family, E. faecalis and B. fragilis are both known and well documented 
intestinal bacteria. Corynebacteriaceae and Staphylococcaceae bacterial families, to which 
C. renale and S. aureus belong, are also documented residents of the gastrointestinal 
tract. H. influenzae is a member of the Pasteurellaceae family and whilst H. influenzae 
specifically is not found in the gut, members of the Pasteurellaceae family are found in oral 
microbiome and upper respiratory tract.  There is increasing evidence of a link between 
the oral and gut microbiome, particularly if patients are on proton-pump inhibitors (192), 
indicating that microbial communities may not be site specific discrete environment, but 
fluid communities so  (129, 193, 194). Analysis of the mock community returned the 
expected 16S profile dominated by Proteobacteria (Y. enterocolitica and H. influenzae), 
Firmicutes (E. faecalis and S. aureus), Bacteroides (B. fragilis) and the low abundant 
Actinobacteria (C. renale). This demonstrates that the resulting community profile is 
consistent with the known inputs and that the sequencing and analysis methods are 
producing accurate profiles. This also demonstrates that the methods used are not 
introducing unwanted bias to the community profiling results (195), nor are the less 
abundant bacteria being swamped by more dominate bacteria.  
  
Taken together, this demonstrates that the observed microbial profile differences are not 
due to differences in overall bacterial quantity between cases with different diseases, but 
are qualitative. PCoA was able to show the clear and distinct grouping of AS cases from 
HC; larger studies will be required to define the individual bacterial species involved. Four 
HC samples were found to group separately and away from the other HC, closer to the 
mock community control. Three of the four HC samples contained increased proportion of 
Proteobacteria (HC01, HC08 and HC09) and HC04 that had increased levels of 
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Actinobacteria which has been associated with obesity (114, 196), compared to the other 
HC samples, skewing their profiles. Increased levels of Proteobacteria can be associated 
with issues such as poor sequencing quality, however all samples were processed and 
sequenced at the same time, and thus would all have potentially been affected by any 
such bias.  With only these there HC samples seemingly affected, poor sequencing quality 
is an unlikely explanation for the observations. There is limited metadata on the HC 
patients with regards to medications, gastrointestinal issues, diet or other co-morbidities, 
therefore a biological reason for the increased Proteobacteria cannot be excluded. There 
is evidence to suggest that a reduction in overall microbiome diversity can lead to 
increased proportions of Proteobacteria (196), with experiments in mice demonstrating 
that increased dietary fat leads to the reduction of microbial diversity and the expansion of 
Proteobacteria leading to a diet induced dysbiosis (197-199). 
 
To examine if these outlying samples were affecting the clustering seen on PCoA, the four 
outlying were removed and the remaining samples reanalysed. Even excluding the four 
HC samples, clear clustering of AS samples away from the HC was seen with the 
exception of AS02, which upon further investigation also had higher percentage 
Proteobacteria compared to the other AS samples. As well as diet induced dysbiosis, 
increased Proteobacteria has also been linked to colitis in animal studies (200), 
demonstrating there are several possible biological reasons for an increase in this phyla.  
Despite the incidence of Proteobacteria in several of the samples, statistically the 
relationship between disease status and microbial community composition was confirmed 
indicating that the differences between the microbial community compositions were not 
due to heterogeneity in the biopsy or lack of technical reproducibility, but that the driving 
force is disease state.  
 
Of the seven families of microbes with differences in abundance within the AS microbiome, 
Lachnospiraceae, Ruminococcaceae and Prevotellaceace are strongly associated with 
colitis and CD (102-104) with Prevotellaceace especially known to elicit a strong 
inflammatory response in the gut (104). Further investigations showed that correlations 
between these families of bacteria further shape the AS microbial signature, and that these 
microbes are present in all AS samples studied suggesting that they are not only driving 
the microbial signature, but they are at the core of the AS microbial signature. Increases in 
Prevotellaceae and decreases in Rikenellaceae have also recently been reported in the 
intestinal microbiome in the HLA-B27 transgenic rat model of spondyloarthritis, suggesting 
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that underlying host genetics may play a role in sculpting the gut microbiome in this animal 
model (201). 
 
There is an increase in the diversity of the AS community without an overall change in 
microbial load, showing there is not an overgrowth or dominance of a particular microbe 
driving the signature. However, murine experiments demonstrate that both the overall 
composition of the intestinal microbiome, and the presences and/or absence of specific 
microbes can have a substantial impact on host response, regulation of inflammation and 
development of intestinal cells. In the K/BxN mouse model of arthritis it was shown that the 
introduction of a single gut-residing species, Segmented Filamentous Bacteria, into GF 
animals was sufficient to reinstate the Th17 cells, leading to the production of 
autoantibodies and arthritis. If IL-17 was neutralised in specific-pathogen-free K/BxN mice, 
arthritis development was prevented. Thus, a single commensal microbe, via its ability to 
promote a specific T helper cell subset, can drive immune mediated disease (101).  
 
Further studies are needed into whether the changes in intestinal microbial composition 
are due to host genetics, and how this affects the overall function of the gut microbiome in 
AS cases, including how the microbiome then goes on to shape the immune response and 
influence inflammation.  In particular, given the strong association of HLA-B27 with AS, the 
hypothesis has been raised that HLA-B27 induces AS by effects on the gut microbiome, in 
turn driving spondyloarthritis-inducing immunological processes such as IL-23 production 
(67, 202). Further experiments comparing the intestinal microbiome of HLA-B27 negative 
and positive patients would shed light of the influence of HLA-B27 on overall intestinal 
microbiome composition, particularly given the work in B27 transgenic rats showing that 
HLA-B27 was associated with altered caecal microbiota (201).  
 
Our data here, showing intestinal dysbiosis in AS cases, is consistent with this hypothesis 
however further studies are clearly required to distinguish cause and effect interactions 
between the host genome and immune system, and the gut microbiome.  These 
investigations will provide new insights and help us to better understand AS disease 
pathogenesis. 
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4 Chapter 4 Effect of ERAP1 genotype on the intestinal microbiome 
and the impact on the immune system in the ERAP mouse model  
 
4.1 Introduction 
 
To date, over 40 loci have been associated with ankylosing spondylitis, and one of the 
strongest associations, along with HLA-B27, is Endoplasmic reticulum aminopeptidase-1 
(ERAP1) (21, 24, 55, 62). Interactions between HLA-B27 and ERAP1 have been 
described in ankylosing spondylitis (AS) such that variants of ERAP1 were shown only to 
influence AS disease risk in the presence of HLA-B27 (62), suggesting that ERAP1 
operates through effects on peptide processing prior to MHC class I presentation. Fine 
mapping studies indicate that the ERAP1 single nucleotide polymorphism (SNP) rs30187 
is directly associated with disease risk and that this loss of function variant is protective in 
AS (62, 187).  Therefore AS-associated ERAP1 variants may change either the amount 
and length of peptides presented or even influence the stability of the peptide loaded onto 
the MHC class I, or the peptide MHC complex and its cell surface retention (203).  
Consequently, ERAP1 could influence AS disease risk via changes in the type or amount 
of volume of peptide presented.  In this chapter we are asking very different questions of 
ERAP’s function and role in AS pathogenesis by exploring how loss of ERAP1 impacts on 
the gut microbiome and how that subsequently affects the immune system.  
 
Early functional studies suggested two roles for ERAP1, one as a ‘molecular ruler’ 
trimming peptides prior to presentation on the MHC class I, and the second as a 
‘sheddase’, which acts by cleaving cytokine receptors off the cell surface, including IL-6R, 
IL-1R2 and tumour necrosis factor receptor (TNFR). However studies in mice showed no 
difference in the levels of these receptors over time, indicating that ERAP1 does not have 
a major influence on cytokine receptor trimming, at least in mice.  Further, ERAP1 SNPs 
were shown not to be associated with variation in serum cytokine receptor levels, 
confirming in humans that this gene does not play a significant role in cytokine receptor 
shedding (204). This strengthens the case that ERAP1 acts as a ‘molecular ruler’ and is 
responsible for the trimming of peptides prior to presentation (205). ERAP1 is a 
ubiquitously expressed, multifunctional enzyme that trims peptides and antigen for 
presentation by MHC class I to the immune system. The endoplasmic reticulum (ER) 
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localised ERAP1 is critical in the MHC class I presentation pathway. Once peptides have 
been process through the proteasome, the Transporter associated with Antigen 
Processing (TAP) takes the subsequent peptide from the cytoplasm into the ER. ERAP1 
then further trims any N-terminally extended peptides to no longer than 9 amino acids in 
length which generates or destroys antigenic epitopes prior to loading onto MHC class I 
molecules (187, 206-208).  Interaction between ERAP and the AS associated MHC class I 
HLA-B27, was the focus of a recent study by Akram et al., 2014. The authors suggest that 
ERAP may play a role in stabilising the heavy chain B27 during assembly of the MHC 
class I by presenting it with appropriate B27-specific peptides(209). Interestingly, this 
stabilisation seems to be B27 specific. When compared to B7, presence/absence of ERAP 
had no effects on host immune response, whereas the absence of ERAP significantly 
altered the immune response to infection with B27 was present (209).  
 
The establishment and maintenance of beneficial interactions between the host and their 
microbiota are key requirement for overall health. The bacteria that inhabit the gut and the 
human immune system have both developed a number of strategies to maintain gut 
homeostasis. The gastrointestinal tract is dynamic environment heavily populated with 
microbes and is the primary site for interaction between microbes and the host immune 
system. Furthermore, the microbes found in the gut help to shape host immune systems 
from an early age (210, 211). The incomplete development of the immune system in 
neonates and mice raised under germ free conditions, tells us that microbiota sculpt the 
host immune system (28, 212). The dysregulation of either gut or microbial homeostasis is 
increasingly recognised as playing a pivotal role in autoimmunity.  Fluctuations in microbial 
composition due to changes in diet, environment, hygiene and use of antibiotics, presents 
a major challenge to the immune system (30). Controlling activation of the immune system 
in response to these changes in gut microbiota has to be tightly regulated as to avoid 
chronic inflammation. The body has a number of physiological processes that respond to a 
disruption in gut homeostasis or a bacterial insult, involving both the adaptive and innate 
immune system, and the barrier function of the intestines themselves (94, 213).  
 
4.1.1 Peptide presentation and infection 
 
Aminopeptidases play integral roles in modulating the adaptive immune responses to both 
host and pathogen derived antigens. Unlike humans, mice only carry one isoform of 
ERAP1, which will be referred to from here as ERAP.  Recent animal studies have 
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revealed how ERAP shapes the antigenic peptide repertoire against microbial and viral 
infections. This is dramatically demonstrated in ERAP-/- mice infected with the obligate 
intracellular parasite Toxoplasma gondii, that causes toxoplasmosis. Mice lacking ERAP 
are unable to trim and present immunodominant and appropriate length peptides derived 
from T. gondii. This leads to aberrant peptide presentation, an inability to mount an 
effective immune response to infection with fatal consequences (214).  ERAP-/- mice 
infected with lymphocytic choriomeningitis virus (LCMV) were shown to present drastically 
different immunodominant epitopes derived from LCMV for presentation than wild type 
(WT) mice (215). ERAP’s role in modulating the immune response to viral pathogens is 
further validated by the finding that human cytomegalovirus (HCMV) has evolved an 
immune evasion strategy where by a micro RNA miR-US4-1 is expressed and specifically 
targets ERAP, down regulating expression and altering peptide trimming and presentation 
as to prolong viral infection (206).   Down regulation or the loss of ERAP not only affects 
peptide presentation during infection, it also significantly alters the composition of the 
endogenous MHC class I peptidome. Murine studies have shown that a lack of ERAP, in 
the absence of infection, presents unstable and structurally unique peptide-MHC 
complexes and that these complexes elicited a potent CD8+ T cell response (207, 208).   
 
Antigen presenting cells (APC), such as dendritic cells (DCs), internalise antigens from the 
environment, process and present these exogenous antigens to MHC class II for 
presentation to CD4+ T cells. However, many viruses and bacteria have developed a 
number of evasion strategies and presentation of peptide from DCs to MHC class I 
mitigates this by eliciting a potent CD8+ T cell immune response. This cross presentation 
is critical for immune surveillance defence against viruses, bacteria and even tumour cells 
(216). Peptides presented by DCs in this manor are processed mainly via the phagosome 
to cytosol pathway. There is recent evidence to suggest that peptides generated in the 
cytosol may be transported by transporter associated with antigen processing (TAP) to 
MHC class I in the ER via ERAP1, or may do so in phagosomes (214). One phagosome 
peptidase of interest is Insulin regulated aminopeptidase (IRAP), a homolog of ERAP1, 
which also trims amino acids from the N terminus and its important for cross presentation 
(217). Studies have shown that DCs that lack IRAP are capable of presenting antigen 
normally however, their ability to cross present antigen is substantially reduced; not unlike 
what is seen with the loss of ERAP1 (217).  This further highlights the vital role ERAP1 
plays in modulating the adaptive immune responses to both host and pathogen derived 
antigens.  
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4.1.2 Intestinal cytokines and gut homeostasis 
 
IL-23 is a key cytokine in the development of IL-17 and IL-22-secreting cells. IL-23 signals 
through a receptor consisting of the specific IL-23 receptor p19 subunit (IL-23R) and the 
IL-12 shared subunit p40 (54). Loss of function polymorphisms in IL23R are associated 
with protection from AS (24, 55), psoriasis (56) and IBD (23, 57), and there are many other 
genes in the IL-23 pathway that are known to be associated with these diseases. IL-23, IL-
17 and IL-22 producing cells are enriched in intestinal mucosa and have been shown to be 
overexpressed in the intestinal mucosa of AS patients with sub-clinical gut disease (218). 
IL-17 and IL-22 work together in concert to regulate intestinal health with IL-17 playing 
important roles in intestinal homoeostasis in several ways including maintenance of 
epithelial barrier tight junctions (58); as well as the induction of anti-microbial proteins such 
as β-defensins, S100 proteins and REG proteins. Innate IL-17 producing cells have been 
found to reside mainly in the skin and mucosal tissues, especially the gastrointestinal tract, 
and act as a first line of defence. IL-17 released during an inflammatory response is 
produced by innate immune cells in response to injury, stress or to pathogens (91). IL-17 
has been shown to be produced 4-8hrs after a microbial infection and is secreted by T 
cells including T helper cells (Th17) and γδ T cells (63, 92, 219). IL-22 is known to induce 
secretion of anti-microbial peptides (98) and has been shown to play a critical role in host 
defence, tissue homeostasis and inflammation with the IL-22-IL-22R pathway contributing 
to regulating immunity, inflammation and tissue repair. IL-22 is expressed by innate and 
adaptive cells and seems to act almost exclusively on non-haematopoietic cells, with basal 
IL-22R expression in the skin, pancreas, intestine, liver, lung and kidney (94). IL-22 can 
act synergistically or additively with IL-17A, IL-17F or tumour necrosis factor (TNF) to 
promote the expression of many of the genes that encode molecules involved in host 
defence in the skin, airway or intestine. This demonstrates the functional importance of IL-
22 in promoting barrier immunity and mucosal integrity, particularly against Gram negative 
pathogens, where IL-22 is critical for limiting bacterial replication and dissemination, 
possibly in part by inducing the expression of antimicrobial peptides from epithelial cells at 
these barrier surfaces (98, 99).  Containment of normal flora is another important arm of 
homeostasis.  IL-22 producing innate lymphoid cells (ILCs) found throughout the gut, play 
a critical role in the physical containment of resident microbes (100). Loss of epithelial 
integrity leads to dissemination of intestinal commensals and systemic inflammation.  
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The initial immunological characterisation of the IL-23/Th17 axis was performed largely in 
the collagen-induced arthritis (CIA) mouse model of autoimmune arthritis, which 
phenotypically resembles rheumatoid arthritis (RA). In the CIA model, mice that lack IL-23 
are protected against the development of disease. In IL-17 and IL-22 deficient mice CIA is 
suppressed, implicating the IL-23 pathway in pathogenesis of disease (220, 221).   
4.1.3 Interactions between intestinal microbes and the immune system 
 
A number of immune cells play critical roles in inflammation, cytokine production and 
homeostasis within the gut. Natural killer T (NKT) cells are protective in Th1-mediated 
models of inflammatory bowel disease but pathogenic in Th2 models (73, 74). Recently, it 
has been shown that microbial stimulation of NKT cells in the gut of mice affects NKT cell 
phenotypic and functional maturation (75). NKT cells recognise glycolipd structures 
presented to them by the non-classical antigen-presenting molecule CD1d. NKT cells are 
rapid responders to antigenic stimuli and are capable of producing a range of 
immunoregulatory cytokines. Given that NKT cells have protective roles in models of 
arthritis (76) and spondyloarthropathy (77, 78) their functional maturation in the gut 
provides evidence for a role for mucosal T cell priming in inflammatory joint disease. 
 
Lymphoid tissue inducer (LTi)-like cells are found in spleen, lymph node and gut lamina 
propria. LTi-like cells constitutively express hallmarks of IL-17-secreting cells including IL-
23R, RORγt, AHR and CCR6 (86, 87). A common characteristic of ILCs, specifically ILC3, 
is the expression RORγt, a transcription factor important for the development of these 
cells. ILCs were initially described as important for development of lymphoid tissues and 
more recently in the initiation of inflammation at barrier surfaces in response to infection or 
tissue damage. It has become apparent that the family of ILCs (Table 4.1) plays more 
complex roles throughout the duration of immune responses, participating in the transition 
from innate to adaptive immunity across varying insults and contributing to chronic 
inflammation. ILCs have been linked to gut inflammation through colitis models where IL-
23 responsive ILCs secrete IL-17, IL-22 and IFN-γ and to promote intestinal inflammation 
(89).  RORγt expressing ILC3s are abundant in the intestinal lamina propria and produce 
IL-17 and/or IL-22 in order to preserve mucosal integrity against extracellular pathogens 
and maintain equilibrium between host and microbes. These NKp46+ ILCs have been 
found to be critical for host defence against pathogens such as Citrobacter rodentium 
infection through secretion of IL-22 (87, 90).  
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Table 4.1 Innate lymphoid cells including cytokine expression and immune function. 
 
Classification Transcription 
factors 
Cytokine expression Immunity roles 
ILC group 1 
(NK cells) 
 IFNγ, TNF-α Bacteria, intracellular 
parasites, autoimmune 
disorders,  
ILC group 2 
(Natural helper 
cells) 
RORα, GATA 3 IL-5, IL-9, IL-13 Parasitic worms, allergic 
disease, obesity,  
ILC group 3 
(Lymphoid 
tissue inducers 
(LTi) 
RORγt IL-22 and/or IL-17 Bacteria, autoimmune 
disorders, homeostasis 
γδ T cells   IL-17, IFN-γ, TNF-α Bacteria, mediate innate 
and adaptive immunity 
 
 
Taken together, this suggests ERAP1 plays a critical role in overall immune system 
modulation with systemic effects.  In this chapter we are asking how a lack, or down 
regulation, of ERAP1 influences the inherent gut microbiome composition, and how this 
impacts on the antigen repertoire and consequently the local and systemic immune 
system. We hypothesise that the loss of ERAP1 leads to altered T cell selection, impairing 
immune recognition of inherent gut microbiota, and leading to an overall shift in microbial 
community composition.  
 
4.2 Methods 
4.2.1 Antibodies and Flow Cytometry 
4.2.1.1 Mice 
C57BL/6 mice were purchased from Animal Resources Centre, Perth, Australia. The 
generation of ERAP-/-, which are on a C57BL/6 background, has been described 
previously (207). ERAP-/- mice were a kind gift from Dr N. Shastri (University of California, 
Berkeley). All mice were housed in the specific pathogen–free animal facility and fed 
standard rodent chow at Translational Research Institute (TRI) Biological Research 
Facility, according to the guidelines of the Australian NHMRC code for ethical use of 
animals. All animal studies have been reviewed and approved by The University of 
Queensland Animal Ethics Committee. F2-intercross mice were bred to generate 
littermates that were ERAP-/- (KO), ERAP+/- (HET) or ERAP+/+ (WT).  To minimise cage-
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effects on the gut microbiome, littermates were raised together throughout the experiment, 
and analyses were adjusted for cage. 
 
4.2.1.2 Antibodies 
Antibodies against CD4 (GK1.5), CD3 (145-2C11), CD69 (H1.2F3), CD44 (IM7), CD335 
(29A1.4), CD25 (PC61), CD11b (M1/70), NK1.1 (PK136), IFNγ (XMG1.2), IL-10 (JESS-
16E3) were purchased from Biolegend (San Diego, CA). Antibodies against γδ (eBioGL3), 
RORγt (AFKJS-9), FOXP3 (FJK16s) and IL-22 (IH8PWSR) were obtained from 
eBiosciences (San Diego, CA). IL-17 (TC11-18H10) and TNF (MP6-XT22) were 
purchased from BD Pharmagin (San Diego, CA). 
 
4.2.1.3 Cell preparation  
Spleen and mesenteric lymph node (MLN) cells were prepared from freshly harvested 
ERAP-/- and C57BL/6 mice.  Whole spleens and MLN were disrupted and strained using 
70mL filters (BD Pharmingen) to create single cell suspensions. Splenic cells were lysed 
using ACK lysis buffer for 2 minutes. Cells were washed in PBS prior and half transferred 
to 48-well plate for stimulation with PMA (phorbol myristate acetate, AKA phorbol ester, 
Biochimika) and Ionomycin (Ca2+ salt, Calbiochem) as previously described (222), with 
the other half being used for activation marker and transcription staining.  
 
Splenic and MLN cells were stained for extracellular markers, transcription factors and 
intracellular cytokines. For detection of T cell markers cells were stained for CD3, CD4, 
CD8 and γδ. For detection of non-T cells, NK1.1 and CD11b were used. Activation status 
was determined with CD69, CD44, CD335 and CD25. Transcription factors were assessed 
through FoxP3 and RORgt. Cells were fixed (Fixation Buffer, Biolegend), permeabilised 
(Perm/Wash buffer, BD Pharmingen) and stained for intracellular cytokines TNF, IFNγ, IL-
10, IL-22 and IL-17. Cytometric data was acquired on the Beckman Coulter Gallios 
cytometer.  
 
4.2.1.4 Statistics 
All data are presented as the mean ± standard error of the mean (SEM). Data were 
compared by unpaired T test, using GraphPad Prism 6 (GraphPad Software). P≤0.05 were 
considered significant. Power calculations were computed using an on-line power 
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calculator (http://www.statisticalsolutions.net/pss_calc.php) with effect size and Cohen’s d 
computed as outlined by Olejnik and Algina, 2003 (223).  
 
4.2.2 Sequencing and analysis 
 
4.2.2.1 DNA extraction  
Faecal pellets were collected and DNA extraction was performed using the Qiagen 
DNeasy tissue extraction kit as per manufacturer’s instructions.  
 
4.2.2.2 Mock community 
A mock community consisting of seven different bacteria, Gram positive and Gram 
negative, was employed as a control for both sequencing and bioinformatic analysis and 
was processed alongside the mouse faecal samples. The seven bacteria used were 
Staphylococcus aureus (ATCC 25923), Enterococcus faecalis (ATCC 51299), 
Haemophilus influenzae (ATCC49247), non-mucoid Pseudomonas aeruginosa (ATCC 
27853), Klebsiella oxytoca (ATCC 700324), Escherichia coli (ATCC 35218) and Yersinia 
enterocolitica (ATCC2 3715). Bacteria were extracted using the Qiagen DNeasy tissue 
extraction kit as per manufacturers instructions. The community was then labelled Mock1. 
 
4.2.2.3 16S rRNA PCR 
Bacterial 16S rRNA amplicon PCR was conducted using V4 primers spanning the region 
517F 803R of the 16S rRNA gene. The master mix for the reactions was conducted in a 
25ul total volume using Bioline 10x reaction buffer, dNTP(0.625mM), MgCl2 (2.0mM), 1U 
of Bioline TAQ, both primers at 5uM each and 2ul DNA. Thermocycling conditions 
comprised 10 min at 94ºC then 30 cycles at 94ºC for 50 s, 54º for 30 s, 72ºC for 45 s and a 
72ºC single step for 10 min. 
 
4.2.2.4 Sequencing Library preparation  
16S rRNA amplicon libraries were assembled and dual indexed for multiplexing using the 
Nextera XT dual indexing library protocol as per manufacturer’s instructions. Samples 
were then normalised and pooled for sequencing at a concentration of 2nM.  To create the 
required complexity for sequencing, PhiX was added to the pool at 75/25 for a final pool 
concentration of 3.5pM.  
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4.2.2.5 Illumina MiSeq Sequencing 
Dual barcoded 16S amplicon sequences were sequenced using 2x250 base paired-end 
protocols on the Illumina MiSeq.  There were 6.1million reads generated overall with an 
average of 200,000 reads per sample.  
 
4.2.2.6 Bioinformatics and statistics 
Samples were demultiplexed using CASAVA. Reads were quality filtered for Q30 and 
above using split_library.py and then analysed using the QIIME pipeline 
(qiime.sourceforge.net). OTU assignment was based on 97% similarity with taxonomic 
assignments made using BLAST to Greengenes as implemented in QIIME (Caporaso et 
al., 2011).  
 
Alpha diversity metrics were generated using the QIIME workflow alpha_rarefaction.py 
with five repetitions at each sampling point. Rarefaction curves for the observed number of 
OTUs were based on the outputs of alpha_rarefaction.py. UniFrac distances between 
microbial communities were evaluated using FastUniFrac (Louzapone and Knight 2005). 
UPGMA clustering was employed both weighted and unweighted, to detect significant 
differences between microbial communities. UniFrac enabled in QIIME was used to 
generate sample distance metrics as well as Principal Co-ordinate Analysis (PCoA) (189). 
 
PERMANOVA analysis was conducted at the genus level using the R package ‘vegan’ 
(version 3.0.2) to test the relationship between the whole microbial community, genotype, 
cage and litter effect (176). Co-occurrence network analysis was conducted using the 
‘Spaa’ package in R (version 3.0.2).   
 
4.3 Results 
4.3.1 Alterations in host genetics influences gut microbiome composition 
 
The effect of underlying host genetics on the microbiome structure and function, especially 
in AS, is still poorly understood. Taking a reductionist approach, we examined the effect 
that loss of ERAP1 has on the gut microbiome and subsequent effects on the local and 
systemic immune system using a mouse model of ERAP-/-. The loss of ERAP1 is 
protective in AS, we therefore explored if the loss of ERAP in a mouse model caused a 
shift in the intestinal flora and if that shift was anti-inflammatory in nature.  
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Faecal pellets from eight ERAP-/- and 11 wild-type C57BL/6 mice were collected and 
bacterial DNA was extracted, amplified for microbial 16S rRNA and sequenced. This proof 
of principle study aimed to determine if the loss of a single gene in is sufficient to cause a 
shift in the intestinal microbiome.   
 
16S rRNA community profiling of the mouse gut microbiome revealed distinct clustering of 
communities separating ERAP-/- from wild-type C57BL/6 mice (Figure 4.1). Microbial 
communities were compared using Weighted and Unweighted UniFrac distances, a 
phylogenetic metric that accounts for differences in both community membership and 
relative abundance (174).  These distance metrics allow us explore whether it is the 
presence or absence of bacteria that is driving the overall community structure, or if it is 
simply a change in the relative abundances of particular microbes in the community (189).  
Unweighted UniFrac analysis indicated that overall structure, the presence or absence of 
bacteria, was driving the distinct clustering between these mice. The Phylum level 
differences between C57BL/6 and ERAP-/- (Figure 4.1B) included changes in the 
Bacteroides and Firmicutes ratio that constitutes fundamental changes in community 
structure, driving the clustering on PCoA (Figure 4.1A). Several of the species observed 
driving the clustering of these mice are also indicator species driving the clustering of 
microbial communities in terminal ileum of AS patients as described in Chapter 2 of this 
thesis (Table 4.2). Whilst there are environmental effects such as background and cage 
effect, this suggests that a single change in underlying host genetics may be sufficient to 
influence microbial community structure in the gut.  
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Figure 4.1 Principal coordinate analysis and taxonomy showing community differences 
between ERAP-/- mice and control C57BL/6. (A) Unweighted Principal Coordinate Analysis 
(PCoA) showing distinct clustering of ERAP-/- mice from control C57BL/6. (B) Bar chart showing 
the difference in taxonomy at the Phylum level between C57BL/6 and ERAP-/-, noting the increase 
in Bacteroides in C57BL/6 and the change in the Bacteroides to Firmicutes ratio between the 
samples. 
 
Table 4.2 Differences in average percentage OTU counts between C57BL/6 and ERAP-/- 
mice showing that changes in proportions of key bacteria contribute to the ERAP-/- microbial 
signature. 
 
Taxonomy C57BL/6 
(OTU Ave) 
ERAP-/-  
(OTU Ave) 
Difference 
 
Result 
 
Bacteroidaceae  
(genus Bacteroides) 
0.008 0.024 0.016 Increase in ERAP-/- 
Prevotellaceae  
(genus Prevotella) 
0.012 0.008 -0.004 Decrease in ERAP-/- 
Rikenellaceae  
(genus Rikenella) 
0.011 0.028 0.017 Increase in ERAP-/- 
S24-7 
(order Bacteroidales) 
0.680 0.442 -0.238 Decrease in ERAP-/- 
Lactobacillaceae 
(genus Lactobacillus) 
0.032 0.014 -0.018 Decrease in ERAP-/- 
Clostridiaceae 
(genus Clostridium) 
0.129 0.301 0.172 Increase in ERAP-/- 
Lachnospiraceae 0.031 0.062 0.031 Increase in ERAP-/- 
Ruminococcaceae 0.007 0.016 0.009 Increase in ERAP-/- 
Desulfovibrionaceae 
(genus Desulfovibrio) 
0.024 0.012 -0.012 Decrease in ERAP-/- 
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Thus the overall structure of the gut microbiome in the ERAP-/- mice was different to 
control C57BL/6.  Additionally, key indicator species also seen in AS TI biopsies shown to 
be driving the clustering between mouse strains differing in AS-associated genetic 
makeup.  Therefore I sort to explore how the microbial community members are interacting 
and how these interactions shape the community structure and signature. Co-occurrence 
analysis, which looks at the correlation between microbes, was undertaken to explore 
correlations between keystone members of the ERAP-/- intestinal community compared to 
controls. Positive correlations, shown with blue lines, were seen between the indicator 
families Lachnospiraceae, Prevotellaceae, Clostridiaceae and Rikenellaceae with negative 
correlations, shown with red lines observed between S24-7, Prevotellaceae, 
Ruminococcaceae (Figure 4.2). The thickness of the line denotes the strength of 
correlation between the bacteria and demonstrates that bacterial interactions further shape 
the ERAP-/- microbial community signature (Table 4.2).  
 
  
 
Figure 4.2 ERAP-/- Intestinal community Co-occurrence network showing the positive (blue 
lines) and negative (red lines) correlations between indicator species. The thickness of the line 
denotes the strength of the correlation (Pearson correlation). 
 
 
Dissecting the effects of genetic variation, in this case comparing ERAP-/- with C57BL/6 
mice, it is important to consider that these experiments can be subject to variation due to 
other factors such as strain differences, cage effect and founder effect may be driving the 
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differences seen between these mice (165).  To minimise such potential confounders, we 
explored the gut microbiome differences within a single litter of ERAP mice comprising of 
ERAP-/-, ERAP+/- and ERAP+/+.  Given that these mice were the offspring of sibling 
ERAP HET founder mice, were from the same litter, and were cohoused from birth, 
variation due to background strain and cage/litter effects were minimized or excluded.  
Faecal pellets were collected and processed as described previously.  
 
  
Figure 4.3 Unweighted Principal coordinates analysis (PCoA) of a single litter of ERAP mice 
comprising three ERAP+/+, four ERAP+/- and one ERAP-/- showing distinct grouping of ERAP+/+ 
away from the other genotypes and separate clustering of ERAP-/- and ERAP+/-.  
 
The unweighted PCoA, which shows structural differences between microbial communities 
(Figure 4.3), illustrating that genotype does alter the structure of the intestinal microbiome 
(P=0.001; PERMANOVA). The three ERAP+/+ mice, our controls, are seen to cluster 
together and away from the ERAP+/-and the ERAP-/- mice. As expected, the ERAP+/- 
and the ERAP-/- cluster away from the WT and are more similar to each other than to the 
ERAP+/+ mice. It is apparent that a change in genotype, from ERAP+/+ to ERAP+/-, is 
enough to influence the community structure of the microbiome. The clustering of the 
ERAP+/- and the ERAP-/- together, but separately from the ERAP+/+, suggests that 
change of one allele is sufficient to alter the microbiome structure.  Further litters will need 
to be studied to confirm this apparent dominant effect. 
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4.3.2 Loss of ERAP does not change overall proportions of Immune cell subsets  
 
Given that we observed that the loss of a single gene influences gut microbiome 
composition, and the gut is the primary interface between microbes and the immune 
system, we were interested in how changes in the microbiome affect the immune system 
both locally and systemically.  We began by examining the major immune cell subsets in 
eight ERAP-/- and eight ERAP+/+ mice to determine if an altered gut microbiome altered 
the immune system (Figure 4.4).  Following removal of doublets, dead cells were excluded 
using Aqua Viability dye discrimination. Cell subset specific analysis of cell phenotype and 
activation status was performed by analysing cell surface protein expression. Transcription 
factor expression was determined intracellularly following cell permeabilisation. Cytokine 
production was determined intracellularly following in vitro stimulation for 4 hours with PMA 
and ionomycin in the presence of the Golgi-transport blocker monensin.  
 
 
Figure 4.4 Example gating strategy for isolation, identification and characterisation of T 
cells. Doublets were removed and dead cells were excluded using Aqua Viability dye 
discrimination. Cell subset specific analysis of cell phenotype and activation status was performed 
by analysing cell surface protein expression, with transcription factor expression determined 
intracellularly following cell permeabilisation. Cytokine production was determined intracellularly 
following in vitro stimulation. 
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A post hoc power calculation indicated our study had 80% power to detect an effect with 
Cohen’s d >0.2 α =0.05 between ERAP-/- and ERAP+/+ cells isolated from the spleen, 
however our results indicated effect sizes of Cohen’s d  <0.34. In cells derived from the 
MLN our study had 80% power to detect an effect size Cohen’s d >1 α =0.05 and our 
results indicated effect sizes with Cohen’s d >1.3. No significant differences were seen in 
overall numbers of T cells (CD3+, CD4+, CD8+ or γδ), NK cells (CD3- NKp46+), 
Macrophages (CD11b+) or regulatory T cells (CD4+ CD25+) either systemically in the 
spleen or locally in the MLN (Figure 4.5, Table 4.3).  
 
Table 4.3 Frequencies of cell subsets showing no significance between ERAP+/+ (WT) and 
ERAP-/- (KO) strains in spleen and mesenteric lymph nodes.  
 
 Spleen Mesenteric lymph nodes 
Immune cell 
subset 
PValue Mean± 
SEM WT 
Mean± 
SEM KO 
PValue Mean± 
SEM WT 
Mean± 
SEM KO 
CD3+ >0.1 
 
15.08± 
1.197 
 
14.74± 
1.514 
 
>0.05 
 
32.62 ± 
1.129 
27.83 ± 
2.432 
CD4+ >0.1 
 
22.99± 
2.110 
 
22.84± 
0.733 
 
0.054 
 
44.02 ± 
2.546 
37.39 ± 
1.865 
CD8+ >0.1 
 
16.24± 
1.314 
 
14.97± 
0.499 
 
>0.1 
 
22.77 ± 
1.435 
21.74 ± 
1.314 
γδ >0.1 
 
0.66± 
0.061 
 
0.57± 
0.045 
 
>0.1 
 
0.77 ± 
0.069 
0.76 ± 
0.063 
NK cells >0.1 
 
3.11± 
0.240 
 
2.98± 
0.343 
 
>0.1 
 
21.30 ± 
2.603 
22.27 ± 
1.283 
Macrophages >0.1 
 
6.056± 
0.956 
 
4.93± 
0.540 
 
>0.1 
 
3.34 ± 
1.213 
3.78 ± 
1.091 
Treg cells >0.1 
 
0.96± 
0.110 
 
0.96± 
0.083 
 
>0.1 
 
3.07 ± 
0.218 
3.46 ± 
0.696 
 
 
There is trend towards fewer CD3+, CD4+ T cells and NK cells in the MLN, this is 
countered by a slight increase in regulatory T cells. A non-significant reduction in overall 
numbers of Macrophages and CD3+ NKp46+ cells and increase in NK cells in the spleen 
of ERAP-/- is observed. There were no other notable differences in any of the immune cell 
subsets investigated suggesting that at least systemically, the loss of ERAP does not lead 
to significant shifts or changes in the T cell and non T cell compartment.  There were no 
differences functionally in T cell activation as measured by CD69 expression (Figure 4.5).  
CD69 is a marker of early activation and involved in inducing T cell proliferation and 
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lymphocyte migration, and is normally expressed at low levels on resting CD4+ or CD8+ T 
cells. Increased activation in CD4+ and CD8+ T cells in either the spleen and MLN of 
ERAP-/- mice, may have suggested T cell activation and mobilisation, possibly in response 
to the shift in gut flora. Together this data suggests that the effect of the loss of ERAP on 
the immune system is not systemic; the effect may be more subtle and localised to the 
intestinal tissue at the vanguard of immune system and microbe interaction.  
 
 
 
Figure 4.5 Frequencies of major immune cell subsets in ERAP+/+ (WT) and ERAP-/- (KO) 
from the Spleen (A) and mesenteric lymph nodes (C) and activation status respectfully (B and D) 
shown as mean ± SEM and compared by unpaired t test. 
 
 
 
 
 
 
 
 
109 
4.3.3 Loss of ERAP leads to differences in cytokine potential 
 
Although the intestinal flora of ERAP-/- mice are skewed more towards containing families 
of bacteria known to elicit a strong immune response, it is notable that there is minimal 
evidence of an immune response to this shift in flora. There are no detectable differences 
in the immune cell subsets either in the spleen or the MLN, so the lack of response is not 
due to an absence of immune cell subset. Therefore, we were interested to see if there 
were differences in how the immune cells responded to the intestinal microbes, and the 
cytokines produced.  
 
There was no change observed in overall numbers of immune cells between ERAP-/- and 
C57BL/6 control mice.  However, there was a trend observed in ERAP-/- mice away from 
an inflammatory IL-17 dominated environment, towards increased levels of IL-22 creating 
a less inflammatory and a more homeostatic gut environment.  
 
In the spleens of the ERAP-/- mice there is a non-significant trend towards a reduction in 
the amount of IL-17 expressed especially from CD3- and CD4+ T cells (Figure 4.6). 
However, there is a statistically significant decrease in production of IL-17 from NK cells 
(P=0.04) in ERAP-/- mice, suggestive of a response by the innate lymphoid system in 
response to the microbiome changes (Figure 4.6, Table 4.4). With a reduction of IL-17, 
there would be an expected increase in the homeostatic cytokine IL-22. However there 
was no IL-22 detected from CD8+ T cells or γδ T cells. There were no differences in 
expression of IL-10, TNF or IFNγ (Figure 4.6, Table 4.4). 
 
In the MLN, IL-17 expression was mixed across the immune subsets however there was 
an increase in expression in macrophages, although not significant (Figure 4.7, Table 4.5). 
There was an increase of IL-22 expression from CD3+ T cells, although not significant, 
and unexpectedly a decrease across all other T cell and non T cell subsets. This 
demonstrates that the IL-22 is being expressed predominately from CD3+ T cells with a 
slight increase in IL-10 expression from macrophages, adding to the homeostatic 
environment (Figure 4.7, Table 4.5).  
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Table 4.4 Frequencies of cytokine expression from Immune cell subsets in the spleen of 
ERAP-/- (KO) and ERAP+/+ (WT) mice. There was no significance in expression between ERAP 
WT and ERAP KO strains in spleen as determined by unpaired t test. 
 
Spleen 
Immune 
subsets 
IL-17 IL-22 IL-10 TNF 
 PValue Mean± 
SEM 
WT, KO 
PValue Mean± 
SEM 
WT, KO 
PValue Mean± 
SEM 
WT, KO 
PValue Mean± 
SEM 
WT, KO 
CD3+ >0.1 
 
0.052± 
0.019, 
0.061± 
0.015 
>0.1 
 
 
6.220± 
1.164, 
5.800± 
1.251 
>0.1 
 
 
1.043± 
0.437, 
0.940± 
0.796 
>0.1 
 
 
0.262± 
0.092, 
0.636± 
0.348 
CD3- >0.05 
 
28.55± 
5.290, 
15.93± 
4.043 
- - - - >0.1 
 
 
2.615± 
0.528, 
5.583± 
3.012 
CD4+ >0.1 
 
 
16.44± 
1.131, 
13.82± 
2.155 
>0.1 
 
 
0.491± 
0.204, 
0.218± 
0.068 
- - >0.1 
 
 
21.86± 
5.255, 
17.86± 
3.030 
CD8+ - - - - - - >0.1 
 
 
9.890± 
2.858, 
7.486± 
1.601 
γδ >0.1 
 
 
4.183± 
2.108, 
6.671± 
1.671 
- - - - >0.1 
 
 
9.519± 
2.199, 
10.23± 
1.239 
NK cells 0.0397 
 
0.698± 
0.279, 
0.061± 
0.026 
>0.1 
 
 
8.346± 
2.317, 
9.755± 
3.467 
>0.1 
 
 
1.948± 
0.375, 
2.105± 
0.439 
>0.1 
 
 
17.14± 
2.191, 
17.30± 
4.316 
Macrophage >0.1 
 
 
1.501± 
0.645, 
1.369± 
0.318 
>0.1 
 
 
12.16± 
1.545, 
11.25± 
2.608 
>0.1 
 
 
3.983± 
0.807, 
3.098± 
0.480 
>0.1 
 
30.05± 
2.961, 
28.35± 
4.323 
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Figure 4.6 Immune cell subsets and expression of cytokine from the spleen of ERAP-/- (KO) 
mice compared to ERAP+/+ (WT). (A) Expression of IL-17 in the spleen, noting the increase in 
secretion from γδ T cells, and the absence of IL-17 secretion from CD3+ T cells as a whole and 
CD8+ T cells. (B) Expression of IL-22 showing a slight decrease across all cell types except for NK 
cells and no significant differences in expression of either IL-10 (C) or TNF (D).  Data shown as 
mean ± SEM and compared by unpaired t test. 
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Figure 4.7 Immune cell subsets and expression of cytokine from the mesenteric lymph 
nodes (MLN) of ERAP-/- (KO) mice compared to ERAP+/+ (WT). (A) Expression of IL-17 in the 
MLN, showing an increase in secretion from macrophages. (B) Expression of IL-22 showing an 
increase in secretion from CD3+ T cells, but undetectable levels across other T cell subsets. A 
slight increase in IL-10 secretion was detected in macrophages (C) and TNF secretion in the MLN 
mirrored what was seen in the spleen (D). 
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Table 4.5 Frequencies of cytokine expression from immune cell subsets in the MLN. There 
was no significant difference in expression between ERAP+/+ (WT) and ERAP-/- (KO) strains in 
spleen as determined by unpaired t test. 
 
 
MLN 
Immune 
subsets  
IL-17 IL-22 IL-10 TNF 
 PValue Mean± 
SEM 
WT, 
KO 
PValue Mean± 
SEM 
WT, 
KO 
PValue Mean± 
SEM 
WT, 
KO 
PValue Mean± 
SEM 
WT, 
KO 
CD3+ >0.1 
 
0.008± 
0.006, 
1.244± 
1.221 
>0.1 
 
 
5.150± 
1.253, 
5.536± 
1.956 
>0.1 
 
 
0.7500
± 
0.3543, 
1.619± 
1.069 
>0.1 
 
3.061± 
1.368, 
3.068± 
0.823 
CD3- >0.1 
 
20.03± 
3.159, 
18.96± 
4.603 
- - - - >0.1 
 
8.066± 
2.134, 
8.850± 
2.024 
CD4+ >0.1 
 
0.976± 
0.656, 
0.926± 
0.277 
>0.1 
 
 
- - - - - 
CD8+ - - - - - - >0.1 
 
29.16± 
4.637, 
33.87± 
8.483 
γδ  >0.1 
 
4.083± 
0.951, 
3.334± 
0.661 
- - - - - - 
NK cells 0.059 
 
7.023± 
1.794, 
3.023± 
0.767 
0.013 
 
2.675± 
0.562, 
0.921± 
0.254 
>0.1 
 
 
11.80± 
3.954, 
10.59± 
1.788 
0.055 
 
20.92± 
4.451, 
11.31± 
1.186 
Macrophage >0.1 
 
21.67± 
3.942, 
23.71± 
3.701 
>0.1 
 
 
4.595± 
1.117, 
2.455± 
0.997 
>0.1 
 
 
66.10± 
8.980, 
70.75± 
7.556 
0.054 
 
51.38± 
9.148, 
31.34± 
2.772, 
 
4.4 Discussion 
 
The association of variants of ERAP1 is one of the strongest non-MHC associations seen 
in AS. In this chapter I investigated if the loss of a single AS-associated gene was 
sufficient to alter the intestinal microbiome and the immune response. Given that loss of 
function genetic variants of ERAP1 in AS are protective, and that an estimated 70% of AS 
patients have either clinical or sub clinical gut disease, we explored how a lack or down 
regulation of ERAP1 influences the inherent gut microbiome composition, and given the 
gut microbiome is the educator of the immune system, the subsequent impact this has on 
the antigen repertoire and immune system. 
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To investigate this hypothesis that ERAP1 leads to altered T cell selection, impairing 
immune recognition of inherent gut microbiota, and leading to an overall shift in microbial 
community composition; we examined if the loss of ERAP, in a mouse model, caused a 
shift in the intestinal flora. Consistent with this hypothesis, 16S community profiling 
revealed that the gut microbiome in ERAP-/- did shift, however it was surprisingly towards 
a more inflammatory profile, with increases of bacteria such as Rikenellaceae, 
Lachnospiraceae and Ruminococcus which are not only known to elicit a strong immune 
response, but are also key bacteria in the TI of AS patients (102-104). The shift in the 
ERAP-/- mouse microbiome was further explored to determine if it was the overall 
structure or simply the presence or absence of bacteria that was driving the signature. 
Unweighted UniFrac analysis revealed that the loss of ERAP triggered a fundamental shift 
of bacteria at the phylum level, causing an overall shift in community structure. 
Interestingly, this also included a shift in the Bacteroides-Firmicutes ratio leading to an 
increase in Firmicutes in the ERAP-/- mice, which is consistent with what we observe in 
the AS gut microbiome as described in Chapter 3 of this thesis. Indicator species analysis 
revealed that alterations in specific species, and not just entire Phyla, were contributing to 
the microbial signature. The bacterial families that varied in ERAP+/+ and ERAP-/- mice 
were Rikenellaceae, Lachnospiraceae, Ruminococcaceae, Bacteroidaceae and 
Clostridiaceae which are also bacteria associated with the microbial signature in AS. 
Whilst the association of particular bacterial families seen in both AS intestinal biopsies 
and ERAP-/- gut microbiome is interesting, it is however incidental.  
 
Given the loss of ERAP caused such dramatic change in gut microbiome structure an 
experiment for cage and litter effects was conducted. In order to minimise such potential 
confounders, the intestinal microbial composition of a single litter of ERAP mice 
comprising of ERAP+/+, ERAP+/- and ERAP-/- were explored. These mice were the 
offspring of sibling ERAP+/- founder mice, from the same litter, and were cohoused from 
birth so that variation due to background strain and cage/litter effects were minimized or 
excluded as much as possible.  It is clear from the unweighted PCoA that the ERAP+/- 
and ERAP-/- mice were more similar to each other and clustered away from the WT mice. 
This suggests that a change in genotype, from WT to HET, is sufficient to influence the 
overall structure and composition of the gut microbiome. The clustering of the ERAP+/- 
and ERAP-/- together, but separately from the ERAP+/+, suggests that change of one 
allele is sufficient to alter the microbiome structure, but as only one ERAP-/- mouse was 
present in the litter, whether homozygous loss of ERAP has additional effects compared 
 
 
115 
with heterozygotes remains unclear. While only one litter was studied, and larger numbers 
are needed to better characterise the impact of genotype on the intestinal microbiome, 
these results are consistent with the hypothesis that AS-associated genes contribute to 
disease aetiopathogenesis through effects of the underlying host genetics on intestinal 
microbial composition.  
 
The intestine is the front line between the immune system and the gut flora, and a shift in 
gut flora is usually met with a strong and swift inflammatory immune response dominated 
by IL-17 in an effort to return to balance and homeostasis.  ERAP-/- mice demonstrated a 
shift towards microbiome composition akin to what was observed in AS cases.  Therefore, 
we examined the affect the loss of ERAP had on the local and systemic immune system, 
and how the immune system in turn sculpted the gut microbiome. There was no significant 
change or alteration in the T cell or non T cell compartments. This is in keeping with 
previous work that has shown that there are no differences in the profile of CD4+ T cells or 
CD8+ T cells of ERAP-deficient mice when compared to ERAP competent mice (208, 209, 
214, 215). There was also no significant change in the cytokine potential in ERAP-/- mice 
compared to control ERAP+/+, although there was a trend towards an increase in IL-22 
secretion from CD3+ T cells as well as an increase in IL-10 secretion from macrophages in 
the MLN.  Coupled together, this data suggests that the effect of the loss of ERAP on the 
immune system is subtle and site specific. To dissect the effect of the loss of ERAP, not 
only on microbiome composition but the immune system, the local intestinal tissue 
environment needs to be explored. Examining the lamina propria (LP) cells from the 
intestinal walls of ERAP-/- and ERAP+/+ mice would shed light on the front line 
interactions between the immune system and the gut microbiota. However, this would 
require significantly more mice to be studied, as LP cells are isolated in small numbers 
requiring mice to be pooled to obtain sufficient cell numbers for analysis.  
 
The impact the establishment and maintenance of beneficial interactions between the host 
and their microbiota is rapidly becoming a key focus as a requirement for overall health. 
The bacteria that inhabit the gut and the human immune system have developed a number 
of strategies to maintain gut homeostasis in dynamic and every changing environment. 
The gut also is the primary site for interaction and education between gut microbes and 
the host immune system. The dysregulation of gut homeostasis is increasingly recognised 
as playing a pivotal role in autoimmunity and controlling activation of the immune system in 
response to these changes in gut microbiota has to be tightly regulated as to avoid chronic 
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inflammation. The role that underlying host genetics plays in gut microbiome composition 
and the flow on effect to the immune system requires more interrogation. In this chapter 
we described how the loss of a single AS-associated gene, ERAP1, led to dramatic shift in 
the overall composition and structure of gut microbiome. Of particular interest, was the 
finding that the clustering in the murine experiments was driven by bacteria that are AS 
also seen in the microbiome of patients who have AS. Further investigation into the impact 
of genotype on microbiome composition revealed that the change in even one allele led to 
detectable shift in relative abundance of microbes. The role the immune system has in 
helping shape these microbiome changes is unclear. By better understanding the 
interactions locally in the intestinal tissue at the interface between gut microbes and the 
immune system, we may better understand ERAP mechanism in conferring protection 
from AS and possibly harnessing and modulating an anti-inflammatory immune response. 
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5 Chapter 5 Effect of underlying host genetics on intestinal 
microbiome composition 
 
5.1 Introduction 
 
The more we learn about the microbes that live in and on our body, the more we 
understand about how they interact with our genes and the environment, to affect overall 
health and wellbeing (211). There is an estimated 10-fold increase in the number of 
bacterial cells in our body relative to human cells, essentially making us more microbe 
than human (125). The majority of these microbes reside in the gut, the primary site for 
interaction between microbes and the host immune system (38, 123, 126). The exact 
composition of a ‘healthy’ gut microbiome differs markedly between individuals, however 
microbiome composition is increasingly viewed as a risk factor in a number of chronic 
diseases such as rheumatoid arthritis (224), obesity (114), IBD (102, 225), and diabetes 
(226). The gut microbiota is increasingly being looked at as a target for novel therapies, 
including microbiome modulation with pre- and probiotics and even faecal transplants. 
These novel therapies are being increasingly used to treat patients with CD (227) and 
Clostridium difficile infections (228), where conventional treatments and antibiotics have 
failed. The successful use of the gut microbiome as a therapeutic target requires a deeper 
understanding of factors that shape the community composition including age, diet, gender 
as well as underlying host genetics.   
 
The role of the host genetics in shaping intestinal microbial community composition in 
humans is unclear. In animal models, host gene deletions have been shown to result in 
shifts in microbiota composition (135). In addition, a recent quantitative trait locus mapping 
study linked specific genetic polymorphisms with microbial abundances (136). These 
studies highlight the importance of underlying host genetics in community composition in 
animals.  This is of great interest in diseases such as IBD, where many of the genes 
associated with disease are associated with handling, processing and response to 
microbes such as IL23R, NOD2, NOS2 and CARD9. Genetic studies in CD, one of the two 
common forms of IBD, shows a marked over-representation of genes, especially NOD2 
and TNFRSF18, which are associated with an increased risk of developing mycobacterial 
diseases, including leprosy and tuberculosis (23). For example, seven of the eight known 
genetic variants associated with increased risk of leprosy, including SLC11A1, VDR and 
 
 
118 
LGALS9, also increase the risk of Crohn’s disease, compared with only two being 
associated with risk of any other immune-mediate disease. Coupled with the dramatic 
shifts in the gut microbiota that have been associated with IBD (23, 135), this strongly 
indicates a potential link between host genetics and the microbiome in IBD patients. The 
genetic influence over microbiome composition is further highlighted in a study of 416 
monozygotic and dizygotic twin pairs that found the most heritable taxon was the recently 
described family Christensenellaceae (137).This family of bacteria was also shown to be 
central to a network of co-occurring heritable microbes associated with lean body mass 
index. In mice it was shown that the introduction of any of the members of the 
Christensenellaceae family of protected the mice from weight gain (137). Until recently 
variation and changes in the gut microbiome have been explained by diet and 
environment. While the exact genes associated with the Christensenellaceae family are 
unknown, this study demonstrates that microbiome composition may in part be due to host 
genetics.  
 
AS is a common inflammatory arthritis that affects over 22,000 Australians (1).  Up to 70% 
of AS patients have either clinical or subclinical gut disease, which suggests that intestinal 
inflammation is important in the disease (7, 8).  Increased gut permeability has been 
demonstrated in both AS patients and their first-degree relatives compared with unrelated 
healthy controls (11-13, 229). This is consistent with the hypothesis that increased 
‘leakiness’ of the gut may increase the microbial dissemination and drive inflammation in 
the disease.  
 
In the SKG mouse and B27-transgenic rat models of spondyloarthritis, animals raised in 
sterile conditions remain healthy and do not develop disease (230, 231). When the gut of 
these mice and rats are recolonised with bacteria, arthritis often develops (15, 232).  
Whilst this data supports a role for gut pathogens or the gut microbiome in AS, current 
studies using antibody tests have not produced convincing evidence to demonstrate that 
increased infection with any specific triggering agent influences the development of AS. 
Several specific bacteria have been suggested to have a role in AS pathogenesis 
particularly Klebsiella pneumoniae (138, 139), Bacteroides vulgatus (140). These two 
bacteria have been of considerable focus for several reasons. When HLA‐
B27/β2 microglobulin transgenic rats, that have been raised germ free, are colonised with 
an intestinal bacterial cocktail with increased amount of Bacteroides vulgatus, the rats 
developed more several colitis (141). Significant research has been directed towards the 
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involvement of K. pneumoniae. Early work reported the presence of K. pneumoniae in the 
faeces of AS patients during active disease (142). Studies have reported the presence of 
K. pneumoniae in faeces during active inflammatory disease (142) elevated levels of 
serum antibodies against K. pneumoniae in AS patient sera have been detected (143), as 
well as the antigenic similarity noted between Klebsiella and HLA‐B27 (144). Recent 
studies however have been unable to confirm a role of Klebsiella AS.  
 
Understanding how the gut microbiota communities are assembled and maintained is 
becoming increasingly relevant not only to general healthy, but also potentially to the 
treatment of complex chronic diseases. In recent years only a few studies have examined 
the composition, diversity and function of the human gut microbiome. Studies comparing 
the gut microbiota of lean and obese twins have shed light on the importance of intestinal 
microbes and how a change in microbiome composition can affect food metabolism in the 
gut (114, 117, 118). Turnbaugh et al showed that even with a similar genetic make-up, 
obese twins had substantial differences in the composition and diversity of their gut flora 
with a dominance of Gram positive bacteria from the phylum Firmicutes, compared with 
discordant or lean twins (114). This shift in gut flora composition altered how food was 
broken down and metabolised in the gut, leading to increased body mass index, adiposity 
and obesity (114, 117, 119). This demonstrates that shifts in the intestinal microbiome 
have functional consequences on the health of the individual (120). To further investigate 
structure and function of the gut microbiome, as well as the consequences of shifts and 
alterations, faecal samples from four twin pairs discordant for obesity were transplanted 
into germ free mice (121). The authors found that the Firmicute phylum dominated 
microbial communities from the obese twin lead to obesity in the germ-free mice. The 
Bacteroides dominated microbial communities from the lean mice kept the germ-free mice 
lean. When the mice were co-housed, the invasion of Bacteroides from the lean mice lead 
to a decrease in adiposity and body mass in obese mice and transformed their 
microbiota’s metabolic profile to a lean-like state (121).  
 
These studies have shown that shifts in microbiome can change metabolism; however, 
they do not provide details of what constitutes a ‘normal’ microbiome or how it behaves.  
Two major studies into the ‘normal’ microbiome have been undertaken by the European 
MetaHit project and the National Institute of Health Human Microbiome Project in the USA 
(123, 126, 233). The European MetaHIT project was developed to catalogue all the 
bacteria living in the intestine. The consortium combined published data sets from across 
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the world, in addition to 22 newly sequenced faecal metagenomes from four different 
European countries. They identified three clusters, or groups of bacteria, that they termed 
‘enterotypes’. The authors suggested that particular enterotypes, due to their functional 
capacities, might be associated with diseases such as obesity or IBD (123) Enterotypes to 
date have not been confirmed in other datasets; however, the idea of groups or clusters of 
bacteria being related to disease because of function is gaining popularity. The Human 
Microbiome Project was developed to identify and catalogue the human microbiome by 
sequencing samples from 242 individuals (129 males, 113 females) from five major body 
areas. A total of 4,788 specimens were sequenced with females sampled from 18 different 
habitats and males from 15 habitats (126). Metagenomic carriage of metabolic pathways 
was stable among individuals, despite the variation seen in community structure. When 
clinical metadata was present, ethnic background proved to be one of the strongest 
predictors of both pathways and microbes. This suggests that environmental factors such 
as diet, location/region and host genetics could play a role in sculpting the microbiome. 
These studies further define the range of structural and functional configurations that are 
present in normal microbial communities in a healthy population (123, 126).  
 
Genes are the primary determinant of the risk of developing AS, with heritability about 97% 
(4), implying that the trigger for the disease is environmental. CD is closely related to AS 
with a similar prevalence and high heritability. The two commonly co-occur with an 
estimated ~5% of AS patients developing CD, and 4-10% of CD patients developing AS 
(234, 235). The propensity to occur in families implies shared aetiopathogenic factors, and 
extensive sharing of genetic risk factors.  There is strong suggestive evidence to support a 
role for the gut microbiome in the aetiopathogenesis of both diseases. Understanding the 
influence of host genetics on the bacterial composition of the microbiome is vital because if 
the underlying genetics dictates the response of the immune system to the microbiome, or 
how the body tolerates or processes microbes, then no amount of microbiota modulation 
or probiotics will permanently shift the intestinal microbiome; not without doing something 
to influence the gene actions. However, if host genetics favours microbiota modulation, 
then the potential for the microbiome as a therapeutic target via faecal microbiota 
transplants (FMT) or probiotics presents a new avenue for therapeutic developments for 
AS.  
 
We hypothesise that the major genetic predisposing factors to AS influence the gut 
microbiome in healthy and affected individuals, and that genes predisposing to AS do so 
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by influencing the gut microbiome composition.  We explored the association between AS 
associated single nucleotide polymorphisms (SNPs) and intestinal bacteria. The intestinal 
communities of 982 faecal samples were characterised in 287 DZ pairs and 204 MZ pairs, 
from the TwinsUK registry as described by Goodrich et al (137). 
 
5.2 Methods 
5.2.1 TwinsUK dataset 
As detailed in Goodrich et al, 982 faecal samples from as many otherwise healthy 
individuals, none of which were known to be diagnosed with AS, were sequenced. Most 
subjects were female aged from 23 to 86 years (average age: 60.6 ± 0.3 years). 
78,938,079 quality-filtered sequences were generated and mapped to the Bacteria and 
Archaea in the Greengenes database (average sequences per sample: 73,023 ± 889). 
5.2.2 Sample collection  
All work involving human subjects was approved by the Cornell University IRB (Protocol ID 
1108002388). Faecal samples were collected at home by participants in the United 
Kingdom Adult Twin Registry (TwinsUK); (Moayyeri et al., 2013) in 15 ml conical tubes and 
refrigerated for 1-2 days prior to the participants’ annual clinical visits at King’s College 
London (KCL). Upon arrival at KCL, the samples were stored at -80ºC and shipped by 
courier on dry ice to Cornell University, where they were stored at -80ºC until processing. 
5.2.3 DNA extraction and 16S rRNA amplification 
Genomic DNA was isolated from an aliquot of ~100 mg from each sample using the 
PowerSoil® - htp DNA isolation kit (MoBio Laboratories Ltd, Carlsbad, CA). 16S rRNA 
genes were amplified by PCR from each of the 982 samples (287 DZ twin pairs, 204 MZ 
twin pairs) using the 515F and 806R primers for the V4 hypervariable region of the 16S 
rRNA as previously described (127). 
5.2.4 16S rRNA filtering and analysis 
As described in Goodrich et al matching paired-end sequences (mate-pairs) were merged 
using the fastq-join command in the ea-utils software package and merged sequences 
over 275 bp in length were filtered out of the dataset (137). The remaining merged 
sequences were analysed using the open-source software package QIIME 1.7.0 
(Quantitative Insights Into Microbial Ecology; (169)).  
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Quality filters were used to remove sequences containing uncorrectable barcodes, 
ambiguous bases, or low quality reads (Phred quality scores ≤ 25). Closed-reference 
Operational Taxonomy Unit (OTU) picking at 97% identity against the May 2013 
Greengenes database (97% OTU reference sequences), which excluded 15.6% of total 
sequences. The taxonomic assignment of the reference sequence was used as the 
taxonomy for each OTU. α-diversity, Chao 1, Observed Species as well as β-diversity 
(Unweighted and Weighted UniFrac) (189) metrics, and Bray-Curtis Dissimilarity using the 
Greengenes phylogenetic tree where necessary, were calculated. β-diversity was 
calculated with a rarefied OTU table containing 10,000 sequences per sample and PCoA 
on the distance matrices. α-diversity metrics were calculated from 100 iterations using a 
rarefaction of 10,000 sequences per sample. Summaries of the taxonomic distributions of 
OTUs were generated at six levels from genus to phylum from the non-rarefied OTU table.  
 
5.2.5 SNP selection, genotyping and imputation 
Individuals were genotyped on the HumanHap 300k Duo array or the HumanHap610-
Quad array. Of the 491 twin pairs, 4 were genotyped on both chips, 252 were genotyped 
only using the Illumina HumanHap 300 duo array, with the remaining 235 genotyped using 
the Illumina HumanHap 610k duo array. Previous studies have identified 43 SNPs to be 
associated with AS, some of which are in the MHC (24). Genotype data was extracted 
1MB around the 43 confirmed susceptibility loci; SNPs with a MAF <0.05 were excluded. 
For each locus we phased data with MACH (236) using the default parameters. For each 
locus we imputed missing genotypes from the European panel of the 1,000 Genomes 
Project (2010-11 data freeze, 2012-02-14 haplotypes as downloaded from the MACH 
website*) using minimac (237). Imputed SNPs with low imputation quality score (Rsq < 
0.5) were removed from all analyses. The reported index SNP for each of the susceptibility 
loci was then used for subsequent analyses, unless otherwise stated. Genotyped data was 
used where available otherwise the dosages from the imputed data were used (i.e. 
expected number of copies of a given allele, ranging from 0 to 2). 
 
Due to the large effect of HLA-B27, two allelic risk scores were constructed using AS 
associated imputed SNPs (Table 5.1). The first score for each of the twins was derived as 
a sum of AS-risk alleles across the imputed dosages for all 43 SNPs. The second score 
weighted the risk allele dosage by the effect size reported in the relevant published papers 
and then summed the weighted dosages. Allelic risk scores were calculated using custom 
scripts in R 3.0.2 (238).  
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* http://www.sph.umich.edu/csg/abecasis/MACH/download/1000G.2012-02-14.html 
 
5.2.6 Statistical analysis 
We assessed whether each of the 768 16S rRNA OTUs followed a Gaussian distribution 
through plotting histograms and calculating the mean, skew and kurtosis. The mean 
allowed the assessment of central tendency for each OTU. Skewness and kurtosis 
describe the shape of the distribution for each OTU; skewness quantifies the asymmetry of 
the distribution and kurtosis quantifies the peakedness of the distribution. Based on these 
summary statistics and the histograms, it was determined that some of the OTUs did not 
follow a normal distribution. The statistical tests used in the remainder of this chapter 
assume the data follows a normal distribution; we therefore applied an inverse normal 
transformation to each of the OTUs to ensure normality before analysis.  
 
Linear mixed effects models were used to investigate the association between each of the 
OTUs and the 43 individual AS SNPs or allelic scores. These models account for the 
correlation between twins within a family. Analysis of the single SNPs was conducted in 
Merlin (239) using the following command line:   
 
merlin -d zygosity dat file,SNP dat file –p Twins zygosity pedigree file,SNP pedigree 
file -m SNP map file --assoc --tabulate Results-chr22-assoc-Jan14 
 
This uses a likelihood ratio test to compare a model including the individual SNP to a 
model without the SNP. Descriptive statistics and the analysis of the allelic score was 
conducted in R (version 3.0.2) using the nlme library (238). 
 
5.3 Results 
5.3.1 Distribution of OTUs is not linked to infection or Phylum 
The distribution of OTUs is often ignored because currently used methods of normalisation 
and quality control are deemed sufficient.  However, the statistical tests used to investigate 
the relationship between host genetics and the microbiome assume the OTU is normally 
distributed. Figure 5.1 shows the histograms for a selection of the OTUs, and Table 5.2 
shows the mean, skew and kurtosis. Histograms demonstrated a mixture of modalities 
across the OTUs, with some OTUs following a normal distribution but the majority showing 
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bimodal distributions. Table 5.2 indicates that there is a large range of skewness and 
kurtosis in the OTUs (Skew: -0.503 to 0.952, Kurtosis: -1.616 to 0.744), further 
emphasising the departure from normality for many OTUs. This demonstrates the need for 
normalisation prior to applying a statistical model.  
 
 
 
Figure 5.1 Representative OTUs prior to normalisation, demonstrating the range of 
distributions present within the OTU table and the same order of bacteria, showing the range of 
mean, skew and kurtosis of each OTU. Taxonomy is shown with full classification from phylum 
through class (c_), order (o_), family (f_), genus (g_) and species (s_). 
 
To establish if the variation of distributions of the OTUs was due to pathogenic bacteria, 
such as E. coli, or if particular modality patterns were specific to Gram negative or Gram 
positive bacteria, OTUs within a family or genus of bacteria were compared. Comparisons 
showed that OTUs within the same family or genus have very different distributions (Figure 
5.2). Distributions of known pathogenic bacteria, such as pathogenic E. coli, were also 
compared and no trend or pattern was observed (Figure 5.3).  This demonstrates that the 
variability seen across the OTU table was not driven by bacterial pathogenicity or by 
taxonomy. This also indicated that OTU distribution cannot be predicted through 
taxonomy, and variation seen within the OTUs may be a due to temporal variance or 
normal variation with the bacteria and the microbiome.  
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Figure 5.2 Distributions of the family Lachnospiraceae demonstrating variation of distribution 
patterns within the same family of bacteria. Taxonomy is shown with full classification from phylum 
through class (c_), order (o_), family (f_), genus (g_) and species (s_). 
 
 
Figure 5.3 Distributions of selected members of the family Enterobacteriaceae, which 
contains a number of pathogenic bacteria including Shigella, Klebsiella and E.coli, showing no 
clear pattern of distribution. Taxonomy is shown with full classification from phylum through class 
(c_), order (o_), family (f_), genus (g_) and species (s_). 
 
5.3.2 AS susceptibility variants are associated with overall microbiome structure 
 
AS is a complex highly heritable disease with over 40 loci known to be associated with AS. 
Due to the large effect of HLA-B27, two allelic risk scores were constructed to investigate 
the combined effect of AS susceptibility variants on microbiome composition (Figure 5.4). 
No OTUs were significantly associated with either the weighted or unweighted allelic risk 
score, using a Bonferroni corrected experiment-wide significance level. However, 13 OTUs 
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reached nominal significance (P<0.05) on the weighted risk score (Table 5.2) and 102 
OTUs reached nominal significance with the unweighted risk score (including the 13 OTUs 
from the weighted score) (Table 5.3). Within the 13 OTUs that were nominally associated 
with the weight risk allelic score, six OTUs belonged to the family of Ruminococcaceae, 
three belong to the family Lachnospiraceae and the remaining four OTUs belonged to 
Bifidobacteriaceae and the order Clostridiales. The families of Ruminococcaceae, 
Lachnospiraceae and the order Clostridiales are known to be associated with AS and are 
members of the core microbiome as described in Chapter 3 of this thesis. Of the 102 
OTUs reaching nominal significance in the unweighted risk score, the major families of 
bacteria represented were again Ruminococcaceae, Lachnospiraceae, Bifidobacteriaceae, 
the order Clostridiales and Veillonellaceae. This demonstrates that regardless of whether 
the risk score is weighted for effect size or not, the same AS core families of 
Ruminococcaceae, Lachnospiraceae, and the order Clostridiales are associated with AS 
SNPs, with only the membership and number of OTUs expanding. This is similar to what 
we observed in intestinal dysbiosis in AS cases in Chapter 3.  As the threshold for core 
membership was reduced to 90, 75 and 50% of the time, the families of bacteria present 
remained the same however the number of genus and species within these families 
increased, especially in the order Clostridiales, Lachnospiraceae and Ruminococcaceae 
families. This suggests the structure of the core microbiome is not only robust, but may be 
influenced by underlying host genetics. 
 
 
 
Figure 5.4 Histogram of weighted allelic risk score demonstrating the effect of HLA-B27 
genotype (GG, AG, AA). 
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Table 5.1 Reported AS associated loci including correlation of genes associated with 
inflammatory bowel disease.  
 
 
Reported gene SNP Locus AS 
Risk/Non-
risk 
Alleles 
Position  
RUNX3 rs6600247 1p36 C/T 25,177,701 
IL23R rs11209026 1p31 G/A 67,478,546 
  rs12141575 1p31 A/G 67,520,024 
GPR25-KIF21B rs41299637 1q32 T/G 199,144,473 
PTGER4 rs12186979 5p13 C/T 40,560,617 
ERAP1-ERAP2-LNPEP rs30187 5q15 T/C 96,150,086 
  rs2910686 5q15 G/A 96,278,345 
ERAP1-ERAP2 rs10045403 5q15 A/G 96, 173,489 
IL12B rs6871626 5q33 T/G 158,759,370 
 rs6556416 5q33 G/T 158,751,323 
CARD9 rs1128905 9q34 C/T 138,373,660 
LTBR-TNFRSF1A rs1860545 12p13 C/T 6,317,038 
  rs7954567 12p13 A/G 6,361,386 
NPEPPS-TBKBP1-
TBX21 
rs9901869 17q21 T/C 42,930,205 
21q22 rs2836883 21q22 G/A 39,388,614 
IL6R rs4129267 1q21 G/A 152,692,888 
FCGR2A rs1801274 1q23 T/C 159,746,369 
 rs2039415 1q23 C/T 159,121,069 
UBE2E3 rs12615545 2q31 C/T 181,756,697 
GPR35 rs4676410 2q37 A/G 241,212,412 
NKX2-3 rs11190133 10q24 C/T 101,268,715 
ZMIZ1 rs1250550 10q22 C/A 80,730,323 
SH2B3 rs11065898 12q24 A/G 110,346,958 
GPR65 rs11624293 14q31 C/T 87,558,574 
IL27-SULT1A1 rs7282490 16p11 A/G 28,525,386 
 rs35448675 16p11 A/G 28,236,248 
TYK2 rs35164067 19p13 G/A 10,386,181 
 rs6511701 19p13 A/C 10,486,067 
ICOSLG rs7282490 21q22 G/A 44,440,169 
EOMES rs13093489 3p24 A/C 27,769,911 
IL7R rs11742270 5p13 G/A 35,917,200 
UBE2L3 rs2283790 22q11 C/T 20,286,653 
BACH2 rs17765610 6q15 G/A 90,722,494 
 rs639575 6q15 A/T 91,047,852 
NOS2 rs2531875 17q11 G/T 23,172,294 
 rs2297518 17q11 A/G 23,120,724 
HHAT rs12758027 1q32 C/T 208,861,431 
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IL1R2-IL1R1 rs4851529 2q11 G/A 102,013,732 
  rs2192752 2q11 C/A 102,135,805 
2p15 rs6759298 2p15 C/G 62,421,949 
GPR37 rs2402752 7q31 T/C 124,226,835 
HLA-B27 rs4349859 6p21 A/G 31,365,787 
ANTRX2 rs4333130 4q21 A/G 81,168,853 
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Table 5.2 OTUs with taxonomy associated at P<0.05 from the weighted allelic risk score, including beta and standard error. Six of the 
OTUs associated belong to the family of Ruminococcaceae, three belong to the family Lachnospiraceae and the remainder belonging to 
Bifidobacteriaceae and the order Clostridiales. Taxonomy is shown with full classification from phylum through class (c_), order (o_), family (f_), 
genus (g_) and species (s_).  
 
OTU Beta Standard Error P-value Taxonomy 
178760 -0.0256 0.0107 0.0172 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
179572 -0.0261 0.0112 0.0202 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
681370 -0.0487 0.0211 0.0216 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__pseudolongum 
324894 -0.0392 0.0176 0.0267 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
330469 -0.0307 0.0138 0.0267 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
4347159 -0.1122 0.0505 0.0269 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__adolescentis 
178642 -0.0235 0.0106 0.0275 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
2688035 -0.0313 0.0143 0.0292 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
16054 -0.0590 0.0272 0.0310 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__callidus 
232828 -0.0340 0.0162 0.0367 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
185814 -0.0589 0.0282 0.0376 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
48084 -0.0950 0.0465 0.0419 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
193946 -0.0339 0.0172 0.0498 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
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Table 5.3 OTUs reaching nominal significance (P<0.05) in the unweighted risk score. The major families of bacteria represented are 
Ruminococcaceae, Lachnospiraceae, Bifidobacteriaceae, the order Clostridiales and Veillonellaceae, which are the same families of bacteria 
observed in the weighted analysis and in the core microbiome in Chapter 3 of this thesis. Taxonomy is shown with full classification from 
phylum through class (c_), order (o_), family (f_), genus (g_) and species (s_).  
OTU Beta SE P-value Taxonomy 
16054 -0.0292 0.0085 0.0006  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__callidus 
324894 -0.0190 0.0055 0.0007  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
330469 -0.0141 0.0043 0.0012  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
2617854 -0.0525 0.0164 0.0015  Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
189937 -0.0116 0.0039 0.0031  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
177207 -0.0224 0.0078 0.0045  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
185558 -0.0123 0.0043 0.0047  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
193477 -0.0123 0.0044 0.0051  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
198947 -0.0141 0.0051 0.0058  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
185814 -0.0244 0.0088 0.0060  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
197698 -0.0203 0.0074 0.0061  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
348642 -0.0289 0.0105 0.0061  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; s__gnavus 
196513 -0.0191 0.0070 0.0066  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
319275 -0.0187 0.0069 0.0077  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
182036 -0.0233 0.0087 0.0080  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
193969 -0.0242 0.0091 0.0084  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
193968 -0.0284 0.0109 0.0094  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
197343 -0.0134 0.0051 0.0094  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
184114 -0.0325 0.0126 0.0103  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
181826 -0.0125 0.0048 0.0105  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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3530697 -0.0174 0.0067 0.0105  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
190169 -0.0231 0.0091 0.0116  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
189092 -0.0320 0.0128 0.0127  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
191734 -0.0072 0.0029 0.0132  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
535955 -0.0210 0.0085 0.0144  Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__SMB53; s__ 
295258 -0.0243 0.0099 0.0145  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
180721 -0.0159 0.0065 0.0152  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
175729 -0.0233 0.0096 0.0160  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
183970 -0.0162 0.0067 0.0165  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
181139 -0.0222 0.0092 0.0167  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
185583 -0.0271 0.0113 0.0171  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
310979 -0.0167 0.0070 0.0178  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
2943548 -0.0299 0.0125 0.0178  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
44151 -0.0103 0.0043 0.0180  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
187924 -0.0203 0.0086 0.0185  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
4425669 -0.0354 0.0150 0.0186  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
175836 -0.0077 0.0033 0.0194  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
192127 -0.0143 0.0061 0.0197  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
186772 -0.0181 0.0077 0.0199  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
185575 -0.0488 0.0209 0.0200  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
4466275 -0.0108 0.0047 0.0216  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
199279 -0.0089 0.0039 0.0220  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
192370 -0.0098 0.0043 0.0227  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
193769 -0.0169 0.0074 0.0233  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; s__gnavus 
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178760 -0.0076 0.0034 0.0235  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
182577 -0.0189 0.0084 0.0246  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
189924 -0.0114 0.0050 0.0249  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
179572 -0.0079 0.0035 0.0252  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
179200 -0.0196 0.0087 0.0252  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
317814 -0.0206 0.0092 0.0259  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
305318 -0.0157 0.0071 0.0268  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
193709 -0.0226 0.0101 0.0269  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
187504 -0.0258 0.0116 0.0269  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
4347159 -0.0350 0.0158 0.0273  Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; g__Bifidobacterium; 
s__adolescentis 
4425663 -0.0216 0.0098 0.0278  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
295485 -0.0116 0.0053 0.0280  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
110192 -0.0117 0.0053 0.0282  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
183439 -0.0297 0.0135 0.0288  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
1820513 -0.0218 0.0099 0.0291  Proteobacteria; c__Betaproteobacteria; o__Burkholderiales; f__Alcaligenaceae; g__Sutterella; s__ 
189877 -0.0102 0.0047 0.0310  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
2688035 -0.0097 0.0045 0.0312  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
178642 -0.0071 0.0033 0.0320  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
179486 -0.0081 0.0037 0.0320  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
3709990 0.0132 0.0061 0.0327  Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__[Eubacterium]; 
s__dolichum 
174695 -0.0193 0.0090 0.0335  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
174818 -0.0215 0.0100 0.0335  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
48084 -0.0311 0.0146 0.0341  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
180473 -0.0172 0.0081 0.0341  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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180352 -0.0128 0.0060 0.0343  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
357261 -0.0140 0.0066 0.0348  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
191214 -0.0131 0.0062 0.0348  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
177581 -0.0169 0.0080 0.0349  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
179201 -0.0103 0.0049 0.0352  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
177758 -0.0136 0.0065 0.0357  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
193946 -0.0114 0.0054 0.0364  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
181754 -0.0146 0.0070 0.0368  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
192461 -0.0079 0.0038 0.0371  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
4414476 -0.0269 0.0129 0.0375  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
216710 -0.0216 0.0104 0.0377  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
181008 -0.0145 0.0069 0.0378  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
189828 -0.0227 0.0109 0.0383  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
185584 -0.0173 0.0083 0.0384  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
681370 -0.0136 0.0066 0.0399  Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; g__Bifidobacterium; 
s__pseudolongum 
178965 -0.0137 0.0067 0.0411  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
4465124 -0.0310 0.0151 0.0412  Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
300620 -0.0235 0.0115 0.0422  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
188676 -0.0254 0.0125 0.0424  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
198909 -0.0099 0.0049 0.0425  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Lachnospira; s__ 
182116 -0.0138 0.0068 0.0431  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
4357811 -0.0074 0.0037 0.0434  Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
288651 -0.0178 0.0088 0.0443  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
196957 -0.0229 0.0114 0.0451  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
193148 -0.0072 0.0036 0.0455  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
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4458959 -0.0102 0.0051 0.0462  Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__ 
1952 -0.0356 0.0179 0.0470  Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Porphyromonadaceae; g__Parabacteroides; 
s__ 
190772 -0.0168 0.0084 0.0474  Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
198127 -0.0112 0.0057 0.0482  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
232828 -0.0101 0.0051 0.0489  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
187404 -0.0182 0.0092 0.0489  Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
214036 -0.0245 0.0124 0.0490  Firmicutes; c__Clostridia; o__Clostridiales; f__[Mogibacteriaceae]; g__; s__ 
189176 -0.0130 0.0066 0.0499  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; s__gnavus 
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5.3.3 Genes involved in peptide presentation and microbial sensing are 
associated with AS core families of bacteria 
 
We were interested in examining the association between individual AS 
associated SNPs and the microbiome. We began by investigating the 
strongest associations to AS susceptibility HLA-B27, ERAP and IL-23R as 
well as NKX2-3, ICOSLG, NOS2, CARD9, BACH2 and SH2B3. These genes 
are of interest because of their strong relative effect in AS and for their roles in 
processing, trimming, presenting antigens in the class I antigen presentation, 
microbial sensing and immunity. A total of 13 SNPs across the 10 genes 
(Table 5.4) were each tested against the each individual OTU in the 
microbiome. 
 
Table 5.4. AS associated loci investigated for association with each OTU in the 
microbiome.  
 
Locus SNP Chr Risk /Non-
risk Allele  
IL23R rs11209026 1p31 G/A	  
ERAP1-ERAP2-
LNPEP 
rs30187 5q15 T/C	  
 
  rs2910686 5q15 G/A	  
ERAP1-ERAP2 rs10045403 5q15 A/G	  
HLA-B27 rs4349859 6  
NKX2-3 rs11190133 10q24 C/T 
ICOSLG rs7282490 21q22 G/A 
 
NOS2 rs2531875 17q11 G/T 
 rs2297518 17q11 A/G 
CARD9 rs1128905 9q34 C/T 
BACH2 rs17765610 6q15 G/A 
 rs639575 6q15 A/T 
SH2B3 rs11065898 12q24 T/C 
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Whilst none of the OTUs were associated with the SNPs involved in 
processing, trimming, presenting antigens at a Bonferroni corrected 
significance level, a total of 212 OTUs reached nominal significance P<0.05. 
SNPs in the ERAP1 locus were more significant with OTUs than IL23R SNPs 
or the HLA-B27 allele. There were 53 OTUs, predominantly 
Ruminococcaceae and Lachnospiraceae families (Table 5.5), associated with 
the ERAP1-ERAP2 SNP, rs10045403, and 44 OTUs belonging to the same 
families of bacteria associated with the ERAP1-ERAP2-LNPEP SNP, 
rs2910686. The aminopeptidase ERAP1 SNP, rs30187, which is known to 
interact with HLA-B27 in AS, showed association with 50 OTUs all belonging 
to Ruminococcaceae and Lachnospiraceae bacterial families. There were 25 
OTUs associated with the IL-23R SNP, rs11209026, predominantly 
Ruminococcus, Lachnospiraceae and Bacteroidaceae families (Table 5.6). An 
additional 40 OTUs belonging to the order Clostridiales, Ruminococcaceae 
and Lachnospiraceae families were associated with the HLA-B27 allele (Table 
5.7).  
 
Microbial sensing genes NKX2-3, ICOSLG, NOS2, CARD9, BACH2 and 
SH2B3 were also examined to assess for association with individual microbes 
within the intestinal microbiome (Table 5.4). These six loci are of interest 
because they are involved in sensing and responding to microbes and 
microbial antigen with four of the six loci also associated with dysregulated 
microbial sensing and response in Crohn’s disease (23).  Whilst none of the 
OTUs reached Bonferroni corrected significance, a total of 404 OTUs reached 
nominal significance P<0.05 across all six microbial sensing SNPs. BACH2 
was the most associated of all the microbial sensing genes with 50 OTUs 
associated with rs17765610 and 81 with rs639575; the majority of which 
belong to Ruminococcaceae, Lachnospiraceae and Bacteroides families 
(Supp table 5.8). NOS2 rs2297518 showed 65 OTU associations and 
rs2531875 with 18 OTU associations, all dominated by Ruminococcaceae, 
Lachnospiraceae and Bacteroides families along with Rikenellaceae and 
Clostridiaceae (Supplementary table 5.9). There were 105 OTUs associated 
with the CARD9 SNP, rs1128905, predominately Lachnospiraceae, 
Veillonellaceae and Ruminococcaceae, including Faecalibacterium prausnitzii 
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(Supplementary table 5.10). The remaining genes NKX2-3, ICOSLG and 
SH2B3 were associated with 36, 30 and 18 OTUs respectively, with the 
families of Ruminococcaceae, Lachnospiraceae dominating the associations 
(Supplementary table 5.11). This demonstrated that no one SNP, or gene, is 
associated with an individual family or genes of bacteria; rather, these genes 
are linked to the three major families of Ruminococcaceae, Lachnospiraceae 
and Bacteroidaceae as well as members of the Rikenellaceae and 
Veillonellaceae families that have been shown to dominate the core 
microbiome in AS, as detailed in Chapter 3 of this thesis.
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Table 5.5 OTUs reaching nominal significance (P<0.05) in the ERAP locus. 53 OTUs, predominantly Ruminococcaceae and 
Lachnospiraceae families associated with the ERAP1-ERAP2 SNP, rs10045403; 44 OTUs belonging to the same families of bacteria 
associated with the ERAP1-ERAP2-LNPEP SNP, rs2910686 and 50 OTUs all belonging to Ruminococcaceae and Lachnospiraceae  
associated with ERAP1 SNP, rs30187. Taxonomy is shown with full classification from phylum through class (c_), order (o_), family (f_), genus 
(g_) and species (s_). 
 
SNP Gene OTU  Beta Pvalue Taxonomy 
rs30187 ERAP 4420408 0.108 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ 
rs30187 ERAP 4256470 0.167 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ovatus 
rs30187 ERAP 182073 0.102 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 199677 0.046 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 4419459 0.079 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 2724175 0.122 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs30187 ERAP 4457427 0.118 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Lachnospira; s__ 
rs30187 ERAP 208739 0.088 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; 
g__Faecalibacterium; s__prausnitzii 
rs30187 ERAP 185420 -0.197 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ 
rs30187 ERAP 352747 -0.111 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ovatus 
rs30187 ERAP 178760 -0.061 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 182167 -0.103 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
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rs30187 ERAP 192676 -0.054 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 194236 -0.042 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 197274 -0.106 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 553080 -0.156 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs30187 ERAP 178642 -0.043 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs30187 ERAP 187196 -0.08 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs30187 ERAP 198626 -0.068 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs30187 ERAP 329597 -0.047 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs30187 ERAP 3856408 -0.117 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs30187 ERAP 189176 -0.079 7.89E-03  Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
s__gnavus  
rs30187 ERAP 348642 -0.119 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
s__gnavus 
rs30187 ERAP 179557 -0.036 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs30187 ERAP 187210 -0.092 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs30187 ERAP 191734 -0.034 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs30187 ERAP 193852 -0.079 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs30187 ERAP 363029 -0.092 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs30187 ERAP 181047 -0.098 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs30187 ERAP 181918 -0.085 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs30187 ERAP 193969 -0.142 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs30187 ERAP 174752 -0.083 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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rs30187 ERAP 177134 -0.06 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 178485 -0.084 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 181826 -0.087 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 194372 -0.073 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 194488 -0.061 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 196518 -0.061 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 198962 -0.047 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 260414 -0.177 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 287790 -0.104 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 313524 -0.066 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 324894 -0.069 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 538322 -0.086 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 571642 -0.106 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 4412540 -0.26 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 4450214 -0.176 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 4480359 -0.091 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs30187 ERAP 4437359 -0.212 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs30187 ERAP 4428714 -0.105 7.89E-03 Tenericutes; c__Mollicutes; o__RF39; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 12574 -0.085 6.33E-04 Actinobacteria; c__Actinobacteria; o__Actinomycetales; f__Actinomycetaceae; 
g__Actinomyces; s__ 
rs10045403 ERAP1-ERAP2 352747 -0.091 6.33E-04 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ovatus 
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rs10045403 ERAP1-ERAP2 4424239 -0.112 6.33E-04 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s 
rs10045403 ERAP1-ERAP2 177207 -0.119 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 2256425 -0.1 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 194659 -0.145 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 178018 -0.14 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs10045403 ERAP1-ERAP2 187196 -0.086 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs10045403 ERAP1-ERAP2 2210028 -0.137 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
s__ 
rs10045403 ERAP1-ERAP2 148279 -0.13 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs10045403 ERAP1-ERAP2 193852 -0.089 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs10045403 ERAP1-ERAP2 181826 -0.089 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 185164 -0.135 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 187404 -0.136 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 110192 -0.099 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs10045403 ERAP1-ERAP2 186133 -0.091 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__ 
rs10045403 ERAP1-ERAP2 192383 -0.139 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__ 
rs10045403 ERAP1-ERAP2 16054 -0.138 6.33E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__callidus 
rs10045403 ERAP1-ERAP2 4374302 0.259 6.87E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs10045403 ERAP1-ERAP2 348009 0.195 6.87E-04 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
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rs10045403 ERAP1-ERAP2 4347159 -0.349 1.26E-03 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__adolescentis 
rs10045403 ERAP1-ERAP2 535955 -0.209 1.26E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__SMB53; s__ 
rs10045403 ERAP1-ERAP2 681370 -0.139 1.40E-03 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__pseudolongum 
rs10045403 ERAP1-ERAP2 185420 -0.309 1.40E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ 
rs10045403 ERAP1-ERAP2 4476780 -0.225 1.40E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 173876 -0.186 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 192676 -0.09 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 192741 -0.21 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 193148 -0.077 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 292758 -0.151 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 4372528 -0.172 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 4377149 -0.164 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 4402903 -0.188 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs10045403 ERAP1-ERAP2 302932 -0.068 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 4434334 -0.325 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 4465124 -0.264 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs10045403 ERAP1-ERAP2 183439 -0.2 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs10045403 ERAP1-ERAP2 186416 -0.229 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs10045403 ERAP1-ERAP2 348642 -0.155 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
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rs10045403 ERAP1-ERAP2 177037 -0.252 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs10045403 ERAP1-ERAP2 177062 -0.155 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs10045403 ERAP1-ERAP2 187868 -0.048 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs10045403 ERAP1-ERAP2 258099 -0.073 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 295258 -0.149 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 312882 -0.176 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 368236 -0.066 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 2835813 -0.128 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 4427290 -0.151 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 4468466 -0.254 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs10045403 ERAP1-ERAP2 300374 -0.095 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs10045403 ERAP1-ERAP2 307238 -0.257 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs10045403 ERAP1-ERAP2 4421273 -0.136 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs10045403 ERAP1-ERAP2 368490 -0.178 1.91E-02 Firmicutes; c__Bacilli; o__Turicibacterales; f__Turicibacteraceae; g__Turicibacter; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
216599 -0.22 1.40E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
368490 -0.274 1.40E-03 Firmicutes; c__Bacilli; o__Turicibacterales; f__Turicibacteraceae; g__Turicibacter; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
174010 -0.111 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
4377149 -0.15 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
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rs2910686 ERAP1-
ERAP2-LNPEP 
555547 -0.109 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
177230 -0.096 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
192983 -0.102 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
4472399 -0.18 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
2210028 -0.103 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
193666 -0.151 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
358798 -0.13 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
178238 -0.117 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
184770 -0.127 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
187924 -0.131 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
312882 -0.26 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1- 688923 -0.2 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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ERAP2-LNPEP 
rs2910686 ERAP1-
ERAP2-LNPEP 
3530697 -0.104 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
4439469 -0.11 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
146554 -0.277 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
180826 -0.137 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
356745 -0.178 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
798581 -0.163 1.40E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__bromii 
rs2910686 ERAP1-
ERAP2-LNPEP 
4428714 -0.108 1.40E-03 Tenericutes; c__Mollicutes; o__RF39; f__; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
4425214 -0.168 1.91E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; 
s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
192684 -0.062 2.64E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
352747 -0.087 2.64E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ovatus 
rs2910686 ERAP1-
ERAP2-LNPEP 
772282 -0.08 2.64E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
 
 
149 
rs2910686 ERAP1-
ERAP2-LNPEP 
4424239 -0.094 2.64E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus;  
rs2910686 ERAP1-
ERAP2-LNPEP 
178420 -0.048 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
2996838 -0.088 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
178183 -0.089 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
194659 -0.077 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
178642 -0.052 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
183147 -0.061 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
192536 -0.072 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
194733 -0.085 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
198626 -0.08 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
4331364 -0.079 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2910686 ERAP1- 179583 -0.063 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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ERAP2-LNPEP 
rs2910686 ERAP1-
ERAP2-LNPEP 
181826 -0.065 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
189924 -0.071 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
258099 -0.06 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
2066056 -0.073 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2910686 ERAP1-
ERAP2-LNPEP 
2835813 -0.083 2.64E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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Table 5.6 OTUs reaching nominal significance (P<0.05) associated with the IL-23R SNP, rs11209026, predominantly Ruminococcaceae, 
Lachnospiraceae and Bacteroidaceae families. . Taxonomy is shown with full classification from phylum through class (c_), order (o_), family 
(f_), genus (g_) and species (s_). 
 
SNP Gene OTU  Beta Pvalue Taxonomy 
rs11209026 IL23R 4453609 -0.777 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs11209026 IL23R 4424239 -0.214 7.89E-03 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs11209026 IL23R 179847 -0.117 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11209026 IL23R 183147 -0.12 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11209026 IL23R 186735 -0.218 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11209026 IL23R 192735 -0.167 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11209026 IL23R 196100 -0.113 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11209026 IL23R 191734 -0.085 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs11209026 IL23R 177663 -0.327 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11209026 IL23R 730906 -0.133 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11209026 IL23R 4426298 0.301 1.71E-02 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__animalis 
rs11209026 IL23R 336559 0.308 1.71E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ 
rs11209026 IL23R 3211875 0.225 1.71E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ 
rs11209026 IL23R 4256470 0.613 1.71E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__ovatus 
rs11209026 IL23R 328617 0.574 1.71E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__uniformis 
rs11209026 IL23R 157338 0.249 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11209026 IL23R 173876 0.378 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11209026 IL23R 173927 0.284 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11209026 IL23R 181059 0.615 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11209026 IL23R 192741 0.365 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11209026 IL23R 192720 0.368 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11209026 IL23R 317677 0.168 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11209026 IL23R 571642 0.216 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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rs11209026 IL23R 4408801 0.205 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs11209026 IL23R 178117 0.193 1.71E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus;  
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Table 5.7 OTUs reaching nominal significance (P<0.05) associated with the HLA-B27 allele, predominantly Clostridiaceae, 
Ruminococcaceae and Lachnospiraceae families. Taxonomy is shown with full classification from phylum through class (c_), order (o_), family 
(f_), genus (g_) and species(s_). 
 
SNP Gene OTU  Beta Pvalue Taxonomy 
rs4349859 HLA-B27 4232045 -0.081 1.42E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs4349859 HLA-B27 2318497 -0.135 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs4349859 HLA-B27 4383953 -0.157 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs4349859 HLA-B27 304779 -0.061 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; 
s__perfringens 
rs4349859 HLA-B27 181485 -0.049 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; s__ 
rs4349859 HLA-B27 193852 -0.054 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs4349859 HLA-B27 28914 -0.054 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs4349859 HLA-B27 177515 -0.177 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs4349859 HLA-B27 3393191 -0.085 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs4349859 HLA-B27 3926480 -0.179 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs4349859 HLA-B27 193644 -0.081 1.42E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 157338 0.092 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs4349859 HLA-B27 176865 0.067 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs4349859 HLA-B27 185558 0.049 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs4349859 HLA-B27 317814 0.133 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs4349859 HLA-B27 3973322 0.11 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs4349859 HLA-B27 4425663 0.115 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
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rs4349859 HLA-B27 217109 0.105 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs4349859 HLA-B27 231952 0.062 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs4349859 HLA-B27 2256425 0.081 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs4349859 HLA-B27 177047 0.129 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs4349859 HLA-B27 192461 0.043 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs4349859 HLA-B27 4349261 0.113 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs4349859 HLA-B27 4398588 0.059 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; s__ 
rs4349859 HLA-B27 193969 0.109 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs4349859 HLA-B27 175148 0.064 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 194320 0.073 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 196982 0.068 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 198221 0.073 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 216710 0.123 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 288810 0.103 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 759816 0.084 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 4153054 0.153 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 4446669 0.053 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs4349859 HLA-B27 2307779 0.093 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs4349859 HLA-B27 147969 0.149 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs4349859 HLA-B27 180826 0.118 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs4349859 HLA-B27 186133 0.056 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs4349859 HLA-B27 4472091 0.172 1.89E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
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rs4349859 HLA-B27 4306262 0.206 1.89E-02 Verrucomicrobia; c__Verrucomicrobiae; o__Verrucomicrobiales; f__Verrucomicrobiaceae;  
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5.4 Discussion 
 
To better understand the possibilities of modifying the microbiome as a 
therapeutic strategy we need to better understand the factors that influence 
the microbiome, from diet to environment and the underlying host genetics. 
Understanding the effect of host genetics in the bacterial composition of the 
microbiome is important, because if the underlying genetics dictates the 
response of the immune system to certain microbes, or how the body 
tolerates or processes them, then no amount of microbiota modulation or 
probiotics will permanently shift the intestinal microbiome. However, if host 
genetics favours microbiota modulation, then the potential for the use of 
microbes as a treatment through faecal transplants or probiotics, as it is 
currently employed in clinical practice for antibiotic resistant Clostridium 
difficile infections, presents a new avenue for therapeutic developments for 
AS. 
 
Studies comparing genotype and the microbiome, particularly in patients with 
IBD, have demonstrated evidence of gene-microbiota interactions (102, 240-
242). Recently, several studies showed that the Fucosyltransferase 
2 (FUT2) gene, in patients with CD, was associated both with a shift of overall 
community composition as well as alterations of abundances of specific 
microbes within the community (241-244).The FUT2 gene is responsible for 
regulating the secretion of the blood group antigens in the digestive mucosa 
and from the secretory glands (243). The suggestion has been that individulas 
that do not secret blood group products in their mucosa due to a FUT2 
mutation, may have a disrupted immunogenic/homeostatic equilibrium, due to 
changes in carbohydrate levels in the mucos, that shifts the community of 
bacteria leaving the patient more susceptible to the development of chronic 
mucosal inflammation (241-244). 
 
These studies, however, did not address the central questions of whether the 
observed alterations were functional nor what their potential mechanisms of 
action risk for developing IBD is. The questions of function and mechanism 
are of particular relevance, because microbial composition has been shown to 
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exhibit large inter-individual variations when compared with function-based 
analyses, even in otherwise healthy individuals (233).  A more general 
approach to this question has also linked genetic loci with alterations of 
bacterial abundances in the intestines of in mice (136), however in humans 
and outside of a specific disease setting, approaches using twins has failed to 
reveal significant genotype effects on microbiome composition and diversity 
(114, 118). 
 
The investigation of underlying host genetics and microbiome composition 
has only recently begun to be explored; therefore we sort to better understand 
the role of AS susceptibility variants on microbiome composition. There are a 
number of genes involved peptide presentation, immunity, microbial sensing 
and response to infection associated with AS, and given the increased 
incidence of clinical and sub clinical gut disease in AS patients, we asked 
what impact does host genetics have on overall microbiome composition. The 
demonstration of individual genes and genetic profiles associated with risk of 
AS, also associated with microbes known to drive the AS microbial signature, 
particularly if found in both health and disease, would be supportive of model 
whereby susceptibility genes modulate the microbiome to influence disease 
risk. We have shown, in an otherwise healthy Twin cohort, that genes 
associated with developing AS were linked to families of bacteria known to be 
inflammatory and key indicator species in the AS microbiome (102-104). 
Given that AS is a complex genetic disease, an allelic risk score was 
constructed to test if the combined genetic profile, rather than single genes, 
was associated with changes in the intestinal microbiome (245). The allelic 
risk score linked an AS genetic profile with the families of Ruminococcaceae, 
Lachnospiraceae and Clostridia, which are keystone species of the AS 
microbiome and members of the core microbiome as detailed in Chapter 3. 
Further investigation of individual genes involved in microbial response, 
peptide processing, trimming and presentation were also correlated with these 
same families of bacteria. There is currently a lack of consensus with respect 
to measuring and dissecting associations between underlying host genetics 
and members of the intestinal microbiome. In this study, many approaches 
were attempted, including false discovery rate and Bonferroni correction, 
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however none of the variants survived multiple testing corrections; therefore, 
we opted for a nominal P-value of <0.05. Nevertheless, the associations seen 
between AS-associated SNPs and particular bacterial families, although not 
statically significant, intimates that host genetics play a role in not only overall 
microbiome composition, but also structure of the core microbiome.  
 
However, whether the underlying host genetics influences the microbiome 
directly or indirectly via the immune system is still yet to be unravelled. In this 
study we were only able to assess the association of AS susceptibility variants 
with microbiome composition in the TwinsUK cohort and we were not able to 
interrogate the effect of genetic variants known not to affect disease risk or 
known to affect risk to other forms of immune-mediated diseases. A more 
extensive analysis would permit the validation of our approach undertaken, by 
providing the appropriate genetic loci to serve as negative controls and 
ascertain possible baseline influence of genetics influence on a healthy 
microbiome.  
 
Whilst further research is required, here we show evidence that genetic 
variants that affect disease susceptibility were also associated with changes 
of the microbiome composition. These observations open a new avenue of 
research for our understanding of AS biology, but caution needs to be taken in 
the interpretations of the results, as the directionality of causation has not 
been explored and warrants further investigation.  
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5.5 Supplementary Tables 
 
Supplementary table 5.8 OTUs reaching nominal significance (P<0.05) associated with BACH2. 50 OTUs associated with rs17765610 
and 81 with rs639575; the majority of which belong to Ruminococcaceae, Lachnospiraceae and Bacteroidaceae families. Taxonomy is shown 
with full classification from phylum through class (c_), order (o_), family (f_), genus (g_) and species (s_). 
 
SNP Gene OTU Beta Pvalue Taxonomy 
rs17765610 BACH2 681370 -0.171 1.87E-03 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__pseudolongum 
rs17765610 BACH2 3439403 0.191 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 3563235 0.343 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 3588390 0.345 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 3600504 0.454 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 3931537 0.282 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs17765610 BACH2 4469576 0.135 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 199761 0.224 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 180468 0.244 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs17765610 BACH2 1504042 0.309 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs17765610 BACH2 4217963 -0.089 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 189524 -0.111 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 216599 -0.298 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs17765610 BACH2 4377149 -0.209 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs17765610 BACH2 182643 -0.186 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs17765610 BACH2 168071 -0.196 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 183439 -0.348 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 186416 -0.32 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 189176 -0.165 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
s__gnavus 
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rs17765610 BACH2 193769 -0.199 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; 
s__gnavus 
rs17765610 BACH2 193666 -0.25 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs17765610 BACH2 363735 -0.209 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs17765610 BACH2 1614788 -0.384 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__catus 
rs17765610 BACH2 176980 -0.376 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs17765610 BACH2 181167 -0.161 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs17765610 BACH2 184114 -0.243 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 185814 -0.182 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 192720 -0.269 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 295258 -0.22 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 312882 -0.231 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 368236 -0.096 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 4468466 -0.297 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 4421273 -0.168 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs17765610 BACH2 163243 -0.228 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs17765610 BACH2 16054 -0.163 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__callidus 
rs17765610 BACH2 157327 0.175 9.92E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 3426658 0.215 9.92E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 211706 0.077 3.17E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 2875735 0.097 3.17E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs17765610 BACH2 4326080 0.085 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs17765610 BACH2 184897 0.08 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs17765610 BACH2 182073 -0.127 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs17765610 BACH2 2996838 -0.123 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
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rs17765610 BACH2 4419459 -0.144 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs17765610 BACH2 173996 -0.135 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 306499 -0.133 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs17765610 BACH2 177758 -0.144 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs17765610 BACH2 181826 -0.127 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 185164 -0.144 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs17765610 BACH2 4428714 -0.161 4.34E-02 Tenericutes; c__Mollicutes; o__RF39; f__; g__; s__ 
rs639575 BACH2 193672 0.23 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs639575 BACH2 125624 0.22 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 168071 0.182 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 178018 0.161 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 190961 0.151 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 192127 0.175 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 193477 0.105 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 305318 0.205 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 3275562 0.321 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 4354235 0.341 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 4464173 0.214 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 4468384 0.179 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs639575 BACH2 4374302 0.207 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs639575 BACH2 184114 0.186 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 185583 0.196 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 185814 0.174 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 187180 0.144 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 187924 0.155 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 332185 0.131 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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rs639575 BACH2 3756485 0.091 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 4437359 0.252 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs639575 BACH2 216599 -0.305 3.49E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs639575 BACH2 217109 -0.088 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs639575 BACH2 231952 -0.121 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs639575 BACH2 181452 -0.072 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 195494 -0.066 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 197624 -0.104 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 718358 -0.056 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 113003 -0.062 3.49E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs639575 BACH2 3709990 -0.103 3.49E-03 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; 
g__[Eubacterium]; s__dolichum 
rs639575 BACH2 181074 -0.096 3.49E-03 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__cc_115; s__ 
rs639575 BACH2 151870 -0.117 3.49E-03 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__Coprobacillus; 
s__ 
rs639575 BACH2 656881 -0.099 3.49E-03 Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__; 
s__ 
rs639575 BACH2 4424239 0.136 3.76E-03 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs639575 BACH2 4347159 -0.355 7.89E-03 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__adolescentis 
rs639575 BACH2 72820 -0.218 7.89E-03 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__longum 
rs639575 BACH2 4449054 -0.165 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs639575 BACH2 193528 -0.266 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__caccae 
rs639575 BACH2 688923 -0.184 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 359872 -0.196 7.89E-03 Proteobacteria; c__Deltaproteobacteria; o__Desulfovibrionales; f__Desulfovibrionaceae; 
g__Bilophila; s__ 
rs639575 BACH2 782953 -0.204 7.89E-03 Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__; 
s__ 
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rs639575 BACH2 4391262 -0.156 7.89E-03 Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__; 
s__ 
rs639575 BACH2 4425571 -0.154 7.89E-03 Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__; 
s__ 
rs639575 BACH2 4454531 -0.141 7.89E-03 Proteobacteria; c__Gammaproteobacteria; o__Enterobacteriales; f__Enterobacteriaceae; g__; 
s__ 
rs639575 BACH2 4425214 0.192 1.54E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs639575 BACH2 157338 0.125 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs639575 BACH2 179744 0.063 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs639575 BACH2 180352 0.089 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs639575 BACH2 196371 0.075 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs639575 BACH2 4419459 0.125 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs639575 BACH2 193831 0.125 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs639575 BACH2 2840201 0.08 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs639575 BACH2 179512 0.068 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__SMB53; s__ 
rs639575 BACH2 179847 0.064 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 186735 0.104 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 191214 0.108 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 192735 0.086 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 193654 0.095 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 2688035 0.099 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 4331782 0.105 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 4450010 0.082 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs639575 BACH2 179557 0.05 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs639575 BACH2 186022 0.069 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs639575 BACH2 189067 0.057 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs639575 BACH2 191779 0.077 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
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rs639575 BACH2 189459 0.054 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs639575 BACH2 105287 0.06 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 188044 0.058 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 189924 0.084 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 192438 0.084 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 313524 0.109 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 3422630 0.09 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 174439 0.112 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs639575 BACH2 357261 0.098 3.17E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs639575 BACH2 681370 -0.134 4.34E-02 Actinobacteria; c__Actinobacteria; o__Bifidobacteriales; f__Bifidobacteriaceae; 
g__Bifidobacterium; s__pseudolongum 
rs639575 BACH2 4365130 -0.131 4.34E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Porphyromonadaceae; 
g__Parabacteroides; s__distasonis 
rs639575 BACH2 4331760 -0.155 4.34E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs639575 BACH2 2442706 -0.16 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs639575 BACH2 212532 -0.151 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 4439469 -0.139 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs639575 BACH2 2979308 -0.128 4.34E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
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Supplementary table 5.9 OTUs reaching nominal significance (P<0.05) associated with NOS2. NOS2 rs2297518 showed 65 OTU 
associations and rs2531875 with 18 OTUs associations, all dominated by Ruminococcaceae, Lachnospiraceae and Bacteroidaceae families 
along with Rikenellaceae and Clostridiaceae Taxonomy is shown with full classification from phylum through class (c_), order (o_), family (f_), 
genus (g_) and species (s_). 
 
SNP Gene OTU Beta Pvalue Taxonomy 
rs2297518 NOS2 182643 -0.159 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2297518 NOS2 4383953 -0.268 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2297518 NOS2 304779 -0.092 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__perfringens 
rs2297518 NOS2 2123717 -0.054 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 181826 -0.068 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 4020502 0.245 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs2297518 NOS2 107044 0.122 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs2297518 NOS2 216599 0.177 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs2297518 NOS2 2617854 0.222 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs2297518 NOS2 4424239 0.078 3.30E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs2297518 NOS2 4425214 0.156 3.30E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs2297518 NOS2 4439603 0.101 3.30E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs2297518 NOS2 4442130 0.052 3.30E-02 Firmicutes; c__Bacilli; o__Lactobacillales; f__Streptococcaceae; g__Streptococcus; s__ 
rs2297518 NOS2 157338 0.122 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2297518 NOS2 176865 0.07 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2297518 NOS2 186468 0.124 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2297518 NOS2 190980 0.058 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2297518 NOS2 192015 0.138 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2297518 NOS2 309391 0.05 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
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rs2297518 NOS2 1646171 0.093 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2297518 NOS2 3931537 0.179 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs2297518 NOS2 167373 0.164 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 184342 0.124 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 185607 0.11 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 192127 0.082 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 289734 0.275 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 2017729 0.063 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2297518 NOS2 175559 0.072 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 178462 0.132 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 184238 0.221 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 186022 0.079 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 187210 0.125 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 189067 0.062 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 194371 0.145 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 292735 0.16 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 302049 0.18 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 307113 0.102 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 318970 0.123 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 4465907 0.072 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs2297518 NOS2 179267 0.248 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs2297518 NOS2 182289 0.2 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs2297518 NOS2 187569 0.147 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs2297518 NOS2 188079 0.18 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
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rs2297518 NOS2 367889 0.116 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs2297518 NOS2 180462 0.106 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 182911 0.153 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 195651 0.109 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 196518 0.079 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 197624 0.079 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 232828 0.074 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 308544 0.158 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 759816 0.062 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2297518 NOS2 199145 0.29 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs2297518 NOS2 199702 0.067 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs2297518 NOS2 146554 0.379 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 178151 0.061 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 180509 0.192 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 180826 0.178 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 189150 0.143 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 191874 0.074 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 356745 0.24 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs2297518 NOS2 798581 0.212 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__bromii 
rs2297518 NOS2 191355 0.191 3.30E-02 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__; s__ 
rs2297518 NOS2 360636 0.311 3.30E-02 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__; s__ 
rs2297518 NOS2 529979 0.053 3.30E-02 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__; s__ 
rs2531875 NOS2 161423 -0.131 2.07E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
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rs2531875 NOS2 3141094 -0.062 2.07E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs2531875 NOS2 4449054 -0.137 2.07E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs2531875 NOS2 193528 -0.219 2.07E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__caccae 
rs2531875 NOS2 368490 -0.139 2.07E-03 Firmicutes; c__Bacilli; o__Turicibacterales; f__Turicibacteraceae; g__Turicibacter; s__ 
rs2531875 NOS2 537219 -0.077 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2531875 NOS2 4372528 -0.147 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs2531875 NOS2 182643 -0.147 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2531875 NOS2 4383953 -0.237 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs2531875 NOS2 304779 -0.088 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__perfringens 
rs2531875 NOS2 125624 -0.229 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2531875 NOS2 191052 -0.089 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2531875 NOS2 2123717 -0.071 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs2531875 NOS2 181826 -0.073 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2531875 NOS2 334336 -0.06 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2531875 NOS2 2835813 -0.063 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs2531875 NOS2 16054 -0.106 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; 
s__callidus 
rs2531875 NOS2 4453501 -0.092 2.07E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__dispar 
rs2531875 NOS2 4477696 -0.115 2.07E-03 Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; 
g__Haemophilus; s__parainfluenzae 
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Supplementary table 5.10 OTUs reaching nominal significance (P<0.05) associated with CARD9 SNP, rs1128905, predominately 
Lachnospiraceae, Veillonellaceae and Ruminococcaceae, including Faecalibacterium prausnitzii. Taxonomy is shown with full classification 
from phylum through class (c_), order (o_), family (f_), genus (g_) and species (s_). 
 
SNP Gene OTU Beta Pvalue Taxonomy 
rs1128905 CARD9 186981 0.144 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__[Barnesiellaceae]; g__; s__ 
rs1128905 CARD9 157327 0.074 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs1128905 CARD9 198449 0.156 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs1128905 CARD9 3426658 0.087 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs1128905 CARD9 3600504 0.277 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs1128905 CARD9 107044 0.141 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs1128905 CARD9 216599 0.165 1.87E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Rikenellaceae; g__; s__ 
rs1128905 CARD9 4425663 0.122 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs1128905 CARD9 217109 0.081 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Christensenellaceae; g__; s__ 
rs1128905 CARD9 181452 0.056 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 193129 0.167 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 3856408 0.122 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 183686 0.114 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 195494 0.063 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 266274 0.1 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 295258 0.13 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 300620 0.139 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 312882 0.191 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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rs1128905 CARD9 358781 0.117 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 688923 0.106 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 4342104 0.056 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Anaerotruncus; s__ 
rs1128905 CARD9 2979308 0.095 1.87E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs1128905 CARD9 3709990 0.081 1.87E-03 Firmicutes; c__Erysipelotrichi; o__Erysipelotrichales; f__Erysipelotrichaceae; g__[Eubacterium]; 
s__dolichum 
rs1128905 CARD9 4472721 0.232 7.45E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__[Odoribacteraceae]; g__Odoribacter; s__ 
rs1128905 CARD9 4357811 0.046 7.89E-03 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs1128905 CARD9 176113 -0.092 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs1128905 CARD9 181008 -0.084 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs1128905 CARD9 188127 -0.072 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs1128905 CARD9 309391 -0.046 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs1128905 CARD9 4419459 -0.123 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs1128905 CARD9 3931537 -0.19 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs1128905 CARD9 175704 -0.041 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 175729 -0.112 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 176604 -0.12 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 186997 -0.136 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 192461 -0.05 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 192536 -0.069 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 192625 -0.048 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 192735 -0.075 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
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rs1128905 CARD9 194177 -0.045 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 194733 -0.08 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 1602805 -0.057 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 2123717 -0.06 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 3134492 -0.184 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 3265161 -0.117 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 4331360 -0.118 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 4448492 -0.117 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 4473509 -0.116 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 4483337 -0.125 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs1128905 CARD9 181754 -0.104 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__[Ruminococcus]; s__ 
rs1128905 CARD9 176381 -0.053 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs1128905 CARD9 180414 -0.105 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs1128905 CARD9 187210 -0.085 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs1128905 CARD9 190162 -0.075 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs1128905 CARD9 191779 -0.052 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs1128905 CARD9 193946 -0.08 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs1128905 CARD9 28914 -0.061 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs1128905 CARD9 313593 -0.112 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs1128905 CARD9 1740283 -0.063 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs1128905 CARD9 4332082 -0.072 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs1128905 CARD9 105287 -0.037 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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rs1128905 CARD9 174818 -0.128 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 174840 -0.128 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 175184 -0.051 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 176507 -0.117 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 180473 -0.097 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 182577 -0.098 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 185584 -0.138 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 186478 -0.041 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 188676 -0.179 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 189828 -0.142 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 190301 -0.051 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 191872 -0.059 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 192406 -0.224 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 192720 -0.186 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 193644 -0.084 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 193968 -0.14 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 194036 -0.092 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 194287 -0.08 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 195436 -0.093 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 195651 -0.101 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 196982 -0.047 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 197970 -0.144 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
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rs1128905 CARD9 198198 -0.094 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 199761 -0.128 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 211907 -0.084 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 317677 -0.068 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 334336 -0.064 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 730906 -0.066 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 2506486 -0.082 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 2700883 -0.147 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 4094259 -0.055 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs1128905 CARD9 174611 -0.221 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs1128905 CARD9 181139 -0.106 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs1128905 CARD9 181422 -0.048 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs1128905 CARD9 189092 -0.167 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs1128905 CARD9 199145 -0.254 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs1128905 CARD9 208739 -0.116 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Faecalibacterium; 
s__prausnitzii 
rs1128905 CARD9 180468 -0.12 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs1128905 CARD9 197890 -0.065 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
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rs1128905 CARD9 348009 -0.103 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Oscillospira; s__ 
rs1128905 CARD9 4458959 -0.071 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__ 
rs1128905 CARD9 4388775 -0.106 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__dispar 
rs1128905 CARD9 4453501 -0.105 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__dispar 
rs1128905 CARD9 4477696 -0.112 7.89E-03 Proteobacteria; c__Gammaproteobacteria; o__Pasteurellales; f__Pasteurellaceae; 
g__Haemophilus; s__parainfluenzae 
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Supplementary table 5.11 OTUs reaching nominal significance (P<0.05) for NKX2-3, ICOSLG and SH2B3. The families of 
Ruminococcaceae, Lachnospiraceae dominating the associations. Taxonomy is shown with full classification from phylum through class (c_), 
order (o_), family (f_), genus (g_) and species (s_). 
 
SNP Gene OTU Beta Pvalue Taxonomy 
rs7282490 ICOSLG 191361 -0.449 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 289734 -0.352 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 195937 -0.397 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs7282490 ICOSLG 182289 -0.415 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs7282490 ICOSLG 4393532 -0.25 1.83E-02 Actinobacteria; c__Coriobacteriia; o__Coriobacteriales; f__Coriobacteriaceae; g__Eggerthella; 
s__lenta 
rs7282490 ICOSLG 176862 -0.139 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs7282490 ICOSLG 322580 -0.12 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs7282490 ICOSLG 1646171 -0.232 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs7282490 ICOSLG 199694 -0.136 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs7282490 ICOSLG 175704 -0.086 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 178642 -0.086 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 184037 -0.216 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 185607 -0.281 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 186687 -0.203 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 186997 -0.222 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 196054 -0.284 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs7282490 ICOSLG 198127 -0.168 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
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rs7282490 ICOSLG 182864 -0.111 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs7282490 ICOSLG 186022 -0.136 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs7282490 ICOSLG 190162 -0.189 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Blautia; s__ 
rs7282490 ICOSLG 176300 -0.121 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs7282490 ICOSLG 177111 -0.174 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs7282490 ICOSLG 177754 -0.232 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs7282490 ICOSLG 187569 -0.312 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs7282490 ICOSLG 191081 -0.216 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs7282490 ICOSLG 174752 -0.199 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs7282490 ICOSLG 184990 -0.223 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs7282490 ICOSLG 258099 -0.123 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs7282490 ICOSLG 2066056 -0.145 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs7282490 ICOSLG 2979308 -0.189 1.83E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs11190133 NKX2-3 197004 -0.393 7.89E-03 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 4343627 -0.302 1.67E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__fragilis 
rs11190133 NKX2-3 197364 -0.249 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11190133 NKX2-3 198183 -0.285 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11190133 NKX2-3 199677 -0.103 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11190133 NKX2-3 2840201 -0.118 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs11190133 NKX2-3 174792 -0.142 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 180312 -0.123 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
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rs11190133 NKX2-3 180999 -0.329 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 197397 -0.114 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 199344 -0.138 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 311820 -0.138 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 3272764 -0.195 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 4281639 -0.202 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11190133 NKX2-3 2740950 -0.165 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs11190133 NKX2-3 4374302 -0.333 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs11190133 NKX2-3 162623 -0.131 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs11190133 NKX2-3 178485 -0.156 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 193915 -0.095 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 358781 -0.169 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 2700883 -0.26 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 4396292 -0.248 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 4414476 -0.297 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 4458959 -0.131 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__ 
rs11190133 NKX2-3 4453501 -0.194 1.67E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Veillonellaceae; g__Veillonella; s__dispar 
rs11190133 NKX2-3 4323124 0.229 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__[Barnesiellaceae]; g__; s__ 
rs11190133 NKX2-3 185420 0.418 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs11190133 NKX2-3 198449 0.219 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs11190133 NKX2-3 336559 0.277 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs11190133 NKX2-3 4401580 0.173 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
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rs11190133 NKX2-3 344525 0.16 3.30E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; 
s__eggerthii 
rs11190133 NKX2-3 4405146 0.124 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11190133 NKX2-3 2318497 0.247 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__; s__ 
rs11190133 NKX2-3 232828 0.113 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 4427290 0.233 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11190133 NKX2-3 147969 0.259 3.30E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__Ruminococcus; s__ 
rs11065898 SH2B3 332732 -0.172 3.26E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs11065898 SH2B3 193654 -0.1 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11065898 SH2B3 189459 -0.077 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Coprococcus; s__ 
rs11065898 SH2B3 1740283 -0.108 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Roseburia; s__ 
rs11065898 SH2B3 19611 -0.152 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11065898 SH2B3 191872 -0.101 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11065898 SH2B3 3236435 -0.296 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11065898 SH2B3 4427290 -0.277 3.26E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11065898 SH2B3 4381553 0.355 4.46E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Bacteroidaceae; g__Bacteroides; s__ 
rs11065898 SH2B3 4436552 0.137 4.46E-02 Bacteroidetes; c__Bacteroidia; o__Bacteroidales; f__Prevotellaceae; g__Prevotella; s__copri 
rs11065898 SH2B3 194597 0.19 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__; g__; s__ 
rs11065898 SH2B3 2840201 0.085 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Clostridiaceae; g__Clostridium; s__ 
rs11065898 SH2B3 181452 0.098 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11065898 SH2B3 193129 0.304 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
rs11065898 SH2B3 3265161 0.121 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__; s__ 
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rs11065898 SH2B3 1667433 0.118 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Lachnospiraceae; g__Dorea; s__ 
rs11065898 SH2B3 182044 0.239 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
rs11065898 SH2B3 350503 0.183 4.46E-02 Firmicutes; c__Clostridia; o__Clostridiales; f__Ruminococcaceae; g__; s__ 
 
 
183 
6 Chapter 6 Final Discussion 
 
6.1 Overview and Conclusions 
 
The work presented in this thesis examines the role of the gut microbiome in AS by 
characterising the AS microbiome. It examines how changes in host genetics influences 
the composition of intestinal microbial composition as well as the association between AS 
susceptibility loci and overall microbiome composition. The key findings of this work, its 
limitations and future directions are summarised and discussed below. 
 
Microbial involvement has been suggested in AS, however, a definitive link is yet to be 
established (17, 138, 142, 143, 202, 246, 247). To date there has been no comprehensive 
characterisation of the gut microbiome in patients with AS. I sought to determine if the TI of 
AS patients carries a distinct microbial signature in comparison to healthy controls. 
Microbial profiles from TI biopsies from subjects with recent-onset, TNF-antagonist naïve 
AS and HC, were determined using culture-independent 16S rRNA gene sequencing and 
analysis techniques developed in Chapter 2. Analysis showed evidence for a discrete 
microbial signature in the TI of cases with AS compared to HC. Distinct grouping of AS 
cases was discriminated from HC on PCoA with clustering shown to be driven by higher 
abundances of Lachnospiraceae, Ruminococcaceae, Rikenellaceae, 
Porphyromonadaceae, Bacteroidaceae and decreases in Prevotellaceae and 
Veillonellaceae. Interactions between these indicator species within the microbial 
community were shown to further shape the AS microbial community signature. No 
difference was noted between AS cases and controls in either bacteria known to be 
associated with reactive arthritis, or Klebsiella species, which have been proposed to play 
a role in triggering AS. Statistically, the relationship between disease status and microbial 
community composition was confirmed indicating that the differences between the 
microbial community compositions was driven by disease state and not due to 
heterogeneity in the biopsy or lack of technical reproducibility. These results are consistent 
with the hypothesis that genes associated with AS act at least in part through effects on 
the gut microbiome.  While the data here shows a clear and distinct microbial signature in 
AS cases, the effect of TNF treatment on the microbiome composition and its contribution 
to disease pathogenesis is yet to be explored. Cause and affect interactions between the 
host genome, immune system and the gut microbiome also remains to be dissected.  
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With over 40 loci currently associated with ankylosing spondylitis, one of the strongest 
associations, along with HLA-B27, is ERAP1 (24, 62). Given that loss of function of 
ERAP1 is protective in AS, In Chapter 4 I asked how a lack or down regulation of ERAP 
influenced inherent gut microbiome composition, the antigen repertoire and the immune 
system. To investigate this hypothesis I explored if the loss of ERAP, in a mouse model, 
caused a shift in the intestinal flora towards an anti-inflammatory composition. Consistent 
with this hypothesis, 16S community profiling revealed that the gut microbiome in ERAP-/- 
mice did shift. However, it was towards a more inflammatory profile, with an increase of 
bacteria such as Rikenellaceae, Lachnospiraceae and Ruminococcus which are not only 
known to elicit a strong immune response, but are also key bacteria in the TI of AS 
patients (103, 248, 249). To minimise such potential confounders, the intestinal microbial 
composition of a single litter of ERAP mice comprising of ERAP+/+, ERAP+/- and ERAP -/- 
was explored. Analysis showed that ERAP+/-and ERAP -/- mice were more similar to each 
other and clustered away from the ERAP+/+ mice, suggesting that a change in genotype, 
from ERAP+/+ to ERAP+/-, is sufficient to influence the overall structure and composition 
of the gut microbiome. This is a small study with only one litter studied, and larger 
numbers are needed to better characterise the impact of genotype on the intestinal 
microbiome.  Nonetheless, this is consistent with the hypothesis that AS-associated genes 
contribute to disease aetiopathogenesis through effects of the underlying host genetics on 
intestinal microbial composition.  
 
The fifth chapter of this thesis further investigated the influence of host genetics, 
specifically AS risk loci, on microbiome composition by examining the association between 
AS SNPs and intestinal microbiome composition in a non-AS, otherwise healthy twin 
cohort. Given the number of genes involved in peptide presentation, immunity, microbial 
sensing and response to infection, and the increased incidence of clinical and sub clinical 
gut disease, I asked what impact does host genetics have on overall microbiome 
composition. Results showed that in an otherwise healthy cohort of twins, genes 
associated with developing AS were associated with families of bacteria known to be 
inflammatory and key indicator species in the AS microbiome. The allelic risk score linked 
the AS genetic profile with the families of Ruminococcaceae, Lachnospiraceae and the 
order Clostridiales, which are keystone species of the AS microbiome. Further 
investigation of individual genes involved in microbial response, peptide processing, 
trimming and presentation showed correlation with these same AS indicator species. This 
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suggests that host genetics plays a role in overall microbiome composition however 
whether the underlying host genetics influences the microbiome directly or indirectly via 
the immune system is still yet to be unravelled. In this study we were only able to assess 
the association of AS susceptibility variants with microbiome composition in the TwinsUK 
cohort and were unable to interrogate the effect of other genetic variants known not to 
affect disease risk or known to affect risk to other forms of immune-mediated diseases. A 
more extensive analysis would permit the validation of our approach undertaken by 
providing the appropriate genetic loci to serve as negative controls and ascertain possible 
baseline influence of genetics influence on a healthy microbiome. Caution needs to be 
taken in the interpretations of these results as directionality of causation has not been 
explored and requires further investigation.  
 
6.2 Future directions 
 
There is mounting evidence for a role of the gut microbiome in the aetiopathogenesis in 
AS, although exact mechanism remains unclear. To further explore the hypothesis that 
genes predisposing to AS do so by influencing the gut microbiome, either directly or 
indirectly via the immune system, will require substantially larger cohorts of several 
hundred patients and controls with matched genetic, clinical and microbiome data. Larger 
studies may identify specific disease triggering bacteria, and further define the AS 
microbiome profile and interactions, raising the possibility both the use of the microbiome 
as a biomarker as well as for novel therapeutic interventions.  
 
The gastrointestinal tract is the primary site for interaction between microbes and the host 
immune system. Moreover, the microbes found in the gut help to shape host immune 
systems from an early age (210, 211), although little is understood regarding how 
individual and bacterial communities interact with the immune system creating an 
inflammatory environment. To date only a handful of bacteria-immune interactions have 
been described, such as Prevotella and the innate immune system (249). The mechanism 
of interaction between other AS indicator species of bacteria such as Ruminococcus, 
Rikenella and Clostridia and the immune system causing disease is yet to be investigated.  
Loss of members of the Bacteroidetes and Firmicutes phyla, especially Clostridia, have 
been associated with the risk alleles of CD genes NOD2 (250) and ATG16L1 (248). These 
two genes are associated with abnormal Paneth cell function suggesting alteration of 
secreted antimicrobials from intestinal Paneth cells perturbs the intestinal microbiome, 
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which leads to inflammation and disease. Unravelling the interactions between AS 
indicator species and the immune system will help us understand to role of the gut 
microbiota in AS pathogenesis and how immune system sculpts the microbiome, and in 
what way microbiome counters the immune response perpetuating the inflammatory 
environment.  
 
The intestinal microbiome is a dynamic and constantly changing environment (127, 128, 
251). Whist the microbiome ebbs and flows with daily living (251), overall the microbiota 
remains reasonably stable for months, and possibly even years (127, 252). However, most 
of what we know regarding the make-up of the human gut microbiome and its stability is 
based off stool studies and not mucosal biopsies (114, 118, 126, 127, 183, 252, 253). 
Several studies have shown that the microbiome profile from stool differs from the profile 
obtained from mucosal biopsy suggesting that stool, while the most accessible sample, is 
not optimal for detailing gut microbiome composition and may skew our understanding 
(152, 153). Moreover, studies across mice and humans suggest that common aspects of a 
modern Western lifestyle including antibiotic use (254, 255) and high fat and fibre poor 
diets (118, 119, 256), can persistently alter commensal microbial communities. In turn, 
these microbial disturbances may increase susceptibility to pathogens (257), obesity (114, 
121, 197), and autoimmune disease (199, 224, 258). This makes dissecting cause and 
effect challenging given the significant environmental factors which can shape the 
microbiome as well as normal temporal variance; and we have only been focusing on the 
bacteria, not archea, viruses or fungi which also inhabit the intestinal tract. The successful 
use of the gut microbiome as a therapeutic target requires a deeper understanding of 
factors that shape the community composition including age, diet, geographical location, 
gender as well as underlying host genetics. Investigations to date have largely focused on 
the bacterial composition of the microbiome, and so know relatively little about the viruses 
and fungi that also inhabit the gut. Despite the considerable limitations in sequencing and 
functional annotation of the eukaryotic viruses present in the gastrointestinal tract, recent 
deep-sequencing efforts have revealed the existence of a complex enteric virome (259, 
260). A recent study revealed the surprising beneficial role viruses may play a role in a 
healthy microbiome. Murine norovirus (MNV) infection of germ-free or antibiotic-treated 
mice rescued both intestinal morphology and lymphocyte function in the absence of overt 
inflammation and disease. This study demonstrated that eukaryotic viruses have the 
capacity to support intestinal homeostasis and shape mucosal immunity, similarly to 
commensal bacteria (261).  This work demonstrates how little we currently known and truly 
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understand about the composition of a healthy intestinal microbiome and work along these 
lines will improve our knowledge of the intestinal microbiome as well as well microbiome 
host interactions critical for overall health. Particularly given that ReA is triggered by a 
bacterial infection and that it is looking likely that microbiome has a critical role in AS 
pathogenesis.   
 
The gut microbiota is increasingly looked at as a target for novel therapies, including 
microbiome modulation with probiotics and faecal microbiota transplants (FMT). These 
novel therapies are being increasingly used to treat patients with debilitating Clostridium 
difficile infections, where conventional treatments and antibiotics have failed. The number 
and frequency of FMT is growing exponentially (262), and in response biobanks for stool 
have been created at Massachusetts General Hospital in Boston and Emory University 
Hospital in Atlanta, Georgia where ‘healthy’ stool is screened and stored for medical use in 
approved cases (263). A small trial comparing antibiotic treatment to FMT for C. difficile 
showed that FMT was more effective at resolving patient symptoms as antibiotics alone 
(264). The effectiveness of FMT caused the trial to be stopped early. Non-randomised 
studies of C. difficile treated with either antibiotics only or FMT have shown a typical 
success rate of about 90% (264-266). While the majority of testimonies surrounding FMT 
are positive, there are still many unknowns. Screening of the donor faeces is currently not 
standardised and can be very basic. We all carry different bacteria, viruses and parasites 
at any given moment (126), and while they not be harmful to donor, potential pathogens as 
well as the healthy flora may inadvertently be to transplanted. Little long-term safety data 
exists for FMT recipients (267), however transient abdominal pain and bloated have been 
observed.   It may not be as simple as taking microbes from one person and giving them to 
another, just as other transplants like bone marrow and solid organ, require typing and 
cross matching prior to transplant. Research is underway in several laboratories, such as 
Openbiome (http://www.openbiome.org/) in the US, working on patient screening 
procedures as well as overall FMT regulation, similar to the model used by the Red Cross 
– except for faeces (263, 266). This is to ensure the microbes transplanted behave as we 
expect them to, as well as minimising unexpected consequences, with the goal of 
eventually not having to use a donor for the transplant at all, but tailoring the combination 
of synthetic microbes grown in the lab tailored to each individual patient (267, 268). FMT is 
becoming more accepted as a valid treatment option for C. difficile infections and is 
currently being trialed for patients with CD (227). Though, the hope that manipulating the 
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gut microbiome to treat diseases other than C. difficile infection is still speculative (262, 
269).  
 
The role of the host genetics in shaping intestinal microbial community composition is 
unclear. Recent animal studies have shown that host gene deletions resulted in shifts in 
microbiota composition as well as linking certain genetic polymorphisms with microbial 
abundances (135, 136). This highlights the importance of underlying host genetics in 
community composition and raises the question: if underlying host genetics influences 
microbiome composition, is FMT in complex genetic diseases futile because the transplant 
will never permanently shift the intestinal flora? In diseases such as AS and CD, the 
expectation is that since the microbiome influences the immune system, then transplanting 
the gut with healthy intestinal flora will lead to interactions with the immune system which 
create a less inflammatory environment reducing gut disease and providing overall 
improvement of symptoms and maybe even disease. The caveat here is that many genes 
associated with AS and CD are involved in mucosal immunology and microbial processing, 
so underlying host genetics may eventually override the transplant. 
 
What is clear is the need to better understand our second genome and to do this we 
require better tools for comparison and analysis. Currently there is a lack of central open 
access database and repository for human microbial community data. There is the NIH 
Human microbiome project database (http://www.hmpdacc.org/) with 16S rRNA and 
annotated microbial genomes img/hmp where all the human microbiome project data are 
deposited, the MetaHit database (http://www.metahit.eu/), National Center for 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/) as well as the European 
Bioinformatics Institute (http://www.ebi.ac.uk/) where the recent TwinsUK 16S rRNA 
sequence deposited (137). This demonstrates how spread out all the data is. Some of the 
data is annotated, meaning the individual whole microbial genome has been sequenced 
and function and biochemical pathways have been described, and some of the data is just 
the 16S rRNA sequence.  What is needed is the microbial equivalent of HapMap or UK10K 
were there is access to samples from varying habitats (mouth, skin, gut) with well 
annotated taxonomy and function so that eventually microbial communities can be imputed 
in the way we currently impute human SNPs. American gut project 
(http://humanfoodproject.com/americangut/) is currently one of the largest open-source 
project endeavouring to understand the microbial diversity of the gut is leading the way 
however, we need reasonable metadata accompanying the microbial data such as age, 
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gender, diet, lifestyle as well as geographic location and ethnicity. Much time and 
development is being dedicated to improving the 16S tools we currently have as well as 
creating new ones such as QIIME (169), Mothur (270) and LotuS (271) . However moving 
beyond 16S rRNA taxonomy is imperative for furthering our understanding of the 
interaction between host and microbes to better understand disease. Whilst using the gut 
microbiome as a phenotype for association studies for the purpose of using Plink (272) 
and Merlin (239) to test for association testing is a start, these programs are not designed 
to be used for microbiome analysis and do not allow within microbiome interactions and 
network dynamics to be taken into account, such as co-occurrence (spa). In fact no 
programs currently do. The microbial network packages such as Spaa (176) and SparCC 
(273), which have been borrowed from environmental microbial ecology are still rather 
crude. There is of coarse OTU networks and cytoscape as enabled in QIIME however, this 
program is more big picture and does not lend its self to the within clade analysis and 
direction of correlation. There are currently tools for the profiling of communities and 
clades in metagenomic data, including bacteria, viruses and archea using MetaPhiAn 
(274); high dimensional biomarker discovery with LEfSe (275);  determining the 
presence/absence and abundance of microbial pathways in a community from 
metagenomic data using HUMaN (276); prediction of function from 16S rRNA data using 
PICRUSt (115); as well as for multivariate analysis with linear models (MaAsLin) for testing 
associations between clinical metadata and the microbial community abundance or 
function (277). However, none of the above packages allow for the integration or 
correlation of human data, such as genotype information, with microbiome and 
metagenomic data and this is currently what is lacking.  
 
16S taxonomy does not inform us about what microbes are active and what they are 
expressing (278), let alone if expression is in reaction to host gene transcription (135, 
136). To better understand how host and commensal microbes interact, we also need 
better tools to examine interaction at the transcriptomic level (279). Metagenome analyses 
of the human intestine has previously identified genes and pathways involved in the 
transport and metabolism of simple carbohydrate substrates are enriched in the intestine 
microbiome (114, 278, 280) and that alterations in these pathways are linked to obesity, 
suggesting their importance for the appropriate functioning of this microbial ecosystem. 
However, elucidation of the actual activity and metabolic role of individual microbial 
members within the intestinal microbiome is still limited. Much of the microbial 
transcriptomic studies have used stool (114, 278, 280), as the use of intestinal biopsies is 
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still technically very difficult due to the shear amount of human DNA. There are microbial 
enrichment kits that can be used prior to sequencing in an effort to reduce the amount of 
human DNA, such as the New England Biosciences microbial enrichment kit (281) and 
MoBio Powersoil isolation kit (282), however the use of these kits prior to sequencing, and 
the impact on microbial community results, is still being explored. Examining host 
transcriptomics in the gut in combination with microbial transcriptions will further our 
understanding into how host genetics influences intestinal microbial community 
composition and function (283), which contributes to disease. 
  
Finally, the pursuit to understand the pathogenesis of AS, enabling accurate and early 
diagnosis and effective treatment, requires better understanding of how underlying host 
genetics influences the immune system and the intestinal microbiome. In the next few 
years, it is expected that larger studies with matched genotype and microbiome data will 
elucidate how it is that genetic variants influence the immune response, which in turn 
shapes the gut microbiome, in such a way that causes disease. Microbial profiling of tissue 
or stool samples, either alone or in combination with genetic tests, may identify individuals 
at high risk of developing AS, enabling either preventative intervention or early diagnosis. 
It is with high hopes that the research presented in this thesis and further studies along 
these lines improves the understanding of AS pathogenesis, which in turn lead to 
improved diagnosis and treatment. 
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Appendices 
 
Ankylosing spondylitis
Ankylosing spondylitis (AS) belongs to a common group 
of arthritides called spondyloarthopathies (SpA). AS 
targets primarily the spine and pelvis and is characterized 
histopathologically by entheseal infl am mation. Disease 
progression in AS is characterized by excessive bone 
formation (ankylosis) that gradually bridges the gap 
between joints, eventually fusing joints and causing stiff -
ness, pain, signifi cant morbidity, and increased mortality 
[1].
Th e coexistence of AS and intestinal infl ammation has 
been known for some time [2]. Between 5% and 10% of 
patients with AS develop clinically diagnosed infl amma-
tory bowel disease (IBD), and a further 70% of patients 
with AS develop subclinical gut infl ammation [1,2]. In 
reactive arthritis, a member of the SpA family, infl am-
matory arthritis develops following urogenital infection 
with Chlamydia trachomatis or gastrointestinal infection 
with Campylobacter, Salmonella, Shigella, or Yersinia [3]. 
Such cause-and-eff ect relationships are not established 
for other SpAs.
Genetic overlap between ankylosing spondylitis 
and gut disease
Strong genetic overlap exists between AS and IBD, and 
the two conditions commonly occur together in families 
[4]. Danoy and colleagues [5] (2010) studied genes known 
to be associated with IBD in a large AS cohort. New loci 
and genes were identifi ed, and of particular note were 
genes involved in the interleukin-23 (IL-23) pathway, 
such as STAT3, IL-23 receptor (IL23R), and IL12B (which 
encodes IL-12p40, the share subunit of IL-23 and IL-12) 
[5-7]. How these genetic lesions infl uence gut homeo-
stasis and function remains unclear. Major diff er ences 
also exist between the genetics of IBD and AS, and AS 
has shown no association to date with NOD2/CARD15 or 
the autophagy gene ATG16L1, which are major suscep-
tibility factors in IBD, whereas IBD shows no association 
with HLA-B or ERAP1, which are the strongest AS 
susceptibility genes [8]. Although no asso ciation has been 
shown with NOD2/CARD15 and AS specifi cally, poly-
morphisms in NOD2/CARD15 have been associated with 
an increased risk of gut disease in patients with SpA [9].
The gut, barrier regulation, and intestinal 
epithelial cells
Homeostasis of the normal microbial fl ora in the gut is 
essential for intestinal health. Th e gastrointestinal tract is 
heavily populated with microbes and is the primary site 
for interaction between these microorganisms and the 
immune system [10,11]. Furthermore, microbes found in 
the gut help to shape host immune systems from an early 
age. Th e incomplete development of the immune system 
in neonates and under germ-free (GF) conditions tells us 
that microbiota sculpt the host immune system [12,13].
Maintenance of intestinal and microbial homeostasis is 
increasingly recognized as playing a pivotal role in overall 
health [14], and dysregulation of either gut or microbial 
homeostasis may play a role in autoimmunity. Physio-
logical processes in the host that maintain gut homeo stasis 
and respond to perturbance in the gut micro environ ment 
involve both the adaptive and innate immune system and 
the barrier function of the intestines themselves.
Abstract
It is increasingly clear that the interaction between 
host and microbiome profoundly aff ects health. 
There are 10 times more bacteria in and on our 
bodies than the total of our own cells, and the human 
intestine contains approximately 100 trillion bacteria. 
Interrogation of microbial communities by using classic 
microbiology techniques off ers a very restricted view 
of these communities, allowing us to see only what 
we can grow in isolation. However, recent advances 
in sequencing technologies have greatly facilitated 
systematic and comprehensive studies of the role 
of the microbiome in human health and disease. 
Comprehensive understanding of our microbiome 
will enhance understanding of disease pathogenesis, 
which in turn may lead to rationally targeted therapy 
for a number of conditions, including autoimmunity.
© 2010 BioMed Central Ltd
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The physical barrier
Th e human gastrointestinal tract is not a complete 
barrier. It is composed of a single layer of intestinal 
epithelial cells (IECs), which form a physical barrier 
separating the intestinal lumen from the lamina propria 
(Figure 1). IECs secrete soluble factors that are crucial to 
intestinal homeostasis, such as mucins and anti-microbial 
peptides, including lysozymes, defensins, cathelicidins, 
lipocalins, and C-type lectins such as RegIIIγ [15-17]. 
Release of these molecules into luminal crypts is thought 
to prevent microbial invasion into the crypt micro-
environment as well as limit bacteria-epithelial cell 
contact [16,18]. Compared with healthy controls, Crohn’s 
disease patients with active disease have pronounced 
decreases in the human α-defensins DEFA5 and DEFA6 
in the ileum, resulting in altered mucosal function and 
overgrowth or dysregulation of commensal microbial 
fl ora [18,19]. Conversely, overexpression of anti-micro-
bials, including α-defensins, are reported in sub-clinically 
infl amed ileum of AS patients compared with Crohn’s 
disease patients and healthy controls [20]. However, it 
remains unclear whether changes in innate mucosal 
defenses lead to alterations in gut-resident microbial fl ora 
or whether early changes in the microbiome sculpt 
intestinal host responses. Furthermore, depletion of the 
mucin layer leads to an IBD-like phenotype and endo-
plasmic reticu lum stress, potentially driving IL-23 pro-
duc tion [21]. IL-23 excess alone is suffi  cient to induce 
spondyloarthritis in mice [22], and genetic evidence, in 
particular, indicates that the cytokine plays a key role in 
the development of spondyloarthritis in humans.
Permeability and disease
Th e dynamic crosstalk between IECs, microbes, and the 
local immune cells is fundamental to intestinal homeo-
stasis but is also suggested to play a part in disease 
pathogenesis [23]. In IBD and celiac disease, tight junc-
tions are dysregulated, causing increased permeability 
between IECs, resulting in a ‘leaky gut’ [24,25]. Studies 
looking at fi rst-degree relatives of patients with AS 
showed that they too have increased gut permeability, so 
it is likely that there is an underlying genetic process 
operating in the gut [26,27].
The immune barrier
Th e complexity of the intestinal immune system is the 
subject of many reviews, but here we will focus on some 
intestinal immune populations that are believed to be 
important in rheumatic disorders.
Innate immunity
Dendritic cells (DCs) densely populate the intestinal 
lamina propria and form a widespread microbe-sensing 
network. DCs recognize a broad repertoire of bacteria, 
sensing with receptors such as Toll-like receptors (TLRs) 
and monitoring the bacteria on the mucosal surface [28]. 
Intestinal DCs orchestrate production of intestine-
specifi c IgA to limit bacterial contact with the intestinal 
epithelial cell surface [29]. Activated DCs can secrete a 
number of cytokines and chemokines, including IL-23 
and IL-6, that are involved in infl am mation and migration 
of DCs [30].
Macrophages patrol the gastrointestinal systems in 
high numbers. Th ey frequently come in contact with 
‘stray’ bacteria, including commensals that have breached 
the epithelial cell barrier. Macrophages phagocytose and 
rapidly kill such bacteria by using mechanisms that 
include the production of antimicrobial proteins and 
reactive oxygen species [31]. Intestinal macrophages have 
several unique characteristics, including the expression 
of the anti-infl ammatory cytokine IL-10, both constitu-
tively and after bacterial stimulation [32,33]. Th is makes 
intestinal macrophages non-infl ammatory cells that still 
have the capacity to phagocytose. Th e importance of this 
pathway is highlighted by the fact that loss-of-function 
mutations in IL10R lead to early-onset IBD [34]. How-
ever, not all intestinal macrophages are non-infl amma-
tory. In patients with Crohn’s disease, a population of 
intestinal macrophages secrete infl ammatory cytokines 
such as IL-23, tumor necrosis factor-alpha (TNF-α), and 
IL-6. Th ese macrophages contribute to an infl ammatory 
microenvironment in patients with Crohn’s disease [35]. 
Intestinal macrophages also play a role in the restoration 
of the physical integrity of the epithelial cell barrier 
following injury or bacterial insult [24]. Re-establishing 
this barrier after injury is imperative to avoid bacterial 
penetration and sepsis in such a microbe-laden environ-
ment [36].
Adaptive immunity
IL-23-responsive cells
IL-23 is a key cytokine in the development of IL-17- and 
IL-22-secreting cells. IL-23 signals through a receptor 
consisting of the specifi c IL-23R subunit and IL-12Rβ1, 
also shared with IL-12R [37]. Loss-of-function polymor-
phisms in IL23R are associated with protection from AS 
[7], psoriasis [38], and IBD [39], and many other genes in 
the IL-23 pathway are associated with these diseases. 
Under physiological conditions, IL-23-, IL-17-, and IL-
22-producing cells are enriched in gut mucosa, and IL-17 
and IL-22 are known to be important regulators of 
intestinal ‘health’. IL-17 plays important roles in intestinal 
homoeostasis in several ways, including maintenance of 
epithelial barrier tight junctions [40] and induction of 
anti-microbial proteins such as β-defensins, S100 
proteins, and REG proteins. IL-22 induces secretion of 
anti-microbial peptides [41]. In the gut, innate-like 
immune cells act as sentinels, responding very rapidly to 
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alterations to the microbial composition of the gut with 
rapid secretion of IL-17. Key among these sentinels are 
γδ T cells, natural killer T (NKT) cells, mucosa-
associated invariant T (MAIT) cells, and lymphoid tissue 
inducer (LTi)-like cells (Figure 2).
γδ T cells
γδ T cells are found in large numbers at epithelial surfaces 
such as the gut and skin, where they can account for up 
to 50% of T cells. γδ T cells not only bear an antigen-
specifi c T-cell receptor (TCR) but also have many pro-
per ties of cells of the innate immune system, including 
expression of the major innate immunity receptors and 
TLRs [42] and dectin-1 [43], which recognizes microbial 
β-glucans. Expression of these receptors supports a role 
for γδ T cells in early responses to microbes. Of further 
relevance, we and others have recently confi rmed that 
CARD9, part of the dectin-1 response pathway, is a 
susceptibility gene for AS and IBD [44]. γδ T cells are 
potent producers of infl ammatory cytokines such as 
inter feron-gamma (IFN-γ), TNF-α, and IL-17 [45,46]. 
Th ey are pathogenic in the collagen-induced arthritis 
model [47] and mouse models of colitis [48], and IL-17-
secreting γδ T cells are expanded in patients with AS 
[49]. Intraepithelial γδ T cells also play an important role 
in modulating intestinal epithelial growth through 
secretion of fi broblast growth factor [50]. Alterations to 
γδ T-cell numbers or functions, therefore, may have 
profound eff ects on intestinal health.
Natural killer T cells
NKT cells are characterized by expression of an invariant 
TCR, Vα24Jα18 in humans and the orthologous 
Vα14Jα18 in mice. NKT cells recognize glycolipid struc-
tures presented to them by the non-classic antigen-
presenting molecule CD1d. Like γδ T cells, NKT cells are 
rapid responders to antigenic stimuli and are capable of 
producing a range of immunoregulatory cytokines 
[51-54]. Within the gut, NKT cells are protective in T 
helper 1 (TH1)-mediated models of IBD but are patho-
genic in TH2 models [55,56]. Recently, it has been shown 
that microbial stimulation of NKT cells in the gut of mice 
Figure 1. The physical barrier. Separating the intestinal lumen and its inhabiting commensal bacteria from the underlying lamina propria is a 
single layer of intestinal epithelial cells (IECs). These IECs are stitched together, creating a tight junction and regulating the paracellular fl ux. IECs 
also secrete soluble factors that are crucial to intestinal homeostasis, such as mucins and anti-microbial peptides (AMPs), including lysozymes, IgA, 
defensins, and C-type lectins such as RegIIIγ. Release of these molecules into luminal crypts is thought to prevent microbial invasion into the crypt 
microenvironment as well as limit bacteria-epithelial cell contact. Toll-like receptors (TLRs) are also expressed on IECs to sense a breach of barrier or 
bacterial invasion. Underneath the IECs, the lamina propria contains T cells, bacteria-sampling dendritic cells (DCs), and macrophages.
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aff ects NKT cell phenotypic and functional maturation 
[57,58]. Given that NKT cells have protective roles in 
models of arthritis [59] and SpA [60], their functional 
maturation in the gut provides evidence for a role for 
mucosal T-cell priming in infl ammatory joint disease.
Mucosa-associated invariant T cells
MAIT cells are a population of innate-like T cells that are 
abundant in human gut, liver, and blood and secrete a 
range of infl ammatory cytokines such as IL-17 and IFN-γ 
in response to antigenic stimulation [61-63]. Like NKT 
cells, MAIT cells bear an invariant TCR (Vα7.2 in 
humans) that recognizes antigen presented by the non-
classic MHC-like molecule, MR1 [64]. In blood, MAIT 
cells display a memory phenotype [63] and express the 
transcription factor ZBTB16 [65], allowing them to 
rapidly secrete cytokine in response to antigenic stimuli. 
Furthermore, they express high levels of IL-23R [66]. 
MAIT cells react to a wide range of microbial stimuli, 
including Gram-positive and Gram-negative bacteria as 
well as yeasts [61,62]. Although the precise role of MAIT 
cells in maintenance of the mucosal barrier remains 
unclear, the rapid postnatal expansion of MAIT cells and 
their acquisition of phenotypic markers of memory likely 
represent an interaction with developing commensal 
microfl ora [67].
Lymphoid tissue inducer-like cells and innate lymphoid cells
LTi-like cells are found in spleen, lymph node, and gut 
lamina propria. LTi-like cells constitutively express hall-
marks of IL-17-secreting cells, including IL-23R, RORγt, 
AHR, and CCR6 [68]. Stimulation of LTi-like cells with 
IL-23 induces IL-17 secretion [68], whereas PMA and 
ionomycin stimulation invokes secretion of IL-22 [69]. 
LTi cells appear to be related to an increasingly interest-
ing and heterogeneous population of innate lymphoid 
Figure 2. The immune barrier. Dendritic cells (DCs) and macrophages patrol the gastrointestinal tract in high numbers. They densely populate 
the intestinal lamina propria and form a widespread microbe-sensing network. Activated DCs can secrete a number of cytokines and chemokines, 
including interleukin-23 (IL-23), IL-6, and IL-1, activating IL-23-responsive cells. IL-23-, IL-17-, and IL-22-producing cells are enriched in gut mucosa, 
and IL-17 and IL-22 are known to be important regulators of intestinal ‘health’. IL-17 plays important roles in intestinal homoeostasis in several ways, 
including maintenance of epithelial barrier tight junctions. LTi, lymphoid tissue inducer; MAIT, mucosa-associated invariant T; NKT, natural killer T; 
T reg, regulatory T; TNF, tumor necrosis factor.
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cells (ILCs). ILCs have been linked to gut infl ammation 
through colitis models in which IL-23-responsive ILCs 
secrete IL-17 and IFN-γ and promote intestinal infl am-
mation [70]. NKp46+ ILCs are involved in host defense 
against Citrobacter rodentium infection through secre-
tion of IL-22 [71].
The human microbiome revolution
Together, the multi-factorial components of the immune 
system shape the microbial population that inhabits the 
gut and (to an extent) vice versa, with each side pushing 
to establish a stable state. Understanding the yin and 
yang of this relationship is at the heart of current micro-
biome research.
Microbiome refers to the totality of microbes, their 
genetic elements, and environmental interaction in a 
defi ned environment [72]. Projects such as the Human 
Microbiome Project, run by the National Institutes of 
Health, and the Metagenomics of the Human Intestinal 
Tract (MetaHit) consortium aim to determine what 
constitutes a ‘normal’ or healthy microbiome. Research in 
this fi eld has recently been greatly accelerated by the 
development of high throughput sequencing methods for 
microbial profi ling, which can profi le microbial popu la-
tions whether or not the microbes present can be cultured.
16S rRNA sequencing
16S rRNA is a section of prokaryotic DNA found in all 
bacteria and archaea. 16S rRNA sequences are used to 
diff erentiate between organisms across all major phyla of 
bacteria and to classify strains down to the species level 
[73]. 16S rRNA sequencing has dramatically changed our 
understanding of phylogeny and microbial diversity 
because it provides an unbiased assessment of the 
microbiome and is not restricted by the ability to culture 
the bacteria present.
Further improvements in sequencing technologies have 
reduced the need for targeted studies such as 16S sequen-
cing and enabled high-throughput shotgun sequencing. 
Th is latter type of sequen cing randomly samples all genes 
present in a habitat rather than just 16S rRNA. Shotgun 
sequencing provides more information about the micro-
biome than just the 16S characterization, which is of 
particular benefi t in determining the functional capacity of 
the microbial community rather than just its phylo geny. 
However, shotgun sequencing is more complex to analyze, 
owing in part to the challenge of distinguishing between 
host and bacterial genomic material, and requires far more 
sequencing to be performed. Th erefore, most studies to 
date have relied on 16S rRNA sequencing approaches.
Advances in tools for metagenomic studies
Several sequencing technologies have been developed for 
human genetic studies and have since been adapted to 
metagenomics. Th e Roche 454 sequencing platform 
(Roche, Basel, Switzerland) uses large-scale parallel 
pyrosequencing to produce reads of between 450 and 
1000 base pairs (bp) in length. Read lengths produced by 
the 454 platform are well suited to 16S rRNA amplicon 
metagenomics studies as well as shotgun sequencing as 
they are easily aligned to reference bacterial genetic data 
sets. Sequencing plat forms from Illumina (San Diego, 
CA, USA), the HiSeq2000 and MiSeq, produce shorter 
reads than the Roche 454. Th e HiSeq was designed 
primarily for human genomic sequencing, and current 
chemistry produces 100-bp paired-end reads. Illumina 
sequencing is best suited for shotgun sequencing or 
indexed amplicon sequencing of multiple samples.
Th is is a rapidly developing fi eld. Advances in chemistry 
are predicted to increase both read lengths and output 
for both of these platforms over the next 12 to 24 months, 
particularly for the Illumina platforms that are less 
mature than the Roche 454. New platforms coming to the 
market are likely to have a major impact on meta-
genomics study design. For example, the Pacifi c Bio-
sciences sequencing technology (Pacifi c Biosciences, 
Menlo Park, CA, USA) provides reads of approximately 
3,000 bases, which will make it particularly suited to this 
fi eld, despite its lower overall output (approximately 
100  Mb of sequence per run). Life Technologies Ion 
Torrent technology (Life Technologies, Grand Island, NY, 
USA) is reported to produce up to 400 base reads and up 
to 1  Gb of sequence per run. Th e relative positions of 
these competing technologies in metagenomics have yet 
to be established.
The normal human gut microbiome
To date, only a handful of studies have examined in any 
depth the function as well as the composition and 
diversity of the human gut microbiome. Two large studies 
interrogating and cataloguing microbiomes from various 
regions of the body in health and disease have been 
undertaken by the National Institutes of Health Human 
Microbiome Project in the US and the European MetaHit 
project [74-76]. Th e European MetaHit consortium 
combined published data sets from around the world and 
added 22 newly sequenced fecal metagenomes from four 
diff erent European countries. Th ey identifi ed three robust 
clusters, termed ‘enterotypes’, that were not nation- or 
continent-specifi c. Th ese enterotypes characterized the 
microbial phylogenetic variation as well as the function 
variation of the clusters at gene and functional class levels 
[74]. Each enterotype had a dominant bacterial genus: 
enterotype 1 was dominated by the genus Bacteriodes, 
enterotype 2 by Prevotella, and enterotype 3 by Rumino-
coccus. Th e three enterotypes were also shown to be 
functionally diff erent. For example, enterotype 2, which 
is Prevotella-dominant, also contains Desfulfovibrio, 
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which may act in synergy with Prevotella to degrade 
mucin glycoproteins present in the mucosal layer of the 
gut. It may be that diff erent enterotypes may be asso-
ciated with diseases such as obesity and IBD rather than 
necessarily specifi c bacterial species, given their diff ering 
functional capacities. Further studies will be required to 
determine whether enterotypes are consis tently found in 
expanded data sets and in studies of intestinal biopsies as 
well as the fecal samples used in the MetaHit study.
The microbiome in immune-mediated arthritis
Th e major fi ndings of microbial profi ling studies in major 
immune-mediated diseases associated with arthritis are 
summarised in Table  1. To date, no study investigating 
the gut microbiome by using sequencing-based methods 
in AS has been reported. Many studies largely using 
antibody tests have suggested an increased carriage of 
Klebsiella species in patients with AS, but this has not 
been universally supported [77]. One study using 
denaturing gradient gel electrophoresis to profi le the 
microbiome by using fecal samples found no diff erences 
between AS cases and healthy controls [78].
Rheumatoid arthritis (RA) is the only infl ammatory 
arthritis for which modern metagenomic studies have 
been reported. Community profi ling studies of gut fl ora 
of patients with RA reveal diff erences in the composition 
of gut microbiota of patients with RA compared with 
those of healthy controls, and a lower abundance of 
Bifi dobacterium and Bacteroides bacteria was observed 
in RA cases [79,80]. However, these studies used fecal 
samples and not intestinal biopsies, possibly infl uencing 
the populations observed [81]. Also, microbial profi ling 
data suggest that gingival infection may be important, 
particularly in anti-citrullinated peptide antibody-posi-
tive RA, although the studies suggesting this have 
generally used antibody tests rather than sequencing-
based approaches (reviewed in [82]).
Several lines of evidence indicate that the gut micro-
biome plays an important role in IBD, including the 
association of genes involved in mucosal immunity with 
IBD (such as CARD15, CARD9, IL-23R, and ATG16L1), 
the therapeutic eff ect of antibiotics on the condition, and 
the benefi cial eff ect of fecal stream diversion in Crohn’s 
disease. Previous studies of human IBD have been under-
taken by using standard culture techniques (for example, 
[83]) or molecular analysis (for example, [84,85]). Th ese 
studies noted alterations in intestinal microbiota when 
compared with non-IBD patients, a fi nding recently 
confi rmed by using 16S rRNA sequencing of intestinal 
biopsies [86]. Th is sequencing study, however, did not 
identify an IBD-specifi c microbial profi le, perhaps because 
of insuffi  cient resolution of the sequencing performed or 
small sample size (12 patients and 5 controls). Much larger 
studies will be required to dissect the relationship 
between the host genetic factors determining risk of IBD 
and the gut microbiome.
Th e microbiome is thought to play a signifi cant role in 
psoriasis, another AS-related condition. It has long been 
suggested that streptococcal infection, especially throat 
infections, may trigger psoriasis in a genetically suscep-
tible individual [87]. Recent studies using 16S rRNA 
sequencing have found signifi cant diff erences between 
the cutaneous microbiota of psoriasis cases and controls 
and in involved and control skin in psoriasis cases, and 
less staphylococci and propionibacteria have been ob-
served in cases and in aff ected skin [88]. Again, further 
studies will be required to determine whether there is a 
particular microbial profi le or specifi c bacterial species 
involved in psoriasis.
Th ese studies are thus consistent with the hypothesis 
that the microbiome contributes to the etiopathogenesis 
of immune-mediated arthritis or seronegative diseases 
like IBD and psoriasis. However, at this point, there is no 
defi nitive evidence of specifi c bacterial infections or 
changes in microbial profi le that play a causative role in 
these conditions (with the exception of reactive arthritis).
Chicken and the egg
Whether the changes noted in these early metagenomic 
studies of immune-mediated disease are a consequence 
of disease or are involved in its development or persis-
tence is unclear. Th is distinction may prove impossible to 
dissect in human studies, but considerable evidence in 
studies in mice supports a role for the microbiome in 
driving immune-mediated diseases.
In the B27 rat model of AS, rats housed under GF 
conditions did not develop disease [89], demonstrating 
that microbes in this model are important for disease 
penetrance. In contrast, in the New Zealand black model 
of systemic lupus erythematosus, mice maintained under 
GF conditions produced higher levels of antinuclear 
antibodies and developed worse disease [90], 
demonstrating a protective role for commensal microbes.
Given the IL-17/IL-22 cytokines, which are of relevance 
to AS, IBD, and psoriasis in particular, strong evidence 
from murine studies indicates that interaction between 
the gut microbiome and the host determines the overall 
level of activation of the immune cells producing these 
cytokines. Segmented fi lamentous bacteria (SFB) are 
com mensal bacteria that induce IL-17 secretion. Mice 
lacking SFB have low levels of intestinal IL-17 and are 
susceptible to infection with pathogenic Citrobacter spp. 
Restoration of SFB in these mice increased the number of 
gut-resident IL-17-producing cells and enhanced resis-
tance to infection [12]. Salzman and colleagues [91] 
illustrated that α-defensins modulate mucosal T-cell 
response by regulating the composition, but not the total 
numbers, of bacteria in the intestinal microbiome. 
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Examin ing the intestinal microbiota of mice expressing 
the human α-defensin gene, they demonstrated signifi -
cant α-defensin-dependent alterations in commensal 
composition, leading to a loss of SFB and fewer IL-17-
producing lamina propria T cells [91]. Furthermore, 
using recolonization studies, investigators recently demon-
strated that, in neonatal mice, commensal microbes 
infl uence invariant NKT (iNKT) cell intestinal infi ltration 
and activation, establishing mucosal iNKT cell tolerance 
to later environmental exposures [92].
Th e mechanism by which the microbiome infl uences 
IL-17-producing cell activation is still being determined. 
Ivanov and colleagues [12] demonstrated that serum 
amyloid A, produced in the terminal ileum, can induce 
TH17 diff erentiation of CD4+ T lymphocytes. It has also 
been shown that development of TH17 lymphocytes in 
the intestine is stimulated by microbiota-induced IL-1β 
(but not IL-6) production [93]. Colonization with 
Clostridial species has been shown to stimulate intestinal 
transforming growth factor-beta (TGF-β) production, in 
turn increasing IL-10+ CTLA4high Treg (regulatory T) 
activation [94]. Clostridial coloniza tion of neonatal mice 
reduced severity of induced colitis by using dextran 
sulphate sodium or oxazolone and reduced serum IgE 
levels in adulthood. So it is likely that alterations to the 
gut microfl ora or invasion of the gut by pathogenic 
bacteria infl uences the balance of IL-17- and IL-22-
producing cells and other immune cells, infl uen cing 
susceptibility to local and systemic immune-mediated 
disease.
Th e above studies highlight that changes in the micro-
biome can lead to infl ammation which may have far-
reaching eff ects and demonstrate experimental approaches 
by which fi ndings of metagenomic studies in mice and 
humans can be explored to successfully dissect the role of 
the microbiome in human immune-mediated diseases.
Conclusions
Th e human gut microbiome is a dynamic and complex 
ecosystem that is only now beginning to be understood. 
Table 1. Alterations in gut microbiota associated with immune-mediated diseases 
Associated microbes Microbiota changes References
IBD – Crohn’s disease
Gut microbiome
Bacteroides ovatus 
Bacteroides vulgatus 
Bacteroides uniformis 
Reduction in microbial diversity when compared with controls [95]
IBD
Gut microbiome
Bacteroidetes 
Lachnospiraceae 
Actinobacteria 
Proteobacteria 
Clostridium 
Firmicutes/Bacteroidetes ratio 
Bifi dobacteria 
Associated with overall community shift and dysbiosis [96]
Celiac disease
Gut microbiome
Bacteroides vulgatus 
Escherichia coli 
Clostridium coccoides 
Overall higher diversity of microbes in patients with celiac disease compared with controls [97]
Psoriasis
Skin microbiome
Firmicutes 
Bacteroidetes 
Actinobacteria 
Proteobacteria 
Overrepresentation of Firmicutes and an underrepresentation of Actinobacteria and 
Proteobacteria when compared with controls 
[98,99]
Rheumatoid arthritis
Oral microbiome
Porphyromonas gingivalis 
Dysbiosis and increased diversity [100,101]
IBD, infl ammatory bowel disease.
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It is increasingly clear that the interaction between host 
and microbiome profoundly aff ects health. It is still 
unclear how interactions between host genes, microbes, 
and environmental factors can predispose patients to the 
development autoimmune diseases such as AS. We are 
only beginning to grasp the infl uence the microbiome has 
on health. Improved knowledge of the composition and 
function of the gut microbiome in patients with AS and 
how the microbiome shapes the immune response and 
infl uences infl ammation, both local and systemic, will 
likely provide important insights into early events in the 
pathogenesis of AS.
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Intestinal Dysbiosis in Ankylosing Spondylitis
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Objective. Ankylosing spondylitis (AS) is a com-
mon, highly heritable immune-mediated arthropathy
that occurs in genetically susceptible individuals ex-
posed to an unknown but likely ubiquitous environmen-
tal trigger. There is a close relationship between the gut
and spondyloarthritis, as exemplified in patients with
reactivearthritis, inwhomatypicallyself-limitingarthro-
pathy follows either a gastrointestinal or urogenital
infection. Microbial involvement in AS has been sug-
gested; however, no definitive link has been established.
The aim of this study was to determine whether the gut
in patients with AS carries a distinct microbial signa-
ture compared with that in the gut of healthy control
subjects.
Methods. Microbial profiles for terminal ileum
biopsy specimens obtained from patients with recent-
onset tumor necrosis factor antagonist–naive AS and
from healthy control subjects were generated using
culture-independent 16S ribosomal RNA gene sequenc-
ing and analysis techniques.
Results. Our results showed that the terminal
ileum microbial communities in patients with AS differ
significantly (P < 0.001) from those in healthy control
subjects, driven by a higher abundance of 5 families of
bacteria (Lachnospiraceae [P  0.001], Ruminococcaceae
[P  0.012], Rikenellaceae [P  0.004], Porphyromon-
adaceae [P  0.001], and Bacteroidaceae [P  0.001])
and a decrease in the abundance of 2 families of
bacteria (Veillonellaceae [P  0.01] and Prevotellaceae
[P  0.004]).
Conclusion. We show evidence for a discrete
microbial signature in the terminal ileum of patients
with AS compared with healthy control subjects. The
microbial composition was demonstrated to correlate
with disease status, and greater differences were ob-
served between disease groups than within disease
groups. These results are consistent with the hypothesis
that genes associated with AS act, at least in part,
through effects on the gut microbiome.
Intestinal microbiome dysbiosis and microbial
infections have been implicated in several immune-
mediated diseases, including multiple sclerosis, inflam-
matory bowel disease (IBD), and type 1 diabetes.
Bacterial infection in the gut and urogenital tract is
known to trigger episodes of reactive arthritis, a form of
spondyloarthropathy (SpA) belonging to a group of
related inflammatory arthropathies, of which ankylosing
spondylitis (AS) is the prototypic disease. The close
relationship between the gut and SpA is exemplified in
patients with reactive arthritis, in whom a typically
self-limiting arthropathy follows either gastrointestinal
infection with Campylobacter, Salmonella, Shigella, or
Yersinia, or urogenital infection with Chlamydia. Micro-
bial involvement in AS has been suggested; however, no
definitive link has been established (1).
Up to 70% of patients with AS have subclinical
gut inflammation, and 5–10% of these patients have
more severe intestinal inflammation that progresses to
clinically defined IBD resembling Crohn’s disease (CD)
(2). The high heritability of AS, the global disease
distribution, and the absence of outbreaks of the disease
suggest that AS is triggered by a common environmental
agent in genetically susceptible individuals (3). Multiple
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genes associated with AS also play a role in gut immu-
nity, such as genes involved in the interleukin-23 (IL-23)
pathway (4), which are important regulators of intestinal
“health.” Marked overrepresentation of genes that are
associated with CD is also associated with AS (5); this
suggests that the 2 diseases may have similar etiologic
mechanisms, possibly involving gut dysbiosis.
Several studies have shown that patients with AS
and their first-degree relatives have increased intestinal
permeability relative to unrelated healthy control sub-
jects, which, again, is consistent with a role for the gut
microbiome in AS (6). To date, no comprehensive
characterization of intestinal microbiota in patients with
AS has been performed. We therefore performed
culture-independent microbial community profiling of
terminal ileum biopsy specimens to characterize and
investigate differences in the gut microbiome between
patients with AS and healthy control subjects.
PATIENTS AND METHODS
Biopsy specimens from the terminal ileum were ob-
tained at the time of colonoscopy from 9 consecutively en-
rolled tumor necrosis factor inhibitor–naive patients with
recent-onset (duration from symptom onset 48 months) AS
(defined according to the modified New York classification
criteria for AS [7]) and 9 healthy control subjects (Table 1)
(see also Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38967/abstract). All patients gave written informed
consent, and the study protocol was approved by the relevant
University of Palermo and University of Queensland research
ethics committees. One patient with AS was receiving non-
steroidal antiinflammatory drugs (NSAIDs) at the time of
biopsy. AS patients 3, 4, and 10 had reported occasional use of
NSAIDs, which was interrupted due to gastrointestinal upset.
Other patients with AS did not report use of NSAIDs but were
receiving either acetaminophen and/or tramadol.
The terminal ileum microbial and mock communities
were profiled by high-throughput amplicon sequencing of the
16S ribosomal RNA (rRNA) gene (2 250-bp barcode) on an
Illumina MiSeq sequencer using dual-indexed v4-region for-
ward primer 517F (5-GCCAGCAGCCGCGGTAA-3) and
reverse primer 803R (5-CTACCRGGGTATCTAATCC-3).
In addition to exploring community-level differences between
disease states, we evaluated technical and biologic replication.
Biologic replication was examined by halving the biopsy spec-
imens and performing all subsequent studies in parallel to
assess the reproducibility of findings from the time of biopsy
forward. Technical replication was performed by analyzing
forward and reverse sequencing reads separately and then
comparing them. The resulting sequence libraries were ana-
lyzed using the Quantitative Insights Into Microbial Ecology
(QIIME) pipeline (8).
Alpha diversity metrics, which are used to examine the
diversity within a sample, were generated using the QIIME
workflow. Hierarchical clustering was performed, using the
unweighted pair group method with arithmetic mean (includ-
ing both the weighted and unweighted UniFrac distance) to
detect significant differences within microbial communities
between patients with AS and healthy controls. The weighted
UniFrac distance metric detects changes in the number of
organisms present in a community, taking into account the
relative abundance of microbes present. The unweighted Uni-
Frac distance metric describes community membership. Uni-
Frac, enabled in QIIME, was used to generate sample distance
Table 1. Characteristics of the patients with AS and the healthy control subjects at the time of biopsy*
Subject
ID
Age,
years Sex
Disease duration,
years†
ESR,
mm/hour
CRP,
mg/liter BASDAI
HLA–B27
status
NSAID
treatment
Histologic
inflammation
AS01 56 M 7 34 18 7 Positive Current Chronic
AS02 33 M 4 22 1 5.5 Positive None Acute
AS03 24 F 5 18 5 4.8 Positive None Normal
AS04 22 M 3 33 3 5.5 Positive None Normal
AS05 33 M 5 41 2.7 6 Positive None Chronic
AS06 28 M 6 28 1.5 6.2 Positive None Normal
AS08 36 M 8 34 1.5 5.6 Positive None Acute
AS09 38 F 6 45 2.2 6.7 Positive None Chronic
AS10 31 M 11 27 1.3 8 Positive None Normal
HC01 58 F – – 0.3 – – – –
HC02 43 M – – 0.5 – – – –
HC03 38 F – – 0.05 – – – –
HC04 65 M – – 0.8 – – – –
HC05 48 F – – 0.02 – – – –
HC06 34 F – – 0.03 – – – –
HC07 45 M – – 0.5 – – – –
HC08 44 F – – 0.8 – – – –
HC09 56 F – – 0.02 – – – –
* In all subjects, the ileum was the biopsy site. AS  ankylosing spondylitis; ESR  erythrocyte sedimentation rate; CRP  C-reactive protein;
BASDAI  Bath AS Disease Activity Index; NSAID  nonsteroidal antiinflammatory drug; HC  healthy control.
† Beginning at the onset of symptoms.
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metrics as well as principal coordinate analysis (PCoA). Core
microbiome analysis as well as supervised learning were per-
formed to further characterize the intestinal microbial signa-
ture, using the workflow pipelines in QIIME (8). The function
of bacteria and communities was predicted using PICRUSt (9).
To determine differences in the microbial load, the
total microbial biomass in biopsy samples was quantified using
real-time quantitative polymerase chain reaction (PCR) ana-
lysis of the 16S rRNA gene, as described by Willner et al (10).
PERMANOVA analysis was conducted at the genus level
using the vegan package in R to test the relationship between
the whole microbial community and disease. Indicator species
analysis was performed using the labdsv package in R. Co-
occurrence network analysis was conducted using the spaa
package in R.
RESULTS
The microbial communities in the terminal ileum
of patients with AS were significantly different (Figure
1A) and more diverse (Figure 1C) compared with those
in healthy control subjects (P  0.001), as determined
using PERMANOVA. PCoA showed that AS samples,
including biologic replicates, grouped separately from
control samples, indicating that disease is the primary
factor influencing the community differences (Figure
1B) (see also Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38967/abstract).
To further demonstrate the distinct groupings of
AS samples and control samples, supervised learning
was conducted to test the predictive capacity of the
microbiome differences, and all 9 samples obtained from
patients with AS had been predicted to be AS samples
(Figure 1B). PERMANOVA analysis further confirmed
the presence of a significant relationship between dis-
ease status and microbial community composition (P 
0.001). This was not due to heterogeneity in biopsy
samples, because biologic replicates showed no signifi-
cant differences between each other. Quantitative PCR
analysis of biomass showed no significant differences, on
average, in the 16S rRNA copy number between AS
samples and control samples, indicating that the ob-
served differences were not attributable to overgrowth
or dominance of bacteria driving community differences
(see Supplementary Figure 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38967/abstract). The average UniFrac
distances demonstrated that differences between both
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Figure 1. A, Difference in taxonomy at the phylum level between patients with ankylosing spondylitis (AS) and healthy control subjects (HCs),
showing the increase in Bacteroides and the change in the Bacteroides-to-Firmicutes ratio in the AS samples. B, Distinct clustering of AS samples
compared with control samples, as determined by weighted principal coordinate analysis (PCoA). Supervised learning showed that all 9 AS samples
were predicted to be AS. C, Alpha diversity box plot showing increased microbial diversity (observed species) in AS samples compared with control
samples. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median,
and the lines outside the boxes represent the 10th and 90th percentiles. D, Comparison of variation within and between disease status, showing
greater significance between and within disease status than between technical replicates and biologic replicates. Values are the mean  SD.
  P  0.001 by Mann-Whitney test. NS  not significant.
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biologic and technical replicates were significantly less
than differences between individuals and disease states
(P  0.001, by Mann-Whitney test) (Figure 1D).
Community profiling showed 51 genera across all
biopsy specimens, with major differences observed at the
phylum level between AS and control specimens (Figure
1A). Indicator species analysis was performed to deter-
mine whether alterations in specific species were driving
the differences observed between communities in pa-
tients with AS and healthy control subjects. This analysis
showed that, compared with the microbial communities
in healthy control subjects, those in patients with AS
were characterized by a higher abundance of Lachno-
spiraceae, including Coprococcus species and Roseburia
species (P  0.001), Ruminococcaceae (P  0.012),
Rikenellaceae (P  0.004), Porphyromonadaceae includ-
ing Parabacteroides species (P  0.001), and Bacte-
roidaceae (P  0.001). Decreases in the abundance of
Veillonellaceae (P 0.01) and Prevotellaceae (P 0.004)
were observed (Figure 2A).
Further drilling down into the AS microbiome
signature using co-occurrence analysis, which examines
the correlation between microbes, showed that bacterial
interactions further shape the AS microbial community
signature, with positive correlations observed between
the indicator species Lachnospiraceae and Ruminococ-
caceae and negative correlations observed between Veil-
lonella and Prevotella (Figure 2B). Microbial functional
prediction using PICRUSt indicated 31 significant path-
ways with differential representation in patients with AS
compared with healthy controls (P  0.02, with Bonfer-
roni correction) (see Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38967/abstract).
These pathways included a decrease in bacterial invasion
of epithelial cells (P  4.33  105), an increase in
antimicrobial production in the butirosin and neomycin
biosynthesis pathway (P  0.002), which is consistent
with an increase in bacteria from the Bacteroidaceae
family, and an increase in the secondary bile acid
biosynthesis pathway (P  0.004), which is consistent
with an increase in Clostridia and Ruminococcaceae
species.
We were interested in further interrogating the
AS microbiome signature, which is the overall combina-
tion of microbes that distinguishes patients with AS from
healthy control subjects, by investigating whether an
assemblage or “core” set of microbes was present in all
AS and control samples at varying levels, and to probe
their functional capacity. Exploring the core microbiome
is imperative to better understand the stable and consis-
tent components across complex microbial communities,
given the distinct AS microbial signature. The Core 100
species (microbes present in all samples) included the
Clostridium, Actinomycetaceae, Bacteroidaceae, Lachno-
spiraceae, Porphyromonadaceae, Rikenellaceae, Rumino-
coccaceae, and Veillonellaceae families of bacteria. These
families of bacteria are also AS indicator species, sug-
gesting that the core microbiome is driving the AS
microbial signature (Figure 2A).
The Core 100 species belonged to 22 significant
pathways (P  0.02, with Bonferroni correction) (see
Supplementary Table 3, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38967/abstract) that again included bac-
terial invasion of epithelial cells (P  0.004), antimicro-
Figure 2. A, Differences in the abundance of bacterial families be-
tween patients with ankylosing spondylitis (AS) and healthy control
subjects. The first 7 families of bacteria (from left to right) are AS
indicator species, and the last 3 bacterial families are control indicator
species. B, Co-occurrence network showing positive (blue lines) and
negative (red lines) correlations between AS indicator species includ-
ing members of the Lachnospiraceae family (Coprococcus and Rose-
buria); Parabacteroides, which is a member of Porphyromonadaceae;
and Faecalibacterium, which is a member of the Ruminococcaceae
family. Increasing thickness of the lines indicates increasing strength of
(Pearson’s) correlation.
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bial production in the butirosin and neomycin
biosynthesis pathway (P 0.007), and the secondary bile
acid biosynthesis pathway (P  0.013). Members of the
Bacteroides, Clostridium, and Ruminococcus groups are
known to be involved in cholesterol metabolism and
secondary bile synthesis; disordered bile acid synthesis
due to intestinal dysbiosis has previously been impli-
cated in the pathogenesis of IBD (11).
As the threshold for core membership was re-
duced to 90%, 75%, and 50%, the families of bacteria
present remained the same; however, the number of
genus and species within these families increased, espe-
cially in Clostridia, Lachnospiraceae, and Ruminococcus.
This demonstrates that the structure of the core micro-
biome is robust, and that decreasing the threshold
expands the number of genera and species of bacteria
only within these families. As the core threshold de-
creased, however, the number of significant pathways
also decreased, suggesting that as the threshold is re-
laxed, the expansion of genera and operational taxo-
nomic units dilutes pathway signals.
Indicator species analysis also determined that
healthy control subjects had an increased abundance of
Streptococcus and Actinomyces compared with patients
with AS. No difference was noted between patients with
AS and control subjects in the presence of either bacte-
ria known to be associated with reactive arthritis or
Klebsiella species, which have been proposed to play a
role in triggering AS (12).
DISCUSSION
Here, we present the first characterization and
identification of intestinal dysbiosis in the AS micro-
biome, using 16S rRNA community profiling of terminal
ileum biopsy specimens. We show evidence for a discrete
microbial signature in the terminal ileum of patients
with AS compared with healthy control subjects. The
microbial profile differences are not attributable to
differences in overall bacterial quantity between patients
with different diseases but are qualitative. PCoA was
able to show the distinct grouping of patients with AS
versus healthy control subjects; larger studies will be
required to define the individual bacterial species in-
volved. Statistically, the relationship between disease
status and microbial community composition was con-
firmed, indicating that the differences in composition of
the microbial community were not due to heterogeneity
in the biopsy specimens or a lack of technical reproduc-
ibility, but that the driving force is disease state.
Of the 7 families of microbes with differences in
abundance within the AS microbiome, Lachnospiraceae,
Ruminococcaceae, and Prevotellaceae are strongly asso-
ciated with colitis and CD, with Prevotellaceae especially
known to elicit a strong inflammatory response in the
gut (13). Further investigations showed that correlations
between these families of bacteria further shape the AS
microbial signature, and that these microbes were pres-
ent in all AS samples studied, suggesting that they are
not only driving the microbial signature but also are at
the core of the AS microbial signature. Increases in
Prevotellaceae and decreases in Rikenellaceae in the
intestinal microbiome have also recently been observed
in the HLA–B27–transgenic rat model of spondylo-
arthritis, suggesting that underlying host genetics may
play a role in sculpting the gut microbiome in this animal
model (14).
The increased diversity of the AS community
without an overall change in microbial load shows that
no overgrowth or dominance of a particular microbe
drives the signature. However, murine experiments dem-
onstrate that both the overall composition of the intes-
tinal microbiome and the presences and/or absence of
specific microbes can have a substantial impact on host
response, regulation of inflammation, and development
of intestinal cells. In the K/BxN mouse model of arthri-
tis, it was shown that the introduction of a single
gut-residing species, segmented filamentous bacteria,
into germ-free mice was sufficient to reinstate Th17
cells, leading to the production of autoantibodies and
arthritis. When IL-17 was neutralized in specific
pathogen–free K/BxN mice, development of arthritis
was prevented. Thus, a single commensal microbe, via its
ability to promote a specific T helper cell subset, can
drive immune-mediated disease (15).
Further studies are needed to investigate whether
the changes in intestinal microbial composition are due
to host genetics and how this affects the overall function
of the gut microbiome in AS patients, including how the
microbiome then goes on to shape the immune response
and influence inflammation. In particular, given the
strong association of HLA–B27 with AS, it has been
hypothesized that HLA–B27 induces AS by effects on
the gut microbiome, in turn driving spondyloarthritis-
inducing immunologic processes such as IL-23 produc-
tion (16). Our data showing intestinal dysbiosis in pa-
tients with AS is consistent with this hypothesis, but
further studies are clearly required to distinguish cause-
and-effect interactions between the host genome and
immune system and the gut microbiome. These investi-
gations will provide new insights and help us to better
understand the pathogenesis of AS.
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Abstract The purpose of this study is to review the potential
causal role of the microbiome in the pathogenesis of
spondyloarthritis. The method used for the study is literature
review. The microbiome plays a major role in educating the
immune response. The microbiome is strongly implicated in
inflammatory bowel disease which has clinical and genetic
overlap with spondyloarthritis. The microbiome also plays a
causal role in bowel and joint disease in HLAB27/human beta
2 microglobulin transgenic rats. The mechanism(s) by which
HLA B27 could influence the microbiome is unknown but
theories include an immune response gene selectivity, an
effect on dendritic cell function, or a mucosal immunodefi-
ciency. Bacteria are strongly implicated in the pathogenesis of
spondyloarthritis. Studies to understand howHLAB27 affects
bacterial ecosystems should be encouraged.
Keywords Inflammatory bowel disease .Microbiome .
Spondyloarthritis
The microbiome is a term coined by the Nobel Laureate Joshua
Lederberg to describe the collection of microorganisms that
cohabit our bodies [1]. Although this assortment of microbes
includes viruses, fungi, and parasites, bacteria are the predom-
inant form of life. In fact, bacterial cells outnumber mamma-
lian cells in the human body by about 10 to 1 [2]. Bacterial
RNA transcripts expressed in a human outnumber mammalian
transcripts by greater than 100 to 1 [3]. The National Institutes
of Health has recognized the importance of characterizing the
microbiome through the initiation of the Human Microbiome
Project [2, 3]. Europe is home to a similar initiative known at
Meta Hit, the metagenomics of the human intestinal tract.
Because the majority of these organisms are strictly anaerobic,
they are difficult to culture. They can now be characterized by
sequencing techniques which have diminished in cost dramat-
ically over the past decade. These techniques exploit differ-
ences in the ribosomal sequence of bacteria compared to
mammals, allowing primers to be designed such that primarily
bacterial DNA is amplified. Some characterization of the
microbiome has also been done bymass sequencing that relies
on databases to sort the sequences into bacterial or other origin
[4].
In this review, we begin with an overview of selected recent
publications that highlight the emerging recognition of the
microbiome’s role in health and disease. We conclude by
describing observations that implicate the microbiome strong-
ly in the pathogenesis of ankylosing spondylitis. The reader is
also referred to two previous reviews on the topic from our
groups [5, 6].
One of the key functions of the microbiome is to educate
the immune response. Many authorities argue that the intesti-
nal tract is the largest organ in the immune system.Whenmice
are raised in a strictly germfree environment, the lymphoid
organs do not develop normally and the immune response to a
foreign antigenic challenge is blunted [7]. Our microbiome
also plays an essential role in the generation of vitamins such
as vitamin K. All food ingested is metabolized by the
microbiome which consequently has immense influence in
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both starvation [8] and obesity [9]. Several dramatic examples
of drug metabolism or efficacy have also been shown to be
dependent on the microbiome including acetaminophen [10],
platinum-based chemotherapy [11], and cyclophosphamide
[12].
The microbiome is now recognized to play a role in nu-
merous diseases. For example, the microbiome generates
metabolites called trimethylamine oxides which are highly
atherogenic [13, 14]. The vegetarian diet alters the
microbiome such that these metabolites are not generated
[14]. Primarily based on data from rodent models, the
microbiome has been implicated in a vast array of diseases
which include inflammatory bowel disease [15], diabetes [16],
hypertension [17], fatty liver [18], several cancers [19], ulcers
[20], inflammatory arthritis [21], multiple sclerosis [22], and
psoriasis [23]. Even personality characteristics may be influ-
enced by the microbiome [24, 25]. The two diseases that are
most clearly linked to the microbiome are ulcerative colitis
and Crohn’s disease. A National Library of Medicine search
on the term inflammatory bowel disease and microbiome in
December 2013 yielded 941 references. The evidence that the
microbiome is critical in inflammatory bowel disease primar-
ily derives from rodents. In most but not all instances, the
murinemodel of bowel inflammation ismarkedly improved in
a germfree setting [15]. In some models, cohousing a mouse
with bowel inflammation with a normal wild-type mouse will
cause the germfree wild-type animal to develop aspects of
bowel inflammation such as in the example of the NLRP6
knock-out mouse [15]. NLRP6 is expressed by intestinal
epithelial cells and contributes to innate immunity. The ab-
sence of NLRP6 results in colitis and an alteration of the
intestinal microbiota.
Some of the evidence that ankylosing spondylitis may be a
microbiome-driven disease is based on the analogy between
inflammatory bowel disease and ankylosing spondylitis.
About 10 to 20% of patients with inflammatory bowel disease
develop sacroiliitis identical to ankylosing spondylitis [26].
Conversely, more than 50 % of patients with ankylosing
spondylitis have microscopic colonic lesions that resemble
Crohn’s disease even if bowel symptoms are absent [27].
Peripheral arthritis and uveitis are characteristic of both anky-
losing spondylitis and inflammatory bowel disease.
A large number of genes associated with inflammatory
bowel disease are also associated with ankylosing spondylitis.
In nearly all cases, the genetic variant carries the same risk
direction for each disease [28]. A high proportion of those
genes are involved in mucosal immunity [29]. For example,
ankylosing spondylitis is associated with variants in the tran-
scription factors RUNX3, EOMES, and TBX21, as well as the
cytokine receptors IL7R and IL23R [29], all of which are key
regulators of the differentiation and activation of innate lymphoid
cells, which are themselves critical components of mucosal
immune defenses.
As is the case for inflammatory bowel disease, the strongest
argument that the microbiome is important in ankylosing
spondylitis derives from animal data. Taurog, Hammer, and
colleagues derived transgenic rats which overexpress HLA-
B27 and human beta 2 microglobulin [30]. These rats known
as 33–3 on the Fischer background develop a spontaneous
illness characterized by diarrhea and subsequent axial and
peripheral arthritis. When raised in a germfree environment,
both the arthritis and diarrhea are largely eliminated [31].
Furthermore, certain probiotics like Lactobacillus rhamnosus
GG can maintain the remission [32], while colonization of the
susceptible rats with other bacteria such as Bacteroides
thetaiotamicron (B. theta) or Bacteroides vulgatuswill induce
disease. In the SKG mouse model, which has features of
spondyloarthritis and inflammatory bowel disease, and like
ankylosing spondylitis shows marked involvement of IL-23
dependent immunological pathways [33], mice raised in
germfree conditions are unaffected [34]. As with all animal
models though, the relevance of these findings to health
and disease will require demonstration specifically in
humans.
A plausible hypothesis is that HLA molecules, either alone
or in combination with other ankylosing spondylitis-
associated genes, determine the microbiome. No alleles within
the genome are as polymorphic as HLA. A teleological argu-
ment is that the diversity of HLA evolved to protect the
survival of the race in case of epidemic infection. Accordingly,
it is logical that the HLA type would affect the response to
bacterial antigens such that different HLA types would deter-
mine the differential survival of specific organisms. Some
experimental evidence to support this has been published in
mice which are transgenic for the expression of the human
HLA type DR4 [35]. In HLA-B27 transgenic Lewis rats,
which have a high penetrance of arthritis resembling human
ankylosing spondylitis without overt colitis (the 21-3×283-2
Lewis strain) [36], we have found key differences in the gut
microbiota compared to wild-type control animals by both
16S rDNA sequencing and short fragment mass sequencing
techniques (unpublished data by Phoebe Lin, Mark Asquith,
Joel Taurog, Russ Van Gelder, and James Rosenbaum).
Several theories have been proposed as to how HLA-B27
might predispose to disease [37]. These theories include the
possibility that B27 dictates an immune response to an
autoantigen. While this theory fits with the concept that
HLA molecules are immune response gene products, no
autoantigen has been identified to explain the pathogenesis
of ankylosing spondylitis adequately. It has also been ob-
served that B27 is unique in that it dimerizes on the cell
surface and thus can trigger a natural killer cell response.
HLA-B27 within the cytosol is relatively unstable and can
trigger a series of intracellular events known as the unfolded
protein response. None of these three observations adequately
clarifies the clinical characteristics of the disease. In theory,
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each hypothesis might be true and the mechanism by which
each contributes to disease could be indirect through an alter-
ation of the microbiome.
It has been proposed that HLA-B27 leads to a state of
mucosal immunodeficiency [38], and that genes associated
with ankylosing spondylitis either contribute to that immuno-
deficiency, or lead to heightened immunological reactions
driven by bacterial invasion permitted by HLA-B27. This
may either be direct (due to reduced ability to drive immuno-
logical responses to particular bacteria), indirect due to effects
on intestinal permeability, or due to alterations in the gut
microbiome such as a loss of protective bacterial species.
Given the strong interaction of HLA-B27 and ERAP1 in
causing ankylosing spondylitis, and the known function of
ERAP1 in preparing peptides prior to HLA Class I presenta-
tion, it seems likely that these genes operate in disease through
altered peptide handling. Two other aminopeptidases are
known to be associated with ankylosing spondylitis (ERAP2
and NPEPPS). The disease-protective variants of ERAP1 and
ERAP2 are known to be loss-of-function variants, leading to
lower HLA Class I cell surface expression. This would be
most consistent with models in which HLA-B27 in individ-
uals carrying the risk, gain-of-function variants, alter the
microbiome in a manner which promotes ankylosing
spondylitis-relevant immunological activation.
If HLA molecules shape the microbiome, multiple hypoth-
eses could explain how this change could result in disease. For
example, a heightened immune response to specific bacteria
could result in synovitis if these specific bacteria escape to the
synovium where they could trigger an immune response.
Specific bacterial antigens have been detected in the joint in
reactive arthritis [39, 40]. Another reasonable hypothesis is
that the change in microbiome changes gut permeability and
allows leakage of multiple bacterial products which could
become arthritogenic. An increase in intestinal permeability
has been shown in the HLA-B27 transgenic rat [41] and in
patients with ankylosing spondylitis [42, 43]. Another expla-
nation is that the presence of the HLA-B27 transgene alters the
transcriptional profiles of the bacteria present in the gut.
Evidence supporting this concept is described in a study by
Hansen and colleagues, in which transcriptional profiles of
cecal B. theta were altered in transgenic animals resulting in a
bias towards bacterial persistence. They also found that bac-
terial genes that encoded nutrient-binding proteins influential
in inducing adaptive immune responses were upregulated in
the transgenic rat [44].
One can surmise that an imbalance of the bacterial species
found in the gut can dramatically affect immune-mediated
disease since the specific components of the gut microbiome
are intricately tied to the host’s balance of immunologic ef-
fector and regulatory function. Experimental data from mice
have clearly shown that specific bacteria or microbial products
induce regulatory T cells that express the transcription factor
FOXP3. Implicated bacteria include Clostridia spp. [45, 46],
Helicobacter pylori [47], and Bacteroides fragilis [48]. Mu-
rine studies have also implicated segmented filamentous bac-
teria in the generation of T cells that synthesize interleukin 17
[21]. Altered dendritic cell function has been noted in
B27-related disease models [49]. Mucus from the gut
alters dendritic cell function [50] so it is likely that the
microbiome will affect dendritic cell function directly
and indirectly.
Although it seems plausible that HLA-B27 shapes the
microbiome and that HLA-B27-related disease is associated
with altered gut permeability, it is unknownwhich comes first:
the change in permeability or the change in the microbiome.
The alteration in the immune response could alter gut perme-
ability or the alteration in the immune response could affect
the microbial population in the gut and this could result in a
change in permeability. We hypothesize that altered gut per-
meability allows the escape of microbial products which be-
come the target of innate and adaptive immune responses.
HLA-B27 might be critical in the response to the microbial
product when it deposits in the synovium or uveal tract.
Alternatively, B27’s role might be essential in creating the
leaky gut but not critical in the immune response to these
products once they deposit in these tissues.
At the time of this presentation, several groups are actively
trying to confirm the preliminary observation that HLA-B27
alters the microbiome either in rodents or in humans. The
complexity of the microbiome and the uncertainty as to which
microbiome population (for example, cecum, skin, or ileum),
is most important increases the difficulty of this quest. What is
certain is that the microbiome is integral to human health and
the understanding of the microbiome will lead to novel in-
sights into disease. Spondyloarthropathy seems highly likely
to be one such disease.
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